var title_f1_11_1200="Cervical flexion teardrop fracture";
var content_f1_11_1200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Cervical vertebral body fractures: Flexion tear drop fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A flexion teardrop fracture results when severe flexion causes a vertebral body to collide with the one below, leading to anterior displacement of a wedge-shaped fragment (resembling a teardrop).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1200=[""].join("\n");
var outline_f1_11_1200=null;
var title_f1_11_1201="Ectopic adrenal adenoma CT";
var content_f1_11_1201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ectopic adrenal adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image of a 45-year-old woman with ACTH-independent Cushing's syndrome. A 3 x 3 cm mass, which is a benign ectopic adrenal adenoma, is noted near the left renal pelvis (arrow). This patient had undergone previous bilateral adrenalectomy in the mistaken belief that she had bilateral adrenal micronodular hyperplasia. This was followed by 125-I cholesterol scanning on two occasions, which did not detect the ectopic mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David N Orth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1201=[""].join("\n");
var outline_f1_11_1201=null;
var title_f1_11_1202="Ebsteins anomaly four chamber echocardiogram";
var content_f1_11_1202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/58746/4chebsan_conv.mp4?title=Ebsteins+anomaly+four+chamber+echocardiogram\" style=\"width:383px;height:276px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ebsteins anomaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 241px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADxAb0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwD4sMf+Fp+MuT/wAhm87/APTd65Xc394/nXU/Fj/kqfjL/sNXv/o96s/CK00O78bWy+KrO7u9JjjkklW3hklCEL8ryJH85jBwSFIP4ZoA43c394/nRub+8fzr37xB8LINf1a1s9MbRob2+0qW+0h9LjlgjvzG4ykkUpJjbaWII4OPaquhfCDw3qura/ZWms6hfTWOotp1tBF5UD3BjjBkdGk+SQ7yQEBBwASQGFAHhe5v7x/Ojc394/nXukvwy8NanH4KgsV1SynvNGk1G/dVEnnmJZGdUBY/vSUwFHG3nGcioY/Aej6RpPiS6jjkure68Jrq9mmoRKLizdp1TnHGeDhgBkHpQB4jub+8fzo3N/eP516/8TfhZo3g7w/dvDrU9xrViYDLGyAxXCSAZaPAygBIwWJ3Dp6V49QA7c394/nRub+8fzptFADtzf3j+dG5v7x/Om1NZ2015cxwWyF5XOFUUAR7m/vH86Nzf3j+degjw1cyw2gvYxOkMQi3BQFRcnA456kmph4d08bkexG8DIKsxB9uv+cUAecbm/vH86Nzf3j+denW/hKKYAx6VGT1wWbkc+/SsnxfoE93Obq0i3TLGBJFEmBhQANoA9PftQBw+5v7x/Ojc394/nUtrEJLuKOQEBnAPY817wPBmmaTq/2TUvBsUukB9v8Aakl9tb7pP+rDZ68dq562IjRaUuvoa06TqbHgW5vU/nRub+8fzq1qyomp3SxIsaCRsIvReeg+nSqddCd1dGbVnYdub+8fzo3N/eP502igQ7c394/nRub+8fzptFADtzf3j+dG5v7x/Om0UAO3N/eP50bm/vH86bRQB9Vk5/YU5/z/AMTOvlSvqr/mxP8Az/0FK+VaACiveF+GHha9k8O6DbDVLfXdW8Lxa8l+1yjwLKY2Zomi2ZCHYfmDZGRwe+Cvwwj1DU9Lg+0JpltJ4fs9VmuIYpJ0BlHWQswVCepywXjAoA8lor2Wy+BV9LqXiGzuNagM2kXf2VorO2e5mcGMSCUxKQwTDAZAY5DAA45h1X4T6a994WtNF14iTUNEGsXxuomIgjVZGeRcKMr8m0Jy2RycHgA8gor16P4Z2Vl4a8R30k66pGdHttT0i6jDQk+ZcCIh0J4bhhg5HQ5rO+IfwmufBWhy3txrNldXVtOlvdWqKUZWZc5jJPzqDwTgc9sc0AeZUUUUAFFFWLO0lvJvKgAL4zgkDP0oAk0y0S8mkjebyiI2dfkLbmA4Xjpk9+1WodAv5gDFGrZ6fOAfyNd34X0S3sbJ45IhLcuSJG5yw9Fz2H9K6SXQ7VLcLbCUlkLhSmSuPf8A+tQB5IfDWphyphQMOoMij+tSf8IzdpY3VxO8UZhXcsQYM0hzggY6YGTXrx8PwlEkeWWX5AU3LtH0PPpStplvHNmICAgMdxOQfcDtQB4GRjrWv4f8Oalr7sumwK4UhWZ3CKCc4yTx2rpvGfheHc11pAyyrmSHIy3IGVA79z+dUvBvijTdH0bVNM1rSJdRtr142KpcmHG3PUgZ7+tZ1XNRvTV2XBRb97YqeKPBOt+F7WG41mCKKOZiibJ0ckgc8Anj39xXNV1finxJY6npFnpulWEllZ20jvHE0pk2hjkjJOTz3rk6KMpuPvrUKiin7oUUUVoQFFFFABRRRQAUUUUAdX8WP+Sp+Mv+w1e/+j3rn9M1K+0m9S80q9ubK7T7k9tK0br9GUgiug+LH/JU/GX/AGGr3/0e9cpQB1nh3x9rui+L4fEz3TanrMMbxxT6lJJOU3IybslgSQGOMkjPasrT/E2u6baXVrp2tanaWt0xa4hgu5I0mJGCXUHDEj1rIooA1YfEetwWtlbQ6xqUdtZSGW1iS6cJbuc/NGM4U8nkY6mkuPEOtXNxe3Fzq+ozT3sfk3Ukly7NcJx8rknLDgcHI4FZdFAGtdeJNcutIj0q61nUptLjxss5Lp2hXHTCE7Rj6Vk0UUAFFFPhieaVY4xl2OAKAH2tvLd3CQW6F5XOABXovh7S4bFYshUuGAEjopONv+NUtDtrfTZ5JY408wYLAsTgHqo9RXX2EEV3sNnOI2zwznABI6E9qANXSorqOUPFBNufKBlA2k44/T3rT0+3dJC0wnEbJ5ZKsGZzjP4df1rFsp5rV2hmI3KMKofP1xj5T7g1vW94rP8Av49PWLA/e7T835HHft6e1AEd+rzRt5cXmocbnL9xgDOM4/yaxNQOGaKBoEdcIRtZSOxz2rZknSMPGk4QOQAUUNjOe+Rj+dZ17fv86wSPKxUqG4Ck+vr3oA868ceGQhN9YRrkj544lwDj+JV5/nXFLe3SnK3M4I7iQ161fSoJVWUNG5G9hgEk+vtXCeJNNhkjN7ZosZZmLR55bkktyf0FDSe4XscySSSSck0lFFABRRRQAUUUUAFFFFABRRRQB9Vf82J/5/6ClfKtfVX/ADYn/n/oKV8q0Adnc/E3xdcaHHpD6sFso7JNOXyrWGOX7MowIjKqCQpjqC3PfNR2nxH8VWpHlampQWEOmGOS1hkQ28PMSlGQqSp6MRu965CigDuF+K3jJb69vRq0f2y8mNxJcfYrfzFkKLGWRtmYztVR8m3pVOH4h+KYRo5j1Vg+kIY7OTyIzIiEEFC+3c6YZhtYkcniuTooA6nUfH3iXUl1FbzUt8d/ax2U8YgiVPIjbckaKFAjUNzhAO/qaTxB488ReIdO+xazfpdxnZuke1hE0m37u+YIJHx/tMa5eigAooqWOGSRcopI3Bc+5z/gaAHW1rLc58ld2CAeRxnP+Fd5oOmQ6dHGYyGu2y3mDuewGe1YOjpDa+URhnc/O59PTFdJbTxW/wBzbKCASD0PpxQB0+krbzoizys0mdxiBwynPPNdLZ29qIMRld6Nt8p5DuPPAAx9e/vXHW10s4hklKuAMMo+U7vyzj/Ctmz1aaxDbAPJkC4AbqB0568dOKAN+dmH7p1EhztMYZiPXAx/niqF7bW8eXieUx4BO9QSuc8Y4z+HAqCXW4eZH8xXYBiyHHz+g/Xn61m3WtozKIoozMM/eU5U44IHToOlAEkzJbeYyluT5hUr5fGD9cjPbNed+JPDayA3WmLlyT5kQIA6Zyv+H5V6RFpOsah4Yl1uCzkudPF0LV5VYFhIQmzKA5P3l9smpPEXgzxDo1trDXGnww/2ZHFJciOVXZRI2FbAJ4OD06Y5oA8AIx1pK7zxl4Gv9NWyn+zbJ722S7ECupPlvypx2OM8HnpxXCEY60AJRRRQAUUUUAFFFFABRRRQB1fxY/5Kn4y/7DV7/wCj3rlK6v4sf8lT8Zf9hq9/9HvXKUAFFFFABRRRQAUUVLaxedcRx84ZgDjqB3oALaF550jjUszHpXW22nx6fudY1YN85bdu2jPQH2/Wi106PTbQsBumY8vwcr2+lLf3UzWyQSEHdyoHWgCWMqzJMkj+ccs2Bjj2xWvZT26gR7ZCkoAJ6Djkkf8A1652OfBBhUDnGSfm6f8A660VulwXM5fHy7Bxz1zj0oA6tb5ZJUBLum3LDauB3GOOaU3pV5EhQeW3IQcFge5PYVh6VdxSr5fDL2Vjx07frW3LaRNAs0UsKE4REZ9zZ9P/ANdADpb0hAqeWqom51ZenHHtk+tULq5kSaR5HAZs4B5I5yDjoT361WvH8uNvMl3rHleSAeD39/esa/nS4yqYaJT8pzyePy/CgCW4nVmdmceigHBxz1pY7Z5I1aZkManKLjJ+v1pmnWkT+dICDgAkHPp6j3roLbTxPZAWkEjlcM7rwFPTHPU0Ach4s0WCBEuLQ7rhixljXnHTHA4B6965GvStWgHK71iA+ZUA5Pvnua5PVtJVIFntkk3MSSBgrj+h9qAMGiiigAooooAKKKKACiiigD6q/wCbE/8AP/QUr5Vr6q/5sT/z/wBBSvlWgAooooAKKKKACiipI4ZJHRUUkt096AEijeWRURcsxwK6nR7O2t7MykObgHDN1HPTj8Kgs7LyIRBIW80tu25yD9B/XrVrGyQKpiEci4yWxg+9AGl4X0G88V63BpOjwxzanOziON8Rhiqs7ck4xtU9fSujh+HfiSG6j+z2tpOTZyX8D295HLHcRRnDtGysQxB/hBzzVP4V+JLHwT4+0vXtWiuZbezMvmpbqrSHfE6DblgDywPUcV0s/wAV7L/hIPA+vWdnd2l1o8f2e9sIIUSzaMkhzAAflLKzZUqBnHXGSAZkGnXlpoljql9AqadqDyNbyhhubbgN8uegJxn1q6bCR7V73Tbiwm2rxF5mZF7DI454zWb4/wDGOn+Jdbt/7Bt7my0OxtUtbK3nAVlUfMxO0sNxZm79MVzhvY0YNKd3BwUOD6UAbF3LcrMy3KqZGH3QSq5P9earNPwjxqRKMhiec9gOtV49SeZNjTOUyGbcckn65z27VSu45pCoLb4QpBfrt+uetAHqPg34hyeGfCi6XYxCTUzqL3brMgeAoYUVf4s7lkRXHGBgc10g8daTc+Mri+vYLu70W70tNL1CFtu98Jyw+bBO4DBznBNeFaPvEzwx7yG74wR9a7nS5I4UUwSKbpxjeq5C9v0oAofEbV5Nf8TajqMbOpuZR9niU8xRLhUXHT7oAP0rzfWNLc5uIoyHY4aMevsK9G1lIo2muJZPPkOQrNkHA9ce5rk7dWuLrfMrIVG7aAQeOmKAOIIx1pK39W0svG13AshJJLZBwfcGsFlKnDAg+hoASiiigAooooAKKKKAOr+LH/JU/GX/AGGr3/0e9cpXV/Fj/kqfjL/sNXv/AKPeuUoAKKK6DwLHo1x4ltLbxFaXl1Z3LLAFtJxC6uzABslWyBzxj8aAOfor3fWfh54PvPEnjTwp4dttXh1/RrSS4s3nu1lW7aIhnQIEByVPAz6muD+IXhOx8PeI7Dw/ZSSnUobCF9SMrZUXbpvaNcDgAMo575zigDkdItYby+SC4meGNg3zpGXIODjgds10VjZwWFnkIJrhlDFuw9ue2Ks2ujw6ZGpOZJDje6twR6A9qkuFigjH2RpCCcqGHQeh96AKcksnlhm3EZyFbrS+W7xKZIxG2flcryopEFuoOJ0aU8bHBxmmyiV42aUYkGARnpQB1t78N/EltoP9qva20tn9iXUCsd1EZRbSD5ZTEG3hffHY+hqncfDzXrHVb7TZLREvLCyOoz/v1MYg2hjJvBwRg9u/HWvRNQ+Keg3vhIeHZrK9gjHh2103+0LeGMT/AGiEnchbcC0DccEg/e+XmsPX/iXaXnwyt9GSyuE8Sy20Om3N8dvlvZROzoqndndkqpyOx57UAedWl7Etoq+QMqSTkbifpU8VyNiqX/fNlj6E9uKx45WiY7lCsRwc9BUqyIAJAGKDqW7+v0oA1LhZL2DeqMzH5QqjOT+FTR6BqEMavPDsXIypHzcnipvDmq2sM3mXFrGyvnBdvu9c49/8K7U3tpfLsLqFVAqJH83HHXnkmgDE0HS5/tflyQm4tlI8wK+0HjIXP19K6LUvtEUa288MCQg/NbQtt+b/AGj0/Mmr/h7TIxPHO07rCYmLKy4C89Bx64ql4ju5pNQ2pIhjIAXy0KqcDHQ9TQByF/btLGihYnkB52EEqOmM5rFu2UsijePLJ3HHygegrsL7T4ILcRMf9LbkhSAAOwwO9Z2pQwiEhmhVwu4qOvTgEeuKAOEvtKh+x3Fz5jrcAr5cKpneP4iTnjFYJGOtdztkhKlVRe+5x/M1zl1YrMJ5oWAdRu8v+9z2oEZFFFFAwooooAKKKKAPqr/mxP8Az/0FK+Va+qv+bE/8/wDQUr5VoAKms7d7u8gtoiiyTSLGpkcIoJOBljwB7ngVDRQB6Z/wpPxgZbGJU0hpL/8A49VXVbcmcc8ph/mHB5FcbL4Z1WHw7ca3PbeVp8F7/ZztIwVvP2ligXqSADn0rqfEPj2Kaz+Hz6ItzDqPhm2CO8yqFaVZd4K4Ykr9cVofGbx5pfjm70608JabdWGmxyT3s0M4UNJdzvulf5SQVACgHjvwKAPMba3lupligQvI3QCuyRGh0q3iaRp2gVowjIDtycnbxnHf/wCtWz4TluNCts2GozW11ImJmhbCOikkAgYzjnrzWje+J9XQvJ59tMuN26SzhnHPH8aHvWM5Vk/cimvNtf8AtrGrdTj5xHNHGzZWUDB7cdqqtbiRvlfa5OMdcj8O9dRL4luFiE1xo+iTZ4Y/Y1jznt+724qI+INJkZZn8M6crngtBNcIc4x3kZc/QYqPbVVvTfya/Vodl3M+0tby7tZzBaz3Qt4/MlxEWCDoWYjoOgyazwrSyKqKzSEk4QHJ+le9fArxJ4X0pdeuLjytIYiH5rm73+YPnyEBAPGORz1FY3xP8SfDPVfNuNKsr99VHK3mmx+QmfVt2Afrtz7146zqv9elhXhpcqt7y13SevT7n8jX2S5ObmR43GbmFy0sfB4bcp445+lSy/vbdiilSoyrAfqfrXR6JrOk3m2HxFbSTMrZWWMjJHoTxV+/0zwzfox0m41CG5I+WOQqU/Pg19CYHIWhIjhkLR5UYAYHnk8H866ey1S0ktoohFbptyCWwGbIPH0+tZN1YxWcbQSNulztUkHj156Vmw20rYC7WO7CAMCAPU0AdaLS5km8xozGeApU4XHTn2HNdfYGU2Mkv7lYREQqpGQF25OfTGT3NYPhhvKt4be6jgijQnMrPg/gOSf5V1k9lGumrJIJXiBwQTw4/hG0dcdfxNAHD6o482VEcZPWRTlD9eMfl+lYrEJIv71WJH3un4fSun8QNCLR/JEW4EhkRdoU5GPlrkbkSQsSfvDO0H+maAJtQgWG3DLJCYyRsUNnv/TrXK+IEmvb6W8klM08p3SevT/61dXYWjSxKxRZZicKnXoMnFZV/avFdykrvlI5wM/060AceRjrSVr6pbS3MzTRwqrY+ZIxgYHf8hWSRjrQAlFFFABRRRQB1fxY/wCSp+Mv+w1e/wDo965Sur+LH/JU/GX/AGGr3/0e9cpQAVNaXEtpdQ3Nu2yaF1kRsA4YHIODx1FQ1LFBJKpMYyAQDyO/t+FAHaeGtX8a6z44uPFOg3Dz+JomNw80SxCRiylSVixhuCQQFIx1q15WoXOoahqWrl7jU7qVpbudxhtxbLcYwBnsB+mKyNH014U324Y3IwSR2OcjH5V6VpniS4ljij1yGPVYNu3/AEgZni46CQYcY9Cce1c9SVaMrxSku2z/AMn+BSsc9GWW0KypG8Z5G7qvvx1FYtyUfcsQcAn5CDlR6gGvp/4b+FfD2o+CpZRYb7bVCwdJmDsqqxUBWAGMEEg4B5rxj4nfDS98H3Lz2ga40SV/knHVD2STsD6HGD7dK8fB8R4XE4ueCfuzi7K/VrdeqfTr0NZUJRip9DzR45Y7jfvZDjcGyMU+UlX2O4mV+SynJzT7r7h5YKDgIeoFVJiJMxw/KWOODjI9xX0BgWBMkeEZWw2SS5waineONFJG4HAwTnj1GORVaJQhO5C2emR0FEgAkVtpxjnA6n/9VADmEctyyg+WW6DtVpULRCBEGwH77Aj86oQqonV8kZODn0rSRkderrn7pVck/rQAllDufkMGXOcYI/Cut0C3nM/mIzh0Xj5eSQOg/Cs6w8P6vJAZra0kkgj+YMgBxz1I/Diul8F6fdiK4upVlWL+I7tr/wAsgc0AdtpVotr4cFzqEzQxzKfKUMvmu2R35IWsHWRbLeyyKssaxkARFyHY9z7CursdGsXs/Mv0vER8GMoh2uvXAJ759xXEeKXhjkaHT0kDOwG1W3DJ6DPUn270AYx1CCK6kVI4kZzlRv8AujpyTzn6VdtIAbPchRy2c7MKXIHOWPQD2rmJ7GVZWMqMJE5kCrynOOfyroLfUrkWdulzbSmyQYjA4RhkdT35oAw9RjDxBViCyE5L44wPQVhzW0cO9wH4H3uxNdLqkzS5kdCflwcjaPYAVRmtmm09AoLHPyxL8xY+poA466sjI0jxYBC7iCcbvXHqef0rMrr72KS2XawAmA+4B932rCn06RiTEvzgFmBYD34oAzaKKKACiiigD6q/5sT/AM/9BSvlWvqr/mxP/P8A0FK+VaACirq6bdNpkt+In+zRuqM204ywJHP5fmKqxRtLIqIMsegoAdbwyXEqxRKWdugrsI9LFlZq8UQNwUXeVBwy8Z61Y0Cwispt7225JTklCeF9FJrojDF5wjhn+XrGkowwPp7g0AcvMyRgeWShHUP2+honuJCn3UCDuOmf84q3exJLcsGj8rDYZXOAD6A1A1tHENqS4ikOCA2SD+FACvLF9njdlTAGDsfkVmmKO5LCNTEMD5j0J9AKcbbNwYs7tp52LyR64q1ED56wuGVAOPlC8/yoAzJS9qFjuEYhSVKgnJB71CseI2aLdz8uDya0ryH52NxhmPoxJqjKW3KFXHXquP1oAkspApIBywHDDsf8K0LTW7+zvEuIxE23I+aMMp6df0rMRN5yoIOSTuPU1KseYyw3Erzt/wA/hQBf1fVL3UZDPN9mT2iUL2HatDR/Dt7LZ/av+WR+XDnCg/yFbFrounLZrLKjlCgZhIxGO/IGOlJYeIPKlkgit4m0wfK0bZBPuPQ1hTrqrK0VsexjsmqYClGpXmry2Su367GppNnKkPlvBG04I2ssxJx0AUDOTmuvvI/O0m1t4osvAmZXmLIVbP15+tYukPZ3LSSJtgTAEe8jAHU9T/nNdrYWsEOgs1wqGFg0gleIsPUDJ4rc8c8r1i5xJ5UO0qFwWUkD39zTJfDrT/Dk+LfNJnXVP7LW0MfG3yfM3g9z2xj8ak123BumjtDvEn+slPCoPcjj1qzp3jW60Dw9c+H00nRtW0z7abwNfxSMfN2BMjbIvGBgfU0Ablv4BWG7sbhNUf8AsKfRJNWkvFiw8ewYaLGcFg5Vev8AF+FeVarPJ5qxwbZE43ugJH0B712A8batD4BXwcpgOmvL5hZlJlClg5QEHAQuA2MZJ744rnLa3J8wzkRQIcYUcsfQCgCpatNK6hbfkYOz0GeP/wBdYXiGxxKZ4hCo6OsfAyO9d/FaJD/qreVpZf4n67fx6D8qxb3TY/Mk3/KUxzJ0H+JoA89orY1WyjGTapwg+ZuRu564Pt6Vj0AFFFFAHV/Fj/kqfjL/ALDV7/6Peud0/wCy/a4/t5mFvn5vJUFvwBIFdF8WP+Sp+Mv+w1e/+j3rmUt5nRXWNyjMVD44JHUZ/EUAaWtwW1xqs0uirK9lK42blwVYjJX8OelXrCxS2iAckSNkMR1+n0qPS7eO3BBUtI3VweMelbaQAurOpIk77f5UAGnJLZsXhEhYjOCduR61oTTLPF9phYRXiDlCeD+FUpZmtYVTP7xDlc/X/PFRXrJcoHjQpc5O6JASv1UUAXrbWp4rhJrbdE56gvnn+o+tRX2pR3EpN1aoLrOVkh4Dcd+35VQtX3su0KOclTxn35pBbs9ztAYsoyA3YYoA0p7R75QnkgSEDIQhQR9D3qjdaY1uSzxPH06Dp6Gg5NrKEZ4zwVJ+4fY0/TdUczBrqOO7BA/dgnt0560AZ7oCxRcgdME8mrtvp1vLLH5srRQkfM7DIX6+vPpVq5urV2leO0jQ5yyBssvvng/nUKybjE5mZoUb5V4IB9KANiy+Ht5qaJPpd3p9xDuw5iulDRem4Hn8s9KuzeBpdMCGW+tJHY4SOJzJIW5OMAfzrBkuoXVpYmYyEY2DC59e1bfh68+yvDfp5XnsOAuMp2PGKAOnvr+ezso4YJHjkbrHuUkHoQcAHv69q0dHWGeIWZUXN5O2E8kEYPfPQYBHHX6UlhLO1jLPc2enXd1PhwtxbhpNvABDZGBx+tdb4dstPbTHN7PBbzoRIuCEVWP8IGcdOKANK50AxeF8nT5Fuk+UZbzD7HriuA8MSmHxtokl9KiRW1/b7iR8kaiVSW3dAOMk+mea6DxX4ht4LVUa7W5m5VlA2rGpHPPc8/0rzq7115Q8ESOFf5m85wnHbA70Aehxx2OifFLWG1HVtNuNA8VyXtvO9vdJKIUkbcjvg4TBZeTjHzelcj8TdQsxd6do2k3i3Ok6LapaRTQ8pNJjdJIGzg5YnpnpXFXkrXd2rgsiABeR8tOZwzCyLAIGx2LE+ntQBYt7dLtGOJPLHJK/M2P6ZzVgPGkipZuyIgzgDJJ7/WpURUMdtK07qDtPzbY8+nHUir8WnRfaYPORY9+QsanG1R3PcmgDnL3T9zedsZ7gj5t3UD3rDubUROBnOOcN6e9d1dTWkLFbW1YhiQJWbrjsO31NczfW4mmbClnY5LMcDHsOtAHF3mlu0ifZV3u+fkA54HX+dZRGOtd1LokwLTXACW55Bzjf7Cue1bTD56myR5C5xsUFjn2FAGLRTmUoxVgQw6gim0AfVX/Nif8An/oKV8q19Vf82J/5/wCgpXy9p8UU17BHcGQQFx5hjALBe+M8dKALFrqWom1bT4bqdrWUbTAXymM56HgdOtb2m2FrEHXJWRiSGB3YH936e9VrKwjill+zeY6gna7rtJXP6fnWzY2zSTqiRhpeoHQMfQUAdLoGlrPZqq/M4OeDg+4I6Y9xVjU9Nit4d5kPmRN8uecj6evtUfh27ijmkguFeIj7pK4K4659Ku6tKHR2d1dl+XzPb0ZfT3oA43Vd0xeRxvVvv7RjFZDRBixDhZlxgMeGFWr67khkdZYsKcYIOAR9arNCzRbjg98BgSB60AOR5DMslypI6fLjihZrjzWWEDHQnvj6UycRwIjRSkkjlGIODSDzWmUx871wT2/DFAEcQKzZwWbPAAz+NStE7gvLG+ScZJ/Sp03vsEiFRGcFlU5/HJq2ltIzSKskjk/dQL1H9KAGQ2crFxLGiqv8bDCqexz3+nemebHbRvLZlGk6NMx+c/7o/h/n9Ks3Lyva24wszpkbG7ehx/jUKQqJxJcOsjAYIGAKjlv8R0qtGkv3S179fl29d/NbEUN3N9iNtFJK0RbewPTNXtI04zu4fzCTyBgkZHcVqaToy6rIqxEmL+8pCgfieK6+1t4dO/0eJrH5evBLn03EHH4Z/OqSS2MZ1Jztzu9tF6BoOnvHDDA9tNdQn7kRBDZNegeIGEOi28LtJDPIuSZSG2D029BWRoc9zqtmyWli0rwEZmfCqAe2eOevHSsPxh4jS9zbKXEYOw7ZPMXd7EHn/CmQZmriztYGjMkbA/OUc4L/APAcVxk9xCqErEifMSF5OPQ5NWL/AFaRl8oRqCpKhu5z/wDrrNvYh5aCYMpzkluB+FADlgMrs+Qqlhl+gz7Zq5p+nfPHJbXCv1yXI2xj15/wqnbwiWSI2sTy9lj++WPsvf8AAVpaDbX2sXcdvZ2ayMTuAiGCAO59APUnFTKcYpuTskFrlrU5fLt1FtLJJJIfmLdXHrjsOuBXvmqeAvBE3inWYvLhfy7SSJNN81t0MyIXaY8527fLAzxlj6V5LqOjQWFtEU1CEypnfHbfNhsjADfxH1PT3NUrm91JtWmuVv72K6dcTXBnYSSgjBEkmckY4xn2pQmqkeaOw2rHWWXhDw9d6HpnjSLTYv7Es9KnXULTzGAlvYzsjBOcjzC6twei+/PztqGmgQobeNmmG4uU5UjqMfTn9K9b8u+l0uTTLK5uf7MmYSSReYyxSHA52dO2M4zwK5bUrNLRZIFILLkEA5P8v0qxHmdFdDq2lQJa74I50uw3zREfLsx155z14rnqAOt+KiNJ8VvGKoMsdavf/R71DZJPBZpALlzAG3+UT8m4jB4P866f4hQLH8TvFsomLP8A2veDa2CuDO5x+f61y08pafaowhH1AoAeodJsABCpzwef/r1d+2iOIAITHyWUDofUelUAnmLtLbcdCTx+BqB5mSLZtV/oevNAF+71N7mIKyrJz8px81U7VmhdbhHxJngVTQSlhx8pPHNSohYhS45OCM8/rQBoNcCWdZQVUg5JU8Z+lTtPHM+7IWTHrkGskDy5tsZO8dQeasLMJBuYjf2bHT60AX5rqSBfs+3eDyU4AFQyxwxQC4tJCrg8x46VFHMUmUthipyO4qaSOKSVWUq6vyUBxj6+lAEQQTRiRpRHKSdwJ6/Spo02x8Sp1xkcnHtTCpMzBUwAMhXyRUsOEQNKvyYwFBGc0AECyA7CzCKM8ll4BPvW3p0sdosY5Ln5gvBDjPoayojGY3McyiHHJdsD9K07S1f7JDLHISC2fLj7+/TNAHaJq91cJHDdh47MptVIwq/QZPvW/qT6RpPhkNHdebqJH3UmUlTkduvWuTtoWNuzMsomT/lnG5X/AD+ArOlleK4Ml6rxv12OfmHpn/IoAdJex3JYrI0ty+dwk+bAz6gDFZNw/mXIY7z23tlgPr71ZeWKKYnJVSOTCOv51Rn2/O8TPt/hzwc0AQC5f7ePIYiGM4JwDn3+tWftLx3Akhj8t2IxI4y2f8adp1urZnnmCLGdw7szfT+uKtWVhNqV7G0iyhBkhz39cDHNAGhYRveN51zeCCMAqTuG9voo/nXT6dZ2z6dKGS6k8xekS5dh/eLH8PaqEVjFEpnk2rEDhVf53Y/nW1DPcxaS7/a0hjfIWNEwxHocdABQBzmpRxjzTZQytCq7cnqB6Z7D6daz9J09IbgXGq8RdViVuW/wFa2q3Xk2yR27ho253E9/89/5UaFpb6jciOdJWBI5J2gDnqT0H50AZ/iB5NYuC0SBYwu1VBwkajoB6+5rlbuL7LKrq5SaMjaytypB6jHSvQ9cj8rdaWsPl2KZUHpvbuc9SK4fX2WJVCQgBRhcmgDjdatTJcvNCGdmy0hJySfWscjHWutETyRSPn92PvMMY/OsbVLdp3a4Ql5CSZDnqfWgD6Zgj839hgINxJBxtXJ/5CfpXzto9ulskU6sST98jqPUYr6S0ghP2JYiwH8Qw3TnUjXzgp8rlUAQnBAJIHoaAOltbZIdkkHML+nO33A/pV9NPdWZ49q/LkAcq/8AUViaCDI5SRgq5yrdFf2z0roJ5pLdVaMiW1HG4feX2PcfWgBLqY3NqZjNtlAAEhPII6BiOf8AGsqbVLuXdb3ccb4yAwOGz7VHqFzOskkkCMpb1GQR6Y7iubvJ5JJA52ggYI6EUAW7q8zGV8teODG3XPqO4qo105iT92qbTjoeR9ajnbJEuPnP3jnI/LqKQzCUZQBX/wBlv1oAnnnkuJYvMGADgjZnH+NaFqsYmdFO5QMYHWsiJ1LYlbCqB0GTUs6hUZhIrdwDwTmgDYR/MiI2qZe4Y5Y/Sq4vmjkGxScnHJyPyqCxnUMpO6KI8ZXoDUgiYEyKA5ByGAxx9KANBZxIx8y4zGOgUY5+hpVlZLZZVVN6uQPl65/+tUdsY3T92iyuTk7lLY/Kp5IkcksfJAXnAIDenFAGr4deKeV3mgMkmDtQKSPT1x+ddxo9zYWjRy3TWlu65BjmgD5B7nnr1rlPC+lxzvHKkojJHVX+8fTGQafqel3s+q/uYZpB0UiPpge/+NAHSeJ/GNxeWz2cdysNvnOFJUMP90Yz+NcSL6T+CUZHQYC4H0ra/wCEfu2lU35it1A++2zgDvg/55qx9q0HTmQGd9QnK8qqhUBx3yP5UAcs1re61MiI8yo5ICiMoo9s96TUNMigVomuS80YwQzfLn8ep9+ldTqniyV7CWLTtPhtI2Xb5qnLlcAYyeg47DtXNW8cV5KYpBhyMjy8O35DqaAPafgX4Ki0TTh4m1oJDcTJi2EpAEUZ/jOehbt7fWs34hTaX/bn2fw9qlrHZXCmW5hslXDS5JLMVHzdupIHNcirXl3P/wATFrq5fHyRy3BZuwyeuP8AP1qc2EcKI8skKXD/AC+QDgAe/c/jXz2GyWosc8fiKvNJ/Ztol0Wt9u+mpvKsuTkiism1LdklBcnmPyxzkdyaqSIiAvcKZLhsbS7ZA/DvWrO4hnMEaLLK4wBDHwgHrz1qnBZqqGaVEEuSqIxyT6/WvoTAgmeZbZ5vNdmAHyxg5OeOT2qlLHLE8RMKLPt4Xr5Y7kk966x7FIrANdI8Kk52gDj8PX6/lXIXod7trgM5x8xDAlU/xNAGBqUQ852U7pn4K7skfU+tc9JpUE1xK08sluc/wxl9x7966S4Ie5Oc9eCePxP+FZ84AbDFQR69/wAqALnxSkP/AAs/xaVADf2vdjIOM/vn61lWkazvtmUq/Ue/19frXUePtNjvPih4tRpCrtq93hTxn983IP8ASsaTTpNNukjnLeR0DsOPz/pQBn30fkM0LIVGPXt1rNRlw2SQ38HtzW/qkTjymjkWaPnaSeR7Z7isNogFI+ZWHGSMg0AQiUYYOTg96US+Y6nBz3Ld6Ty/LkJLDPueDTgTHGzIAVPHAB5oAfM+7A6r2J6j2zUErOd2FVh3OCfzNOj3svJVT25wfWmBzkjIC/zoAdbSlHChgmPXPNXUhbzPMkKbehIyapnyTwXJ7ZPHH50sd20PyjJxxkNQBOH8kmQKM9AxbpSSspnVvM+cjJI47dqgYLK2/aRxz3obO0bWdm9D3oAuMQFcoxVT0J5rV0TUHSApM3yrwBjH6msVRuwkgCYHfI7Vfs7eOeRAzZJ9+DjtQB6p4XupWi8uJLV0b5jO+C6j0OOal1e+0NWWCazjmJGJJIwDIw/2ST61S8LeV9hddrxPtwZfMAx+vP4VzGuyOb92+1B2A4Lv7dc0AdPd/wDCNPbQm0WWBjxi4K/Jz1Kjr+dIYvDEEayXN0by4Y8n7iDt0Hp/WuLW3nECsDGw6ng5P05oDhpQzS9F+ZQcED0oA9F8Par4c/teOCbRGu7TaAXibY4H0BO78xXuHh9fCZtZLnS7exVo4y8m5B5yKOfm3fMBXydY37WzNFaSKF6lhjcPxra0wOj5iKylh85RznaeCOOxrwc4yJZmrqrKD8m+V/8Abt7fd+JtSrez6XO0tLOwlSOSy1aJUUgRi6tpFbOeASqt/nvV+704vGfPv9OlkxklpwqqBzxGfmP0AJNZ+mLai3Yb0e4K/JGsf+rHTJ5wPqea9U0oeHtI8MeF5tXjtUvt8skREXz3TeYyiMnGSMshyey+9eqqNSL0qN+qX6JGd12PGNQieXUnFuk8ip8ouJUCBf8AdXt+PNbXhS1vZLgxRW0rnGcscfie9estp9n4j1rxFoQjtraSyv47iKQIEIiyBKufQA5A9TXH+I/EEtxdaguiJDbWkshy0CY+UcLyO+PTvn610knBa8jw3TxcGbJ3O7ZLEfwqOw9+K4q+Q3F9tmO8/wB0DIH+NdFqaolxLO7bWXAz1JPvWZcqqozxkiSQfebr7kntQBg38EiqwiwkanGWbOPw6ViRL5KSeUWJ+7v6E/St2eASRMpkPHIUcnrWFcu0U4XYGwMrvzgUAfSjZ/4YrO7A47Lgf8hH0FfMyKXHyFT6jNfTyB5v2NAJmAZjyccf8hH0r52OnCMYRh7jv9RQA2zuZ44jCmFz/Bjr3/Or9tdOLZleIEEcqcg/UGoLOzvrO6QSJ+4cblLDIceoNbNxbq8YZVCg9QDn9Oo/lQBz+p3H+i7RKykdRjp6VhXNzM6L5hV/TI5/Ot3XI/KIkKq8RHBHIJ/pWDti3hlJyM8Ecke9ACKrM4lGd2B8v4dhUa7Vc4bLd896fJKfK65CHp2rrvAfgdvFem6xqx1Sz0yz0trZJmuElfc08hRAAisT8wA/Ee5oA5J4WikWWTOD3zwfUU6P966gYIA4Ga9C0b4T65rXjvWPCRutOtLrS8faLp3b7OSWVUVTjOWLjAIz178VwFzbzadqc1ndxqk0LtFIjAAqynBBHrkUAKxIGUQeWvBINAmkWXzCzITwDjOR/WoHZzKDIDz3K4HTtSMJmJKpuHqBmgDQt72ZV3FirngN0zVxnuN0XnsNzcBSf84rHiMgMZYg49cED8+Ksu7yS71PHbAxx7UAeseC5oUEEcaSC89ZCu0Emt/xFf6nYQzSJLHCAB86tnJ9geK5PwfLEbOOe6Coo4IZipyM4xg596seK7i4azKtcIIMZVJJCzYPsBn8zQBys/iG6u4p1uZeeuZAWY/U1nExNOj7miDdWzUt15csIQH93jlo1Iz9apK9l9mONxl6DB4oAuDzrh1EO9414MrLwB7Vp6S8Vg0jyXJ84H5UXoT71mWUsojHlI00nZVJOPc0/R9xuClzt3M33Tz+ZoA7WDxBfyWi20AtrffnzXjxuYe561e0qKdZ2CySfMctvT5n9+mcVj20McU6pBMqSsQAI1wfz7V2AlexhRpZI45GGBHkb3PqS3IHvQBm3biRxBCBGhOZmUEFvY45xVrRdOma9KabBC04+bzpuBGPUemPWq0s7XdyP3ztz/yzPX6D09yK6ewT7Fp7CJSyMuW8w7d/9T+PHNAGXrc6JC6Su13KAFMyDYnuF46fSuKukSWHAUhGPAOQCf6muh1i5lu51E07NI/Cqo4Hb8Kzbm3uhOHhQBgNvmucCMe3YUAcrqiPakxgIrf3RyR9axXhZpW3bQf9o9a6rWPs4xFbwhyOXmYH5j3I9q5u5YecxJH19aAO88daZFdePfE7upIGq3WZIzyh85uo9Kr3EKNaLDdsJrbH3yf5+h96g8Z3lxZfFLxQ8DDb/at1uVjwR5z1FfXCtAX8vyJTwQDwfwoA57VLaCzd7cySeU3Kt3H1A6/UVg3DSwnYGV1/76rR1Cby5g0n7yM9VORtrIlZZLkAZ2dge/40ARyKj5J37T0wORTFITOGDbRgg9x/nFWljWJ3eFmWVOShGfaqsoDvudRu9BxmgCufmyxBCn0NfQfwH8EeHvEfgK3utV03S7u6m8QvZMb6aZHe3FqJDHD5bAebkEjPGN3tXz6y5Plxgn1yOlaFtq2r2dvb2trqd9b2kVyLuJI52REnA2iUAHAcDjd1xxmgD3L4TfDPQ9b0/WJtb0uZU1S/m0zSvtc3lS2Kokh80ruG8hzEm3B59s14NqttcadfXVhewiK6tpWhlQgZRlYgj8xVy/8AEGt3k9rcX2s6pczWztJbyTXTs0LltxZCWO0lsHI6nms68u7jULyW6vZ5bm6lYvLNM5kkkY9SxJyT70ANVgqBc/N6dKTzH5JUEAYzTRjJEgJJ6MT0pyfNJt4Ye3egCSF5SAQcDpx1rWsbvy5IlQh/Xf61kxBy5EO046Ck3kZDAbs9BQB6bo89xHbs6xq0X8So3H65rE1W8tRdO7JCQOBGPmYH8cVk6T4gEFuLdo2LkH5/MKgfgKzrmTzLjfwDk5c85oA6HFy1stwhSOFwQgYnewHBxVKXz1MbOGih6ByuA3sG716fqdpF4h+DngaCw1zQI7zS01Frq3u9QihmUPPlAEZs5IU/mPWuq8eXXhXWvh1f+F9L1uzuJfDkcEtgQojWZkG2bZITiUuWZgF7gY9aAPHtKtIZ4JZFCpMRgOzEDHv61r6RJN9mEXn+XagncIAu5yPf/Guc060TycOHXscdev5Vv29kkRVbaVxC3+sckZ/z9KAOm0/U3t4JRZwABgBmQ7sfTHU81XPmSXXmi1W4mIxtILfN6mpdJtIwu2KMGFj/AKyWTB69fXH613WnWVlFYBHQgvglyQgPpgdf/wBf5gFbS9GjtrdLnV54ppmGEsoD8g/3mAwPp7dazPEOoNcL9ntoRgEYSIYQfQD+ZzVnU9RtrW1MNtcQxLuwHXLn3z71z2o3sf8AqLTz5Xx+8dcqT7e3agDKvpoUCM6ia6U8RYyoOe9ZTtdXUrvcI8ssmTlhhR7/AIVspvRyyW0YdclVzu2+5PrWfcySlHeRmYE/MR8q9ehb+goAqyhYhuBiGAePX3J9P51zeoxNC7y87pPmzj+npWlMzszSJtx/Cf4axNRlkkbbI5dvYcD6UAfSBZof2MdwyHHqc/8AMRr5/sLh5P3jLkY+bBzivfpB/wAYXELk/jnn+0ea8E0BAXQSSNFuXkleOPUdxQB0mlTRtD5cmHgc52E/KT0yp7Gn3Gjw3AdrW9cNH0Rhhhn+Y9xVgaahth9n2RytztjbKSc9V9PpVEPIUkiA8yVM/I3DA+3+FAHG675kG5EK7s4IPesBw6T7gGVvft+VdTr6LcPudiJz1TnP/wBeufuEMSAozMrdRigCpPv8xi5XJ67T1r0D4afFC8+Hula5b6Tah7zUHtHS583aIvJdmZSmDuDhip5GAT1rg+PIdnQ7z3Iz7VHGE/iBPv0xQB67/wALctrFtauvDfh23sLvV9Si1G4e7lF2oKfMEUFFxiUlwc8EgDpmuK8f+ILfxV4w1LXbWw/sw3riV7dZPMAk2gMwbap+ZgWxjqa5uaFYplABZCO5/wAKdJ5sG0DlOSpU5/WgAM8hbMvPfpkU6GQeaHI+XsBkGoQ7KQrhQGGTxQZfLIVArKM4zzQBa8qTG9WVgepB/wAaMzrc7ZAuG96r+Zub7yY+mKmDMIwwy4HQCgDuPD90yN/qYtxGwBskr7jFaGvXUVpahXlRpcc7hkn8etcBY3s0chIV1Y8AgkYNWzfwBj9sEskncgc/zoAiupftGflxH6g4ANXBo+oae9mL+3a1NxCt3brKhUyxNnbIPVTg4PtWfHKjuzxqvlseELY+mR3r2LxK/gvxe/gm6ufFcFqunaTYadfWX2S434jb97hgm3gMcc84460AedajoWsaKIZdVt5tPW6TzYBIhQSp6rnqOlWtHdniYKqGZRjzBwfYc16l8SvFvh/xt4Ycwm5j1WwvmksYboAq1vIAGRCi4VV2qcMRwO9eXaTp8tzen7TGBF1MattUmgDb8O2upz3uyJ1TfkM+VyB/QflXS3GmWFrcxFLnz7wjdJK7lwo9MKP0qz4f02ePT2a2sGl3kfOxxGOmOvJx7CtWK2FlbJe6iYfvZSNVBDewHb+dAEOk6WksbXsrNHCx5ONhOBwTnoPpk1Hqeow2UbpbqLiQjoThUGepNO1XUjqVqzyArGOdi4Uflz6dSaxBcJJEsFrZiV87sE/IvuT3oArwzSzz7nwqtnAhQ7j+J6DjvWfdTNPKfnZgPurnI/E+lWbh7hjIsjhjtG9lOERffH+faoY53t7fMojQH7ikDJ98f1P5UAZmpD9zm7kPljoqDG76d8e9czLGZnLJA+wcARjgfietbmp3XnzhZHyAc7M5JPue5/zxWTfXheUACKJF4UMeaAOv+I2mSr458UTGPzIZNVujlOdv75vyNYCuyweSSQoGAWBwPqO1d54xYt418ThSYphqVzyTkMPNbGRXN3hicBbuERy9BLH/AJ5oA47UEcHEm0KAcN1B/Gq9rHatbOr7lYfxqcgfUVf1OJ0kdYTuXrgjg/h9KxxHJGxcIPQjPGPegBJHeC4CMQygcSJzxUbQqQz8mnx7yGKruUdQ2KiEhUj+E9weh/GgClKgMzKAfr+FMDDiNuM+/NTTn9+WdOo+9nNQOolwcN17UASpgKBx3I9xTx5KHejEfjkg1XKEYJB20Jxzxj0xmgB7M8mScH/ab/69NTIVh5YJxycHiiR85yWyfWgrgZCMe2SOPyoAkiCpJyxZOox0Jp1yiH5o85I5ApI8NGQo4HJyelPDxeXgsdwPAzxQAsUQj2YJEjDOTwFqe2aSFlePYw5yDyPTmh4y6q7Mu0/d2itWx0yaWATiWJFXkYxkD6CgClb+ZLeAiONRnsuR+Vbdj5kd6HTGwf3en5D3qrbRJL+6LFXP8KoVz+da9naSptjs5DNIxxsC9fxNAF21iV7hZX/eN1KtgY/Cuh0uweSVJ/KknG4fLGuec9Dx+HFXfD3hXUZ5IZbtvsMQHLR4IJ6dq6i5eDQYJVtryRpf4d7jk/8A6qAKVzKmnqH1GJlVOFtYCCw7ZPP0FYt/fPeKwt7KKwtjzI28tIw9D3xn1rnNRvTd3TyTT4kBLcuTj6D196rPqE/ywxgLak8sy7FP9W/GgDrbZoLgQxwq5ijH3yuMH3Y/XoKhe5toEeOAecc5ZuwP8yax5LmW7jD3cqNaqvAZyqZ9cDGarXkyk7Uc4IwscabFx/hQBau7+Ly2ccZ4C44PufX6c/Sueur03Uu2eTzIlwFQAqCfpUszG3bzJQw2/dTks34dayBcM1yc7Ffnl+An4UAO1C4Lzb5DtQDAVev59qyWH2mQ7mAVR6YArSkELPl3Mo7sR19gKxr50V3REfb1wTzQB9R6bAJP2N4ovN4OcOP+whxXhcFo9vErfK8JbkKeAfbuDXuGmDH7GUW4Hvxn/qI14jDJOHHlo7DurdT/AI0AaoaWyt8rJKoYE7W7+4I4P1rOku5fPW6LcdCw57961d6y2BQIxXr5Levqp6g+1UYGt1yr7lB6OVwce9AHP+IZIp5GmZFbgcjgH3rnJBsJZAhB7E5/+v8AlXY6tY2zwSNG68++V/Lg/rXETQvFOVdSV9uhoAGZTyoAkIwRng/5+tRsFCc43DjGaRkIbb1wehNNO0scjAoAly8alTg5OeQc0B2Z0AGxvU8CmMQAhDMwHY9qVCu4nPA6AmgCV8tHmQg5PB6flQYwSoVCVPPA/rQx3qSNw/2UJwahzGOmSfc8fSgCURr5zJjC8fU1ajQRplXAA7H6+lVYYw2Gw3tgd6nzIWCFkCZ43AigC1a/MxGwO56HcQB701Y5f3mFaWMHGATimF2kJYR5A4OGzW34fiEkyvPbIVOcMTgjt/nigDKtbU582RNqj+HmtS2iW4dFt4th6/J1q3qNm8byPbW7nOcvkEEewp9jp0+yKSVVRCOSwbigC3C7KADbvNIOMyZ/l/8AXrufDemPAIrq4a2RsE+WFDEemB/9es/T9Nh0+1S8kuvMKHKpGvU9s8Vt2viKH7MWmjkXJwAsSr+bdT3oA0bjXv7MtmZVeWZuPNljH6Dp/wDqrB/tPz3kuJJ/OuCMKGH3evTPT8MVg+KdWv55DGQqRDoCMY/qePasm11CKJGTEaEjG0nbn/PuaAOriu3ulzcE+WDjavC59ye1S3N9Gf3KSGRF5dYV4J9zXNW1ytyu2SQFBnCRjJ/DsKdcTvBC628bqv8Ad7fn3oAseItRMtqtvbKyQEg4Ixk1iXLPbxn5iZW6kfw57lvWo571CCZy3mDjAzx7VmXLyT7ptjKg7tzzQA8zLEjBFG4jJc9f/rVj3Nw3nHyyffbwK0Y42kt28sAknkmsqeKYzMFBbH93p+lAHsXjtbm08eeIZCm+zfVLra45AJlYkZHQ/WuevHdZVkikZN/QEfK/9Aa9F16SKDx34j348t9QuA6jBB/eP1U8Gud1zw6I7ea60ktJCR88Q+dAPXB+YfSgDhdYQmHJwHHYDBH1HasS4ibyt8bc4wyf4V14V4o911A3lj5QzDco9s9R9DVTUdOUJ9qiX912ePt9aAOSaAtEcxvn1H9RUQAWF0cMV7Z/hNdIDJFGZIykqjqCPmH41n3Ful23mJ+6k9V4H5UAc6+SDggYHOe/0qNcjlj+Hp+FaV9aSRBmZDgDO4dDWei7lO98Z7bSaAGsQxbBOT27VEpJlwRhO5qURsU4XP8AMUgOeOBkdTQAgbaxKHj3pwcMwBY59zSnzN6EYJ7E45/GoyuGDljv+tAEhKq5LLvB6c4pYdikFsZI7jNNLkZ3YY9vSrVtbJIfmK49ScCgBbcRsw3vtHsK7nwslqbbY0c5h7yR4FcZawMZgMOU6Fj3/Gu38PSXMTpHYxnsAVQsaAOks/CUFzIXtGuZDIM4yoGM+5zWotlY6FDJCxnDuODGFB5GOv8A9c07Tri4Vzb3aXUrEfMkUOC/45zirTxJcRMrQaZZKp+7cP8AvPoQcn+VAGLfZjQeZelbdTkRvcK7D3P/ANb1qnqtwZrd5LeS6mJUYlVNoP8AwLGa149NhQvNHdwLyPmEGVXnjG4YrJvYbm9DQm+uJoRySITlv/rfkP6AHG3ZvVIJlxk9S3cU5/NWANOwyw+8eSfzq5fabHDcFi0m5f7uMn8qoSLM052JKzZyMruz9aALEbNI4eDhV6yy/Nj+lWIFY72tZXMjcPO7Y/AVUeO4f5p1mcDnb0Gf5CoVlbbiRFRPXOAKAJr6NYon8ktK2P8AWZ4+uax1EUakzEgHpjjJ/rUk7eZNuEmUA+Xd0/AVDJH8yuzfP6+n1zQATzhYR5KsuRwX5/SqZO7kFy2Ms7D+lLNNHuO5mkY989KbHK8pO7cQeuOaAPqXRIftP7HcMWWy27knB/5CBNeS6bEJFEM6AhOC54Za9h0E/wDGIluQvTOAef8AmIGvJ7ONlkDR+ZCXPCMcrn2NAD5NLXdhpXLEZUHhmHqD0zWXPp22Rt0rnafmI6qfcV6BpiadqiHTtSDWzuMKRjAPXOOnXuMZrnPF3hrUdHIuredrpI+FkQfMo/2u/rQBzgjnglaFo45AcEK42hx9CMflWJr2nCA+YLQxxH7wxnb75z0rrrK7lu4I0vb2JFbhkmjAx7/5/GrOoaHdR2P2iOMPH/DNbnerfhQB43PCNxKc/TnNQiPgkAn6iun1ewlB2m1Ct95WjXAI+lY0kMiLvwqsOn196AM/58BcHH0oOVIBC49D/jVwORl5l3AjnBwOtNkhVovMVvlzjGc0AVsjaynPqADxTVK7SCDu7EVM8fy7QBnjHPNAi6ecHBPOD1oAaHkCHIGDzz3/AAo8/gYXn3NKLZmfCEEHpk1di09nUfuix6ZB60ASadCtwVkDMuOoA3YrrdIdJpUSNQ7dC0gK1m6Boc3EgX5RkHdxx19K2yjSyJGi8L94GUjP4kYoA7ezn+zsFiMsyquAkceefXcfxp9xYXF3ArRQNubktdOp+hA/+tVLTLPTwiefOzjHEcMpc/4VtMFHyWFv5ca9FkmwT9QDnr70AZtqfLd47+4k3r1aOTav0zxWPdXF2bmZ7YzrCF/1nLf+PHNdVa2rT27F9Ot0UfxRxb3z+Oarm2t1keMWyliMmN1yc++f6CgDza9Z7iSQu7SSHq8rYA/XJrOt0WJmLhJB7cD8T/hXba9GpuRCtrGjcDJjwo79+P0rAbTZBqCgzIVx94D5V47cUARWEt3KvyKBEOBtG1R71FcTRBW893dyei//AF66K802FLNZXu5jx9wfKD/X9KxX8pUaRYmRz93Ayfrz0oAy7kgg7QwI/hHGB6se9VriSS5wxKbFH3udop90WVgBC0jehy5b3PoKqSCSR83BYsD/AKsHgfh/+ugCGS6d3EKSMsI/ixjP+TURliyVAZ1HTaMAVLcywBWwrBunWoYYmmQFAVA7AE/0oA9o8bMsPjvxI0cg8v8AtK53q4yufNbP61VtdQnsh50KyLEx5aI5H5Hg/pUHjO+t4fiN4mWVFI/tS6Vst/01btUCTIkbPp0zIjfeifnB9QaANmYRaiHurC4EdxjLIPlDfUEY9etY0mnzQtI4kezkHO3Z8h56gdCPpT7OWaKJprO4jMw5eB14P+fwra0vxEJoRFc7Ux/yylAdD7cjI/OgDg7mF4ZHku49/o8Y/wAP61d0vQrPVgJLS4ihuDx5czFQenf1rtZNO02+if8A1cEjc4R8YPsD/jXPy+H7nTppJIlneEdfLw2PfFAGbrHhu9ClLu0dF6B1YMv5j+dcpqmivaxEmB1jzjzFGVr0CC+ZbgR3LXUK4wpwQpHT7pzj86bq1lDeRuVklt93WRB8p+pHFAHlAtJhkxyQyY7BiDVOWNvtBBQL67jxmuzn8MGORnimik/4Fkn9KqRaDkM06yZU8D/63+etAHJxqRJyDVw2kjsD5XJ7jp/hXRQeHGu7nAHlIe7Agfy/lWzbeFlAjW2mW5OP9UrEEn2PegDhUtS8qARHe3oCMV0Oj6DeNeIEj8tHONzkEHPfmvRNE+GzXsvnT293boDnaAJSfrgj2/Ouvh0q00EOjNIWUAAmJ17cDnNAHmd34WaK186e7t0bBxukUfngVb8OG3tTHG86NN6IqsvrjORVzX9aSa5kiMzvGc4ARdv69fxqnod1ZGZQ0sbc84tFZvw5AoA7WJr1p4t0cCRE4BKANjtg5PetS8W3twGWK15xuKKC35kDmse81KGDTt9v9qaRQOZESNR/wGsNNRF3gPIMAYP7v5h+OCKAOmuvsjMrT3CxcfKnnrnHtgcVi3E0l1IYYDcyKAB5aS4H596zIEmW6aW3UB+zEgY+ma27aOB7Qz6pqy2shO0KPmY/QDmgDIl0xINrXAijkY/LF5hLn8AM+9RvZPbR77fTUMzH5Wkk3fmueaiddOj1FvsjXEjkf6yVgo6f3Rn+dXrKayWVsyNJO2RksQPy60AZOoW5W1Jl2yXB6Z+VF/CuamghAzKylu5CEj/69dvqdn521BKJGP8AD90D3OP6msbUbe0tG28SXAGcDG0fgeT+NAHITCNCxPmnd1Y8Ej2FUpsso3KRGfuAjr/jV/U3dJWd8s2MgdSfwrIkuZS2ZPlOPqfwFAEUwIJjzHgZwOhzjrT2JRVQ4HfbjHP0/wAaiDDzd5yvp3Y/4VNFFJcHdHGBg8sf8aAPqvw2Wb9ke1KqrMd3D4wf9PNeUvJH5SMoe3cnLIeR+XevT9K2j9j2LedyjOSvP/MQNePW04hjDRTllHG1xkH/AD74oA7DSJobq3SG5dJtv3XQfOo+npW9bXUJRLOe6ITGEd2ymPr1X6V57DMgYTLE0GOQyH5c/wBK3ri6jmtQSoNyBkqSCceo9aAHa74PKO8lo8Uitz5TcE9Put3/AD/rWPpjXWmgiEyKv8SK5jde/Knhq6rRrq7jt1ez+zzRg7vKkPJ/A1omfRtcJh1tItMnPAkTBVeOnt+eOaAONawt9SQyXbortyZQu1gf9of/AFq57xFoMMULKjnP8Lggq34j613l94L1WAltJuYb60H3WSXDY+hwKz5rLVkU2t1YpIDxh05/BgcGgDyv+z4YYZI5eSBn7u4AZ9uRWXJbW/2jZEXUdM/5FepXvhO6A+0y6ZcopPDoDtH6f1qunhX7TMpQGNhwDMhUD/gWKAPMhprNPsBZyDxtIIqQ6fNHOAYWU+uCVr1VPBV7uZ47f7XIo+VonU1r2/h24hh2ag5i3f8APS3LkD3wMD9aAPJ7Xw7MWjLpnuMd66/Q/DLAD7VZS+Uw/vgD/Guwh0S0ihEcM8U3XKBHjOefatFPEF/bRm20yG3XYMbmRTjpxkr+lAFKPTPDunaUPPSYOOdjSA/4iucv3smObAw2+DnpuP8AL+lR6jqmoi9lS6S32nAxFCATgfTGKxbi5uhPjyQsX94xbf1oA7PSLNvJWWeGJ1HIYHYTx6AVbk17yJv9Et7cNH1IXc47YyQRWAl00toI4rgBj1/eED8eQKqR3KwTCOQRTuecpJuA/pQBv3PiHUHjeTzI1QHO2ScnPr8oxTV165vrYpNfRW5bjy4U2cfgM/zrktTvJEn8xBjHA2gDH40/SdelsrgS/wBnrKx6vNlgfwxQBv3C2MiMAk9zcAbndBhR9WIz3FM06302UBFt7i5uWySd3yIPrVbWvEdxqtsRcXnlg9LaJNij6+tM0/UrvyI1hkYRr8vyvtH9KANWbStJt9z3Ek8zj/lkpxj2ArNkW0kGUsnXb0jOf1PpWmutRWsI3lUlPLLEQXP+fesu/wBbJGLe3XcecffbP16UAc/qySKHaTZawk8KnUj2rnJgkjFI9wHYtxj61t6lehZ2kuIg0pAJLsMCuduLopMZVYO3YKOBQA4WiRyq8pPlrkDI+9TvNSUlnLFf4dp4rLupZLiTe4Yn3Oah/wBIUkR7sdeM/wBKAPS/iWxPxF8ThANy6pdcHkn963NY9veyKAqBkI67c1P8Rb+2m+JviyJ5THMmr3agScA/vnHB/wAcVnB5VjDAqzr2POfxoA2bfUZPtKGZGZh0kUbW6VrB1mlXKxBzyGYbSfY9jXKw3Rm4uVYA8AgdD9Kt295PCwhQZTsSDj9aAOp2yRptMEyEdDGC6H8MkitTSL8uURSyyrwuJOfpg81h6Vqksny3MW6L+/GcSLWzCtldkfaJSxHIYkJIPQHIwfwNAF64FlcyCLUtoc/d3/Ienr3qS30zT47nE63i2pIIaL59vqdw5H0rKv8ATvPVhDem4jXkxmPcw/DOfyqnBqh0pBFDPsIzmNlIAP0OCKAO5trDw5CUfT9Tlju2OCjSBCfqGUg/jUOraXYEh76N+OTdQhY259dpKmuIfXpJJSWmhgb+9gf4GrQv7xodwuobiLuBIMHn04FAHZ2mneH/ACla2v4LqXHC3JLHHP8Aj7Ux/wCz7abe1vYFozwY52X/AMdArgrnVZGmBjRA68YBGT+IqlPqbxymVmVCRzuYZ/XNAHpjeM5jGUilkZO8ZlWRfpyuT+dc5rXieG6haCS1EhIwzxAhl59ziuEOqNLM5Z1GQcYABP1xSi4s5Yz5l2kLnqMZoAr6pLaS3IMLuAe02KtaVeJbusbSyKh/iVgPyOOKyLkxJKHjPnjPXfj/AOvTC1u8qyeZ5bemWf8Ap/WgD0NdVcWwS0aOUf3nUufzA/rWfJcoz7p2mZ/7oBVR+tc/HqMcMARYZGHd2YgVTudQUxsVnj+b+BSSaANmW7gjZneRnk7KGOB+uaozXcImV0yZSc47D8TWJHehW2l1QnqWanS3mGUoIyAPvdc0Aa8l5cu+2JlLPwSorUtpp4bQLb+VBJ1Z3OWNcs+qynCo21F44bH8qSC/wxJiMz+u40AdpaXKrE3nagsecZYAs7/T0rB1LVQryJaQ7IjwZWPzt3+9/hWcbn9/i4aKFf4snJqpqF3FLlY33Dpu+6MUAQNKJHJGc+mMk1SnHlyfMQGHYAccUs0gUfI2M9MNjP0qt5wVyNm5vU80AS7lyAqkv6k1M1xO8ZQsNoGdoqpHdqjM5QMw9f4aglvixOBkk5welAH1jp2X/Yxj5APPOP8AqImvEbO6jUKsyFSB16q349q9cE0g/YZEquyyDoynBH/Ezr5x07xFJCR9o3Fu7pjn6r0/GgD0AXFukW5TKqDvGeB/hVm11EbxJHNFLt5VZI9rD6jofwrmra9i1BS1rPGWPVehP4fhTnfzroIpVW6bScYoA9S8P6jpkyhDffY5HP8Aq3XMZPse351ZvdOuRceYos7uA8HY4fP9a8whU20oVs7ieSr5B+oP/wBauhhurq1CTQFCoB5z1+uMGgDp7PU20p2SOO5tockH5g8YPrz9KuHXy4Z5HtpUIwC2FJP+8MiuM/ty4QnzrVfn6OkpU/41UmupRKzkPDk8kdD9SP8ACgDvrHxGwuCkst1COQNkwP4VeuPEvmApIXuE9JoVP6ivN4ppCxcLFMvfMganxai8BMUds4Vu+88fSgD0XTvFP2eIx20CMucnJVTn2Hf8qgu/FQLARxvaSg4LADHtzkD9K81uLh7WYOyR+YfuuCRj6ipRqd4G+dn29CV5X8jQB2snie6ZmDFJwf4ygz+lc1d6jdTSSD7WIjn5kyVUD2FYs1xk74XcyHqBwMfhVDUtR2R4liQt23zHP5ZoAt6jcsv7pJbeQkfwKxasrznFwjNI6bT/ABqcCqMuoRRuJGcb8f8ALPk0DVLfYSclz3zigDq4LpxCTC8jzY5IwRn8TVG7lcxs9yJHPqzEAVy/2/ZI0i5I7fNSjWpWBVkjGRwfegDR+1pjAZdg+9t5x+OafBNPOwFtISCMD5sgfjWFvimcm4Zmz/dxU9vLDA37sPt9zz+lAHSsY4UAup4w55IHJ/OoZNVcMIYXdkbAwqjA/HpWJLfBhgID9QBTJpZig2W+FI4xk5oA6uxns7Zg8kRnnzxGz8fkKfeavLcs8aCGHrlUUALXLWmpLZoQRmY9Qc4H8qq3NwsmWGeepU4oA0tWdI42JdGYc+5NYbTttyFAB79abJOFUbEA54JPWoWmYqTlWf2oAsSz/uyyqM9gBVYFm5OFz7VDcOEXO8GX0XotR/bHHAVfqeTQB0PxY/5Kn4y/7DV7/wCj3rn7LULi0YeW5KdCjcqfwrsPjVNYv8SfEcNhA6NHqt6Z5ZMbpJDO+cY/hGAB+NYlnD4ZW2Vr661aSYrytvDGoU/Vm5H4U7EuVlexJaa7HnmPyH9QcrW9YajHcAFpUKk9FOKxrS08KXl4jyalf6fb5G+GWESMBjna69efVR1qxcWngyB1EWo6vKySNE5jRAGAxiUZ6KecLyeOcd3yk+1W1n9xttcSMPlk46Bs5xTra9lhJEj5zgn5jg1m2raBHub/AISOdlQ7Aktj8zH+8CG+7168+xrRS58JmNA2u3iXJJBkS2zEuMEHaTnBBx9Qe2MnKL2q7P7mbP8AaiBlMkSsRjEkZKOv9KZqd480JljeVuPuyIWz+NJp02i3AtVtfERWS4U7VmiX5GBwfMwx2gnkYzgcmtP/AIlmnqsTTR6rK5O9o5PLjTngL0LH8h0xRyh7VdEcib1C37+Axf7ak/1q3bAXAWK0uo5ZmIVYwp3MSeBj3rXu9H0W8QyHVLmx3NnypYhIF9cMpyencDrTtD0S207UItViv7S6tLdJGVsiOQuFYKu088t0PoM8UKISqpJ9zHto5lllS9tsNG211OUZT6EVQ1J403GFkz/d35Nbmo2B1WG21M31tbzNHtu2uZSrb1O0EL945XaeM55+lZl3ZaJp+5Ly/vLubAJOnxgxjJ6bmIzxjpSsCq3Wu5htdMLfMkahuzD5arxXPnTHzzGYwMfM2K2BZaHejOnandWsoxvjvUChl5yQykjI9D15xngVp60vgnTrUf2dBf6lKrB94l8sFWzlTlTkjjoB169afKDq9EmcdJMI2cwsgA5GcH9ah+3NHH8jrz1C8Ec109lb+FNTssG4vNIvNw5nkWWLYCMnhM7iM8YxSXeieEoYEmTxJLcHf80cVuRIV4xgHAB+9k/T8TlD2yvZp/cc/Hc3M0OWdzEBn5sYpjXAQgIB74H9a6AaR4de0SK28SyyXTghfMg2RA54DEnI+vOPpVu+svCmg275uX169LBfJhcxxqpHXcBycgdPWjlD2y2Sf3HJN+8XIRVB79TTol2Dg717jkCthF0DUFAW6v8ARzyWjkj+0IOeilcN+Y/Gr2meHdPMkD2ut2MscciC4aQmIoOSSu4DI4IGB/8AXOUbqpLUx9X0m50q88nU0+zXG0P5RweD0xjiq66g0eVyAgGAFUD8a7LVbePxjNfyWrodShun8hJJNhmtmLMNuTyQeceh+lY17aeFdL3JPrVzqEoyAtjCoCHJzkucEHjp6H2ocexMaunvbnNyOJGL7CPU54qMSIjbldSR0HH9a3mj8I3t+Le31TVrKFhxPdxLIgOOAQhz1xzj/Gq0sGgaOx/tCX+2LvfkR2c223CYGNzAAluSflPYA96VivaeTuYDyksJHYEkcZOaiknBOVXn1P8AhXUtF4N1Ga4EUmoaV1EJciWPA/iYY3AnH3QTyeuKhfRfDYSOX/hJGEMoAVPshaWNsc71BwAOOQTnPHQmnyi9quqf3HKUVLcpHHPIkMoliViFk2ldw7HB6VFUmp9baRp1xq37E0FjZKGnmJAycAAamSST6AAn8K+br3wN4ls0LzaPc+WM/MgDjggdj719ERyPH+wsWjdkJBXKnBwdTII+hBI/GvnDSPFmt6QYvsOoTIsecITuXnnkHrzzTVupnPn+xYxzDPDctHskSeNiCuCGUg/oQa2NKfWpwr2tlcXqYJBELPkDryB2yPzrOGp3i6lJqENxJDdu7OZIm2HLdcY+tbZ8d+IzDHF/aTgRzLOpVVU7xnrgcjnkHINNW6jk59Eidr+48qNr2xurbcMpI0bBCvrnHpW3pc895HHFbz7pG5VQW3N34rlIPGHiCAsY9Wu8s/mEtIWy34/y6VaHjzxGs/nLqLK4YMuEXC47DjgcdOnX1NGgr1OyOxZruJvIvLHzGC7+hVgucZOO3vUE0U5vQkVnPHLu2+WwZjn6da5u0+IniW3khZtQedYt2Emyytn+96+2elbNl8U9QS2Ed1AjTjgXagGdRg5UMecfjn3o0Fep2X3mvrmj6laxb7mwm2d2twrhef4tvT8azk1ImERzMSB/eyG/H/8AXTNL8V2auJbXUrjT7ojBZgR9fmX+tdGdfur+RD/aWk6krFg0U6xnfnqOOT29OgpaB+8XZkcVhFJ4bivISX1GbzJI4t2QYkOG7ZJ6njsDWAPNuZlDWuSxwCHzn8K6CT7cL+0ubW1gjS2jMUdvCuYihzuBy2Tncc1FdaprEMUkdppdnZADassUOHTjBIcknJHH/wBfmqumTH2i3MS80m8hV5Es5AQCdwiYgD34rLtNG1DVJnFpayTS7gjYBCqxzjJPToevXFa76x4ljy0V3f7/AHlY/wBasjxD4iNvIFK28k4IneG3VGlPqxx19/r6mloU3UtokYkPhPXUkczaReAgMTiLOAOtVJ9Me2ungexvftSsFaNoiGDemOueRVi6TW/tX21prn7UjiRZS53Bh0Oc9atr468UWpVPPi3g5ZngRi7AfeZiMluOvWj3RP2q2sznTLcSLGos28tiQhKE5I6gevUUq21zKwXypZJSQPL2knJ4Hy+ta0XjrxLHcySLf7Wc527Vwn+6v8P4etXrPxzrkdu6t5Esp2g3UsIeYAElRuPXBJIJzj8qNB81RdF9/wDwDOk8L63DEjy6bOYSN3yLvYAjuoyR+VZShd+3Y6gHpyD78VYn1m7bUZL/AM+ZLxmLtKH2nJ5J46VqxeOdUEa+beWrsF2bpoUkYrnkEkEkevqBRZDvNdEaXhzRtPvtC1CeeKUXkkqW1ifM2gSlXYD3ztA5/vCuQvZLyNnhYyKUJDg/eBHUfhWtr3jU3sCQWdtb2cSSi4CW0e395j7xOecdqmufiHPHEZ9ItILPU7lma9l8sMrnnBUHOM5JPHU0aEL2ibdt/wADIi0bWWiYJpd9uOAzfZ34547cVlPDNHN5RikFwTsEZU7ic4wB69qsy+KdekMhbWNQPmDDf6Q/I9OvSr0fjjWhp0VrNJb3JgObe4uIVkmg5z8rnnv3zjtjFGhd6nZCf8Itr5sjcf2PclEBJH8YHTlPvDnnp056c1h3dre27tHc208LKAWV4ypAPTIPrTl1W/V2cXlwXZ1kYmQkllBCk+4BOK24PHWvxlBJeC4jVSjxzoHWUE5w4P3vTJ5A4GKNBfvF2ZzLKyEblIyMjIxkU2tfVvEeq6vbiDUbszxK5kVSijafYgcD26CsipZor9Tq/ix/yVPxl/2Gr3/0e9cpXV/Fj/kqfjL/ALDV7/6PeuUoGFFFFABRRRQAVPFd3EQAjnkUDoAxxUFFAG7YeKL+zCgLbzBRj97HnP1xjNbkHj1GXbeaNaMT1eE7D+HB9q4aigDvR4t0WdlNxptwgPB2sGx+ozVj+3fDVwhVvOhUDHMbDPX0J/WvOqKAOzuZdBlJe2vXQjHEinn9KjiurKMAf2lAB7QsSfrwP61yFFAHVT6hah/luonXv+6IJrFvLmGSYmOMKueTWfRQBeW5iVAPnLeuBip01NBEqmJvcKQB/WsqigC698xk3Iir7Ek0f2lc87GWMkYyigH8+tUqKAJ47q4juBPHPKk4ziRXIYcY61BRRQAUUUUAFFFFABRRRQB9Vf8ANif+f+gpXyrX1V/zYn/n/oKV8q0AFFFFABRRRQAUUUUAFFFFAE0NxPAQYZpIyOhRiMflVyPXdViTamo3YX081jWbRQBu/wDCW65/0EJP++V/wp8vi7V5Rh54zxjJiXP8q5+igDWk1/UJM75EOevyCq76pduCDJjPoBVGigCUzykk72ye44pGmlZdrSOR6ZqOigBaSiigAooooAKKKKACiiigAooooA6v4sf8lT8Zf9hq9/8AR71ylFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB9Vf82J/wCf+gpXyrRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four chamber view of a transthoracic echocardiogram show a large right atrium (RAA), due to atrialization of the right ventricle (RV) and a large sail-like tricuspid valve (TV). A vestigal septal leaflet can be seen (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1202=[""].join("\n");
var outline_f1_11_1202=null;
var title_f1_11_1203="Diffuse episcleritis";
var content_f1_11_1203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76962%7ERHEUM%2F67740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76962%7ERHEUM%2F67740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse episcleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 214px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADWAVYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzDX9fub+4YK2I6xGj8/gn5vWn20LPx1NSyQlOV4IrwlaCtE+8UL6FON9mYn+8OlOlt2eHzk6ipJ1EsBKKBIOppuk3IaXyZOp7VpfTmRna0lGXXYt6fEt3GDnDitS0snMbhzkdqz5YGsrgTxf6r+IV2Xh+KLVNnknr1rCWusdmVKfKrT0aPP7uKbTtTjlT7ua7q1uXlNtcZzng1N4t8PLAjAgFgMg1H4G0e7v7aTewAQ8Ke9acrqLzRwVKkIO99GdjfwW7WURtyN7LzWj4F0PSRHcfbITJdNyrE9K5e4umtpjDKhBTitHQ9Rfz/kyvvU87TtYiVLmp7mP4ttSdQSGPjMmB+ddb4e0y306CRi+bhl6n6Vi6tCbm+En8QOQa0g7RxqWJz3rOLsbTg5JK5zmradJeapDJKSY4n3Y9ea3Jrma/CK2AIhgCrmE27sDJqlhklJCjmk+xtHXXqdD4ZkNrL50jfMn3adrWpXN9ceZLJmse0mYMdxIpZnZpdq/jScrLQmNH3+Zk1zK867c9KoedcbigbgVcT5WBXk96ZHHid2I4qldxNVaOhmSRXCEyK31rU0e5JJMgyAMYp1/LbiBQmc981VsZY1lxkDNRZbGrbnC7RptukY7Cc9qQzOIyrHk0qXiQK3Cnd3NMhInDHp6Voo6GGu/Q2rS+dLARhsEVuaVdboiJ5OMcHFce5wg54qw+oztGsa7RgYGBTRhOjzbC6pcN9saGGQsmadFI+FXdjHeqVkqvKzyt82easShkDMD8orRaDlG3uj5Gbeyu26rul6vLazoIZDEqn9KxjcFVLHoarrMS5YYxRzLcl0nJWZteKbqS+VxHLvjY5/GuKe2dJB5yBlByDXRx/NjNRXcaSDB61LalqVT/AHa5UZNpd2zzlLiNQhOM46V0/wDZVhZ26Jf4ubeRdyMO1cvJp+JDtUFW9a6V7lX0BLbH72JcCrpyd3czrw25TgvE2jvqWrxJp06xIgHQVU1fQ/EFlCjkwXNuPQYNa9nqFxp2pfajbrMo4ZDT/Enir7ba/wCi2bp229hVwmne6LqRnFxjF6Hm2uR3LKrnTWGByQawTrFpaMFubN1b3r1LQrjWL2C4it9Njm3oQu8j5fevO/ENnewXWdZslZkPGyt6cU43aOadacZcsH95a/4TDS4bDFnaATepWsWfxe8w3zRZftxxXR6HLp95ats0+FGQdHAyawtVW31K48sWsdsE4+QdatU4btGDq1b2i0Yl1rkl46tdnKqeEFdDpHi/7OgSC35HoKRfCKNbLNbbpMfe3DAqJlt7BxEUXzD0AonGm1axdB1k23Kxd1Lx5fmExxJtB9qwtPuNX166MSSnrWsmkG8dd+1dx4Ga7jwvo1jo8gZ2jViO5qG4QVorUvlqzl70tDynxf4fuNGa3Ny+5pRmiu2+MktnNFpzQSq75OcdhRXVRlJwTZ42LjFVXylW2V4UY47U0SZJ8xcUxJpYSBKMoe9aVqYJwOQc9q8iTtq0fZQjbVMz1EZlXYwweopt5o7CZZ7YYcdcV0MekWchBOVb2NSyaTPER9nl3KOgJqIz1vFkVZqS5JINNsje2uGQ5xhhVzwvYXGma0pjJ8gnkHtUVmNWtiSkOV74rZ0W6mkuP3sez1JFVF8j9TjqtzjaT2Oi19Y7yYYAIxWPFcnSLiHZ8ilgCRVi8uZBMNqfuvUVFcxpdRggBqTm07oyjTTios6vxNo0SW1veqFdZk3Zp3hOXSIrW4+2qolA+QYrn7W6uDbpBPIzovCgnpSvbopyp5NKU9boI0W6fJNj2lVriRgBjcdtRXDttJbpSwx5YhecVPPHm2OcZHNZJtnckotECMwjG489qtx/MoCjOetU4Z0nKrj514NaMLxxJxwRTaexUlboW7aGJrebeQrIPlBHWs6NHLMe3rVi5uotgx1rJN4+WAbAp2SQqUJSuyxdXXkDavJqul/Imc81Slm3Pyc5pm2ZvuIzD2FTzPZHZGlFL3iee4eRsseKrSTEHctTjTdRkA/0Ztp6Ui6TegOZEAVeuTStLexpGdJacyGpd70wxNXre9EcYBYg1Qm0+a2h8yTYqHkEmo4rS5nZVhAkYjOAapSewnGnJXT0NQ3jn+P5SelWlfcgYS4J7ViS2l9bOBPA4B6YFAmYH51ZfwpqViXSi9Ys6u1icBXQb8+lWVk/dSCUkH0NctbatJbKAkmCOlTyasZUO8gsfStOZM5ZYedy3M4M4QNkDtU0CqVbmsVbgbuvJrSs33R8kZpXHUp2RbCykgJ34FWLy1msmRbkbXK7sH0qGG5VRjPTpUV9dyzTB5pDIQMAk9qajpc52pOVkSRYkkA7d6siMq7MoyKo2O/Oe561eMgUdeaqMjOrFp2Mi5sme4LxjA9PWoZ0WGM/ugc9Riuht08xdy81BeW25SSK0tbYz9pfRlDw5qUPmMsBWGRAdwPGRXO+KptP84yTspbP3eua2JtMiZ/MwRJ0yvFZ19oFrcxncjF/7xPStE7xsyFFRnzI5N9Jvb3UrK7sNNzYhhuVRjf61seJ7W4mlP2DQFg2rjkVZtm1nS7cW1jdp5YOVDDkVSv/ABDrT6gF1K5SBDgFgK1U1axzypyUuZHPtp+tpaMl1KttCTkp0NTpZafNFHBawGSUjDStzg12H9hJc2n2m6uGnZuV+bgis5podJuI45oSsB/jVc1nOdnyo1ppNXZDp3g2GMg3ckgzypDdKi1Lw/FHIuySWTnGN+a3rvxPpRiWJbhdzcD2qextvKtmu7jBhfhXzxUpS6l06ij70jz74kaPbQaRYNGmH8zBP/AaKk+INzNe+THbRs0KOTuA6nFFdVObUbHn16SnNyKc1lNEcqu+P0pEto2wQGjeujt4ywAxkntWxY6duTMkIP4V5EavNofQ1HyLU5G3tdQYqtu6vk4FaH2TWrO4AdUYYz1rqxaJGR5SBfpTpYpIWDtl17iq5ujRy87vdPQXSNeFvpb293anz2/iC5qBLmGU/KCPqKWGVWuMhcKexFXHjiYEqoB+lRKetmKNJR1XUdtVoQB0quuE+VBU0ecYFSJGoOcVDdzWKsMhifOcVYVcDcanjZTgcU+QJ8uBxVR1E3qRW0IxnoM025lREIY5pJJQgI3YFZ1yzuRhSQxxnFU7RNYQcnqJGVRmcYGacJnkOEyTmrWnaejn9+ec/dp0VpdefPHZIoy2Q57Cs3Usza8dddu4kekX91g7Qin1NaVv4XA+adtx64Bqja6jd2Nz9nvpMEH5SeARXS2+t2L/ACpcIWxzzWseR6s48RUxMNI7eRlX2l2tuitHGFYHnPOa0NMihDKoQYxzx3qS8uLa6t2KMr47j1rHFwgWNlk2Ofet4xUdUcvNOpHlle5vXdwInI3cKOgrlL66ubu5ENupy5OQeKsXGtWaQyfv1aUda5yDU5GuGliZjKfuqBWblfVnVhcNKN3y/edTHpsHlBNSy8h6AdBUsV1pNojGQ7AnG5OK51dO1O6Xz5nfeevOMCnxeG7i4O6ME+xOQTWbct0dKpU9qlT7jf8A7WsbgE/aG2j7u4dao3mrWAtwjQljnqF5+taem6JA8CGWEeYvB44Fb0Gi24gGYYzJ2JAq4xclqzllWoUnon95x0kGky2LHjzCMjB5rDuLWAxD7Pu808YruNZ0yO1R5fJSPaOuOK5HQYbi3vZL+SLzLfJ+U9venyWeux00a3NByjJ/N/gVJdKuYIRI/BxkiovNljT5Q31FemwW0F5aQ3QAKSjOGrL1axhVgsEar/e44roWGjNXizlWaST5ZxucOl03UtzVyC4VwPmyfek1nTZTzbx4B/i9axJBcWR/eqSR6VnKhOK01OuGLo1N3ZncW0iLB8p5NRStnBz9a5ax1dWYKZMH0Nay3QkI5qY+ZMqVndM6W1kVIjtp8soKDcRzWXBMAoGeKY7lmAB4qk2cbppyNBggUng1TA35K9DUdwxiUZPFNsJid3OFJqlPoHs2lcz7iBlud23IFcz4mNuC73SFoyOe9eisiOvAFUbrSrecHzY1ZT1BFHJrcSqLqeTWGsT6eQsF4WtW+6rnpXW6X4hs2njOobDGOckZFS6r4L069UgxmIdsGs1/hlbPYOYZ5Cf97gVtJRdtTBy5FsaPieTwPq1mVs42/tNjwsQwKydP8E+I7vQpY01Bkj3fu4mftiufuPBmp6OFezeOWTd8uDzU1xP47trQAPiN+AVNdCdtmcUo6aHN682v+HmFpeSoQGOCDmin/wDCMa1rLtPfT7mz/E3eiq5qa3DkrPVHeaVdQWrqzzq7e9dRBrMBg2RyIM1ysEGnS5YWspA9BWpYabZzICsDpk9DXhKCTuj26rT3N2GZGUEOpPtViRPMQc1nx2UcJHlAj2rQh4QAnmk53IULalJrcGUBeMUjJKoIWtCJFaT3qd7YNz3rJJyN/aKOjM+zjmOA351JLFL5m3171pxxBYgeBVS6nVG+U5aulQtHUzVRylohgUQrljUL3paRY0HXjNVriWRycjkc4qtG0mQ2MAHNZ8yT5UdMaV1zM6e20lHUPK25uuKbqEKALsUKIjnj1qO1v5I4wXOFAqu0sjOqbgxmfNOortaHPT57tyZqzWZniWSBsOo7UljdPaoy3ERD+o6Vo6XubcZAFA4+tWriBJIWBANONN/EjklXSfJLVHOa1po1SNZ5k2qPukGoLPSLWFmjYDA5zV1LmSS1kh4PlNj8K5/VtSlM2y2H1I7VpCMG22dMHWkvZp2SKt/qq6ZdXES87jhcdKyptRVwrSz4HoKvhLaQfMvnTHkk9qptYNLHPKtsWC9OKalyq0dj0qcKe81qW7TTIHia4ZJGVhwcdatr4emW1W4gZkbOc45FN8N3EtvbZkxJGv8ACe1dPpfiCzlk8q4jMIbgHsanmT0ZjXqVoSfIrpGMEvI1jji1EPuHzBuNtSQa7c6YwiuNjoeA6GrF9pbJdte2q+bAeqilNra3sBlt4gHj6xHrWc3JdNBQlSklza3/ADNrTL21nCyWs+JjyysetbsV4hRVJPmDk+lca2iyXMK3GmOsUyjlR/WpobbWZrfCTJvGQR3rSm2/hOKtRpy15vvL3iLVRd4skZS8jAEA9BWsmmWp0aNUP78YDKOmKy9I8MoYZJ5pS9wR1PY0+3uZYoyskvKnAz3rsijkqcvLyUnsZGtQ3VksbWBfMRyI8/LUul6414JLbUY0iuSM8HqKlN5cXVw8WEV/X1rA8R6ZeLKLqIjzFH3geatKz5oDcozXs6tr9GaOoXkhV4YwHVe9c9eTCbcnl/N3J7VVs9cdA0Fwp80cMfWlv3KSpLDwG+8D3rb2icdDlnTdOXLJHMarZSreeZHlc+lLaane2hUSDeB1zW3IDO6tsG3p9KcLOORTuALVhKHM9TSONlSVkyS18QwOyq77T/tcVqJfo+CjBhXKX+lIq8VkNeXmmsCjb4xzg0p0P5TehmEZaVEd/c3kkoUAfL61csnGOelcvpetWOpWoCz+XdD/AJZPwT9K04Lto+CK55RlF6noxlCrH3DdFwwPDcVegnV4/mrl2uJZW/dAAe9WYJp4gFYEitIOxjOhdG9cbXRsYzWHcahc2NvIIBknqp71eiuSBkjNRXFsLiNj0zVyXNqjnUUtJbHNjW7XUWMe8QTIuWVzjn2qjp+p3umO63EZvLHPUHJWpNb0FJHMiALMvQjjd7VhQXHkSNb/AGlrOQjG2T7rfSla+24SirWZev8AV44ZTJpTB45Dlkz900VzGoeGdYE7T2UysJTk7TxRWqhfqjL2jjo4s9RbTXhUvaMFPdT0qW1a5ix5sGfdasLKztgDCVbTBUCvHctTud2rMiUhskjFTRIzDPanpb5NWUVVXbQo3YOVthkMO07l61O52DJPNHKxkgc1ga1rAtIgGYeYeAtdCioIIQlVlaJdu78qCCwz6VkNM7Shi2BVWCYz5aRskjNKWy6qoyTUuV0dcaSg7Elzcu06hWBHSnGbIKE4YU94443TAG7uKspBCAWlxz61Cg27op1YqKViompvJH5TEAjitHT2L3queVjHA96yWtA9y4ixnqMVbsZZLeZklDDcfvGrjKz94VWMXF+zO30q5DIRIAMHj3q5d3SRRs2eADXJvqCRQFkkG5axb3X7i9PlRthBwWrsdlG6PIhg51Z36BLq0zSTCB/mkY59qS1jkcFERnZjy2O9VdHNoYpWmYmXdjB6Zrq/DzK1n8iABTywHNc0IX0Z6+ImqCfKisvh+KKJDJIBKeW9q1Ioo4bURW6GQEHJxWheWds1uJYzuY85JqSM7LZSVUAjjFaz00PIeIlNXbucJc6beWwkkgysJOSAO1OuIHntYZYYjheM11V9cxJAYkmXzGGQvvVjRdLiW1USZzJ8zA9jXG0ublR6KxjUOea1uYem6pe2kBjjiLxjqpqO4njnHmW3+jzt1J4FdW2lCPfLbnBAxgjg1zF3YTpcMrQtlssoTpQ02rIKVWnOTktGX9Jv5LW3cywMV/ikXoa6rTY42iiljK5POT71h2VpLDpIjk+ZH6+1WNJ1WGK2FpOm1lJCP61tTjZHDiffu4F29upYJ2jtigZuoJrmpvtAkZzImwHJA9al113DtcxsQBwSKqxXMLAHcdpHIPrW0Xd2IjHkhzIgvL+VCsilZGH3lXrWbf6pqEpwtuwiPHNXL5oopfNiBJ/iHpWRd3ru4ZSCuecdRWiTXUylKL1UblFo4LmZzcx+W2asPGHKrGcqB3odROwMg47nvT4Y1iOCenStIJnHXq36jWjWIdDjrVSabbypx7ir80gKe9ZMrYdgB8p5rdaHDfmGvPv4Zsj3qle2YuY28pS2ByBRPkPuBx6Gs2+1KSzVnSTDDuKiTu7HRTTSuYl5am3cOhKOvIPQin2njGezkEd2omj7t3qudeXU7wRXSoRtOWHB4rmNWWP7SfssheJumeorsWG5o+8ZrHShL3HZnrmieKtLvF/16xv/AHXODXUx6hGIwSQ6EcMtfMzFkbIJBHoa6PRPGF7YBIpm8yHPc8iuWphHH4T06OZwqO1XTzPd1vY5VKowya0reVQigkV5zpOvWmoKDBKu/wBM10djqZjBWUjHTJrmd1oehOClG8dTX1ApIxwo965LX9Gtb9fnXEi9GHUV06TC4GVZKz70YJ2jkdapLqZL+VnAm/1fQn8qSTdbkYj3UVo6vvkl2upKg5HFFdMMU4K1l9yf5on6tP7L0PRI0K9RzVy1Q5561Gqnbz1qzaxsp3t0rwoQudU5FoIQmSMVWcgHINPubvCkBhiuX17WEtkdYZAZscDNbaIdGjKo7IvaprIt1ZFYGT0rlLxxfybp+W7VnRzSSkvISXbkk1I7FI2YHkChpyPXpUFRem47T5ZY7h4lJIXkVsw3gLAOuCO5rmtJlbLkH5mPWrF5NIsiYPNNU9Ll14c9XlaN64uB9sjfd+HtVy5kSZUYn5a5IXDmRt2c4x9KuJdP5AXJPpWkIW1OerReluh19iLaBhLuG7HrU11dQiWOUMpHQ1xP2iQY3Mee1WlDSwMVY8c4rdwTRxOg1K8mXfENyspVIcKT1IrIhOxHCS8DqfU02eVnZUJG7GK34dKtBoyyt9/jOfWueq9fdPQpctCEVLqauhaV9pgGyMBOpc9zXV28MdjDtVDyPmIqvp0CppsJtz5bbelMs5bq6lljeQLs4+tTzNK1jxK83Wk3fRF9LdHjUo5UD1qrMbm3coTvizxite0VFjAdTwMGoZE3MyowCjkA0TWljmpz95nO6SI21mQyhUXH8Xauxto45WwrjI5JFYUlnBIrOIB5vqO9TWSXKNHIEVVUAbT3rns46HTVare8nY25nIcxo4PvUNnu+1ys6bsDGfamtcIpZhFiQkZA6VaQS24bzo8GQAqa0i767HK4uKsUTcJAZYZcxgnK571zeoIwspXCttySPb3rq79kuYGRkBbGM+9ZF/BcNZeWE2kDGR3FVZs2o1VHcrpLbPpUaJIrKQNwJ6VQurSMxlLcKSRlWz0qvJpiFY5F3BSMNg8ZpphntEZZYyVA+V1NbU076oms4r4JFVmmthmVPMBOGJ7Vl36xz3mLUYDLnj1q9O7s3LExsOvfNUViaORpFyMdzW6V9DinO2vUkRSgUsDkcGlkcMKfNOGQAYxVOUgtwcV0QSR5tSTkV55HRvl6ehqBMzzRx5Cl2C59M1PKFx1rD1O8S2BO8AjpzVunJ7CjNLc63xf4OvNJh3RSrc4jEjLF8xAP0rx7xA95s+aKRIjxllIzX0t+zLPBq51g3hFxLtC4k5+XNen+Jfh/oerm2SXToDArEugXrXRCMIP3lqc1StUtZao/PKaN4yOoOOtQnCYLHJJ5FfX3x6+HnhnQvCjXunaZDbsqldyDv2r4+kBGM10aNXREJXbT6Fie3aBhvBIcZUjmqh68irdteeTEVK7mz8pPaq0rGRyzdTSla2habH21zLbSiSCRkYdwa63R/F8+4R3jcdN1cXRWM6cZ7nVQxVSg/denY9nsdZEgDQzD8DWhHqgkTDMN2a8Usr6e1bMTke2a6XTNfDnEzBGrllQtsevRx0KnxaM9FFwjMd4DDtRXPWt8GTIcGisHBncqitue1xxqE3P1qreXiopCnFN1SaRZNqDj2rltd1MQxukfMuOvpXnXeyOmhQ52mytrGuvFI8UDAt61y++SeZpJGJY9SaTl2LE5PWmo21iPWi1j6CjTjBWiXgwVB64pk85aEj14pMBgAD2qKSQL8vHStE0TGGpcs7cCIeUQT3Ip80W2RdxqHRp1RMe/NaM8ayPuzxT3RjUbhU1KdptaV/NHfirUDp80RHAPBrPJdZCy9AanklZdskYOD1pxd0KrDXQuW0UbTMH5x0p3mYZwmAMVFaRNcTB0yKbcWU7XGE+VT15rSMrbnLJJvVmc7HzjLkkqamGtTbFjzlFP3au3lkILYhRyRya5poyJD2waxklc9HD8taN30PQ9J168eBo2YblHCk4rM/tm/F+7JKQqt8xBrHjldirIRuxgmtW0s3NrmIKWJy2e9Zz7mP1elTbbS1O3t/E0kFqreZHIpHU9aqnxI884dNgx1B4zWDp+kSEl5Yfk7DqBWr/Zi3kIQJHgcZxj9aHNyR5zw+HpyZq6ZrwkuPLL4wcnHNbb6qt0RFbSBB3LcZrgXtG0y4jlsE2zocOD/EKllur4N9oliTygeQBzUXbHLBU5NSgejRPMibfkOcEmrFxrDsVWYDaowCK4yC/hkhjaC5IlxyGPArTgkjmgVix92J4Jq0n1POqUFF3kbE0khkDmIshGRT5pf3QcPz6Gi0dDEpaQjsfpVK/kFwHij+bByCK1S6nFJ3duxFNJbxW7RyjYDndntmsK7u2yUDbouxHpXSXTQR2RFzD5jFerc1yO1EMjodqf3fSt4t7GDs7srOFMwVZCF68025CpGQrcnsaa4RSZA2c+tULifLE10xVkcdSV2PMgIweMVVmkK55prvkH3qncMRkZpPQmCuRXdyyIea4XXrp5brG7I9K3tZuikTZPauIaZpJyzHnNdWFb1bM8UlGyW59I/skzMNW1NBDlWjGXx05r6au9x2InBJ614D+yRb7dO1W4OPmIX9a+hD1H6VVTWTOOK908d/aklRPh26ufvOMV8MzCvr39rvW4E0ez0tJh5xO90Hp2r5BlrePwpCj8TZEakKqI8sTu9KYOoqSdgcYpmhHtO3OOKbTi7FdpPAptSxijrUoHpUQ61ZiQEc1LLiWbTUp7ZSoJI96KiAV+MdKKhxR0xrTSsmfUniS5jsrV5cgyHhRXmGoXDSSOzHO7k1q63dzzufNbdgcCubd8sd3rXhLU+8wdD2cbt3YiyhG29jUsUW8FgeKz52O7I4q1ZPv+UHk03E9HZXRcjkCgq3VaZEqSyNkZBpi2zSSZLY55FacNssaYx8p71nsKU1DYoRKI5GCDAxVlludq5baDU0VmrsyknjkHNX4Y0lh2H7w6GkpGdWtHcxxM6TeW65LccVs2FspjxL8pHQUxLUGRSR86mrskLyMNo6dxVX6I5K1ZPbQhiuEtVKsD14xUkF1FPlRwc9TUyWCiNnd8svIrOFq0842LtI6EUXaRzpU6jbuSahKTBg8k9BWIVSKYErvz1rWuoJY0/eHBxgYqjp/l5f7RkOegxUrud9BqENNizY6PPdWkk8A6HIA60kUl7ESsEZZl4NbOi362EjwnOxuee1WVMU2o4hyofr2zUuVxSrSUnzq66Gl4USOOxSWW+ZruVtr27KcKPXNaMqPp0hidRLBLyMdQayIbWYzlPL+VPm4Na1tc+fcEE/vEG0I1NPmR49bWbmtU9/0Ks0DRyxGVw6n7pHarzaaJLYsJkAPr1pqII7qMMm7/AGc9DWlf6f5yRtHhWYc4NQo31B17WV7GGvhrdGsxQkk9jjIrdSyKaYoZdqA4296n0yZ2jIkI3RDaOatXOTHGHdSrcgit4w03OSviakpWl0IJ1Kwp5YHAxj1rOiY2zlz8zf3R2q3czsGEYww9aquqqzbz83WtFHVWOOVRpO42S4a4Hlu2FHPIrEveHOwcDj61fupNgbYysTxgjpWJNIwY/NhvSuqPY4n3RDfyIYfLxismTco4OR7067Z/OI35/ComLHGT+FW5GXL5iSMQPmqhdy4U4q3MxAweayr87UJJxUSlc0pQszlPEd0+8ovINc2JMNV/XpS1ycGshmGRivSpK0UcFd3mz6e/ZW8TLpUV7aXaEW0zZWTHQ5r6Z0/U7TUmcWkocp19q+FvhF8R7Pwm01tq1l9ptZejLwVNe1/D74veGLOXUb25uWhiYfJCRk1c4RautziUqinZrQ8m/aYW6tfHc8F3KZCQHXPYHpXjDnJrv/jV4yi8beNJ9UtlKwbFjQH0FeenrVXubU42QClJptFTc0CiiikA5Rk1aiXsKqoMmtK2UVMnY0grj44Qq8jrRWisAKDiiuZ1DsVJ20PR9UuFLnHpWO8YfLAGtG6R5AHC81TkLKpGMeoryoan6AlyxsjIujh8U61YxTI5HAovUQTfI273pwUlAFHFaM6IK61NyJlaVWGMEVZG7GwnHPSsa2ldCit0FajSEkP3Fc8omc42ZdUiHbkZ9cVOq5lVkU7DWVLcEMGxkelaGl6nGE2ONpz3o5Tkqwko8yVzUMeVGAVPrUhLQRhV5Jqs148zhIFyvc1et/LRgZTmTtVxXU82pdJc33FKeSXhVQjPBz2q9psGFfOCR3qxfCMpvBUcc0Wl5AUIC8+1NL3tTGVRuHuorahYloCzHJ6j2rHv9IuBbpOo3EHggV0k1yj2zBhgVPok0bgxynKD1pVI22NsPialJX7GXpFgl1IGvNnI24U/rVnUtFktU8y0fdt6g+lF8qWd8ZEBWPHG3pnNboeO4tElUlgV6CsUrourXnGSmn7rOV07WblZCqrk9CSOlalpKGl3XYCF+VlU9KpXMUNrOrRoW3vgqOtSXUSmFvLDMTyFNJG1RQk7xVrmhZX6efIHDu4OEIHWrqasXbyZ4JI4l4Z/SqmmedIkcjAQlPurtrZtLizeKWO7flz8xPAppnJUUU/huSM9s1soiD+m4d6a7RW6qWJPbbuziobfTrR1fZdsQD8oDcCnGOGDKsQ7HvnOa0iru7OafKtE2xkgYsrKSoPQelQXl0643KDj+IVLv+YLOSq9sVn38ylnWP7oHWtk7HLNcztYhnKyxmRiVz+FZM+5kbvjofWprq5Zo/J4IPf0qtKZViOCMAdPWuiDucdSPKjKlciQ5FN3cZIOaJJCznKHNKrAoCPyqZyu9CYq26K8z46Cs3UTviIx2rUkKkkCqF4AY2HtUwVpaluScdDzPXDi7ZfSsotzWz4ii2XLNWIa9iDTWh5U01LUXNBP0puaSqJFJzSUUUXAKKKKQBRRTkG5gKAJYEya1LWE5z2qC3t84wK2LWBlXkHFZVJWR0U4pk0TbUwRRTXPNFYcrepvzpaI9Et5A0fPT0qndQhi5wapNNJBznp2pn2ppXA3da8+LSWp966Ur3iZcv7u4IxxmpRNsG0CtMxQEv58e4MuAQehrEcvC2yVSPrVOJrTqpuzLscwZQOhqWCdwxUnIqjEyM3XBqdU+YEfnWTRvzJo14SpUEnJqZ415IXrWbE5Dhc8VqRvvUqcfnWTuc1SXKye1822KiEkq3PNbVtdRNzKuGrN0wh42jY/MvQ1Yhj2EhsMvrVxdnqediHGd09zoYhBfW/OMjjioEVUZkZVBHQgVgs8llckwMdh5xmln1J57qOP7qnhquT+85Y4WV/dehuX7JsChe1YMN7Pb37pEu/d2rQvbtfs4jQbgB1FVNBvo4Y5SyqZc8bqiSfU6KCtTbtc2Vvm+ytFcQMCR1IzWfY6lfW0RihXcnbdV95jIwM6HBHBHSqU8kokP2aFimNvSsbtbDpKLTi47/cXNInCyyXM3zyk/N321tWN9A1wjCMHrksK5+zlEURBTbJ/F71v6M1tIGJH7wDpiqjqc+Jsm20XYnLSs8aiMHu3Q0+OKK7bZLH8q9Soqu7IJlyM46rnpR/aLhj5KiNTxWenUzUZNe6WvsEDsFV9qHsvbFOubaMxhQG9sVJFcb4SrrlvYYzUT3eF2lMY9a2hYwm5mLfW8pdV8xio6Vl3QkCFGV/l9O9a91fbpCgQEHuDWVfXkkn7oRMpXoTTVm9GaR57aooIXzyPwzTZseWSS28/lRKGUlsEH3qGW7Jj4Q/TFdMdDgrpy1RXZyDzkfhUcjMFOAPrUc8zHGEbJ9RSPI3ljIxWkEm0cVS6TuV2dtp9arOWKndVh5AFO0c0yL5iS/QVvKnJrRGNOpGL1OJ8S25YscVyR4OK9Q120EsJYLxivO9RtTDIcA4rppe7HlZjVfO+ZFGiiitTEKKKKACiilAzQAAZNXLWLkEim28PcitO3iB2jFJstIuWEa7hWywVUxjNZsEJTmrDyFUNZOSejL5XuincybXO3rRVS4Y7z3orRRRPMzrJpgfvcg1CH546dqrxnPB5qVR+deLax+ok0UhEmHyR2NGs3E13MjyYPloEBAxwKaOFwalt8OjK/T1q4u+hjUST5jKyRzU0M0gOFpkiiOUoelIG2txTcQUjQgmZztkwKuJKdn3sN2rFSbD5NX450bbnINZSgE5Jm3aiRVWRGO5uoqa6uZlwEJU981Wt7nCYOD9KnN0jJtkHzHgZrJnKk+a7VzTsWSW1zKNz+poW0CAOQC2eKZps3loscydehrRnTC7gOnNNK6OWU3CdujEkDWkJJQYcd6rW+m+dZu2xlcnIIp93dJeRoi53p6VYtNRKS+VKjDA6inMUXOMbpajILi4hjCTIXxxz2rc04xNFt3DJ5NZ73EMg+6xY+1QIybyXDDngdMVhs9RSXtFtY0WkWB5I5VwP4Wx1pkJmtY3mjAdW/Oo5LsrCR8rJ23dazrXUE+0OrElT0B6ZpvsVTouSbt6mjAZpElluZGiYjKAd6t2cFwCGVlkAG7k07S/s8khZZFeU9QT0rZGmMSFik5PJxUcjCpXUW4vQom9dEJfqR91arvd+ZhSjI/bPetP7DFakiTcxPJrMu5AXxbx8A/xVa8zKKhL4URpYkZJO5icjmqGouVibEmJV4C1aM+yQOzE7RWcQJ3eRfvMeAa1VlsQ1L4pbEfmMbRTIdzdyR3qFiSMkAGrX2c+Xgvgd8VE6FQSGDexrqje2p5Vezd0Z9ySRnj6CqjZkGK0GUknI/CmJGhl+bgmtabscNbUpfZQVJPBFRC3djhR8tbEtsGQBSc0sUflrgiur2tonHyXZk3UAEBDDtXG6vp6vvJHWu51EqAcmsSSMThhjFccJy5rndyrlPMLu1aFzgHFViK7XUdN68ZrCuNPPWu6NaLOaWHla5jUVo/YD706OxOea050ZOlJbmekbMelXIrbGK07ewJHIq7Fp7HFT7WOxfspJXRQtrfn7vFakEKgDirkVntTGKqyfuc85yaxqNt2RrStbUexJG3GBVeVh070SzZA25qq02OT1qoRa3FKzegMqgndRVSWbLUVrcnlR0QbZ061LE3OTRHb7+pqytjleGrx7o/RHJ2E4I96lj2KmPWoHtJB0Y0wxTr74qouJnLmYzUIv4l5xVLdkVbdpcEFDVMqynlGAq00TqhA2DzTklIPFIpXoQacsSt0anYXMy9b35QjNXhc+a6MuOKwijKemafHIyEYJrOUEy4vU7O0aRwDuA9KvvdTRod20rj1rjI9TmjXaBQ19cTJgscfWsvZtEui5y1Og0vUY4b12lxhjj6VrX08MzRyLIFA6muHTPGRk1ajuTwGQqO9KUWzWeHi58yO0XUWMZVYsgdGHenxK82VZwqnk+tYttq8JiEew8DHFWLc7VaUThGJztJ7Vm4u+pyOnyJ6WNNtqT+VHjkdWNLJpkctoQjDzVOc1g3N80s4JIG3uO9XLa9YgDeV9cdTUSibRp1IJNMu2kht7hJgAoX5SB1rsNI1gtJjcjADjnmuJhmkJcCIkHo1MRPLkb94VkPcGpTsOth41r8252+q3ha5XJwzfwis1o/PZnuHYZ6AVk2srQuJCxnl+vSpnu5TlvKIz2FWnrc5vYOC5Yk86IN2NzDGM1Re3ZGBVyF7GmC/eHcrxH/gVMeUuDI2WX0FWkmJwnH0LCSbYsHJ5xmom3LKG/gNVhcRxsGXJ9jUsjiXOWwp5rqhseTiaTTuMmn2yHZzUaBS+9j81MuSoUHO7HYd6qvM8wAxsX9a0WjPOlG68jWW5UOEz83pVhSrrlqzLSNE+br7mp2uUQketU7yVjlsovQpX+15WGeazJCFOwVfutjSFgc59KhSNGak4uKKjJNmTdIAhJrLMAk7VuanGOApqtBbE1m48sbnXSqc0rPYx5LQBhxip1sEwDnmtKeCNRlnGfSoRJGo561VKTauGItzJIiS1wMYqQIsfBNNNyuDziqFxeqG65NTGnOTKc4xRfmnVVIB5rAuJssSelPuLvcKzpph3Nd1OLS1OGUVfQfLcHpVd5wBzUEswPCjJqS0sJ7p/ukCtW0txQhKbtFEJMkxOxScUV22i6KiRHcMn6UVi6vY9COB0956lmGE4yeDVqHjr2qMx3cQ52SY9BUUd2fN2yRshzz6V5Fmz672ie5d/i9aYQd/TirsMO8BlYEU82/GO9ZuVik4lRIgx+YVI9pEVxip1THB60/aQOnFCkwZnSaNHIuVrPl0iSJvkNdRahghPJzSlcg5HNaqq0Ytu+pxU0EydVP5VWLEH5lNd/HbxyIQyjNVJtKhY52itI1riuk+xyCsGxmrUcS9jWvLokRPy5B9qrvoUwyY3PFO6ZoqlupUj2o4Lg1ZE6A8YP1qtLY3kPP3hVR55VOJIj+VLluU5X1L80aswZDtb2qSK5KZjmGT0BrJ89v8AaHtS+ex61XL0L5k9zoYQ6JuGD7VbhmIG7HPtXLpdyLwHNWF1B1GBg+9ZypspWZ10GqNtESp14zV+C0hmBMsmWPoa4q1v2iy2M1aXVXPKEg/Ws5UiZU3f3NDrphDbW5RSQ/rnrVe2uJdgKMF5+81c+LqWZQ7yYH1qJLv5yCSw9zUqI/YNppu50NwyzSDe5LD7x7VC8xQFVxtHesqOf5i2evamG6y5B6GrSIdLoaLyMVOCKak5xsfJHSs15xkDJ/Op454wRW8XY4q9DQ0gEjGAOT3NU5ZPLc5PBomnR027iCO9UpnUAEncR3NdMWtj5+th3e7Ly3mUKqpx6mmt5zLwrN9BWLNqDD5dwAHStbTNTv4mjngO5gMDEZYCtKcLvU460eVaBslWUI0b726DFWo9Kv5ptiIQfes64vdXm1hrh1uHYn7whbH8q34NSu5ABcwX5IGF8uJgf5V0xpwe7OGcqi2RlahpF9E+yVVVh6mqF1HcWUIeVcITjNS+KhrCEXL2eoqg/jdD/hXI3uvXM6CO4d3C9A1ROnF6I0pzkrM6x7eyn0/z0uwJh1RjXOrerGzbgHNYE9+zdCR+NVTcyHgE0o0klsaObe7ubMl3lyc4FUp7ld3BqkiTSn5VY/hWla6DcTgFsqD7U24x3NIU6lXSKKD3JP3RRDbzXTgKrHPtXX6Z4VUnL5Y+ldNZaLHAP9WB+FZyrpbHXTy97zZxGn6BtIaXk+mK7HSdMiIxgDFaosYxxtGarbGtptwzs9q5nW5tWepTwyiuWGg9oFgYgdKKUypKeDRWTrK51Qoaaj9fsJNKv47YyK+4ZyBVVIA4+YKfwoorlexdKcnFNsv2+mRKA4OD7VObcKAM5oorMbk7kLxDnPY0xIxvA7UUUI3i3YsLHtJCnimOBRRRIUdxMBQMZzUwiGOTzRRSiExJIwOnWpbVxLEflxjiiitE2ZtXjchuoFC9KpvaxP1Rfyooocncum9CBtMt5eqAfhVKbRIQSc0UU1JmsZu9im+kxYyDiov7JUniQiiitOZnQkmI2lkdJTUcli8Y4kBooo5mXFIgYyR8bsioTO4aiitI6kTk1sSC8bHf8KDcnIPNFFXZEc7FM7HPWlF0V7E0UU0iJO61JGvm29KgluXbpxiiirRw1YIzriVnJPSun8LfEfU/DNuILW0sZ0HOZo9xoorog2eNiqMJOzR08fx+1yPGNJ0nj/phT5v2g/EkqFYrDTIye4h6UUVrzM876tSbtYwNU+Jvi7XbaS3utQQQyDBVVrjRor3Um6WfJPXiiisZ1Z9z0aOCoJaRLtv4WhJ+eUmtS38M2sQGcN9aKKyc5PdnXGjTjsjqNJ8PWm0fIv5Vdu9LhtgCoGPTFFFD2M6bbqWCKFIpFZBjNTXDcpwOtFFc/M7nVyq42RBmqtzLHGmGQmiinCKd7mdSbilYw73UraEj9w+T6NiiiitlRg1sc312utFL8j//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Monocular attack of diffuse episcleritis in a patient with relapsing polychondritis. There is diffuse injection of the episcleral vessels, but the underlying sclera is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular episcleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular episcleritis in a patient with Crohn's disease. There is an episcleral nodule with surrounding episcleral vascular engorgement, but normal underlying sclera.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1203=[""].join("\n");
var outline_f1_11_1203=null;
var title_f1_11_1204="Sweet syndrome facial lesion";
var content_f1_11_1204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A brightly erythematous plaque with a pustular component is present on the face of this patient with Sweet syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1204=[""].join("\n");
var outline_f1_11_1204=null;
var title_f1_11_1205="Quinupristin and dalfopristin: Pediatric drug information";
var content_f1_11_1205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinupristin and dalfopristin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"    see \"Quinupristin and dalfopristin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/36/16964?source=see_link\">",
"    see \"Quinupristin and dalfopristin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synercid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Synercid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Streptogramin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"      see \"Quinupristin and dalfopristin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is expressed in terms of combined &ldquo;mg&rdquo; of quinupristin plus dalfopristin: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents: Limited data in infants and children &lt;12 years; the largest reported experience with quinupristin/dalfopristin is the result of an Emergency-Use Program [n=127, mean age: 7.3 years (range: 1.2 months to 17 years)] (Loeffler, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Mild to moderate infection:",
"     </b>",
"     7.5 mg/kg/dose every 12 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Severe infection:",
"     </b>",
"     7.5 mg/kg/dose every 8 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin and skin structure infection; complicated, treatment:",
"     </b>",
"     7.5 mg/kg/dose every 12 hours for at least 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Vancomycin failure salvage therapy; MRSA:",
"     </b>",
"     7.5 mg/kg/dose every 8 hours (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Skin and skin structure infection; complicated, treatment:",
"     </b>",
"     7.5 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment is required for use in patients with renal impairment or patients undergoing peritoneal dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Dosage adjustment may be necessary, but exact recommendations cannot be made at this time",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synercid&reg;: 500 mg: Quinupristin 150 mg and dalfopristin 350 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Reconstitute vial by slowly adding 5 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W or SWI to make a 100 mg/mL solution; gently swirl the vial contents without shaking to minimize foam formation; further dilute the reconstituted solution with D",
"     <sub>",
"      5",
"     </sub>",
"     W to a final maximum concentration for administration via peripheral line of 2 mg/mL; maximum concentration for administration via a central line is 5 mg/mL; if an injection site reaction occurs, the dose can be further diluted to a final concentration of  &lt;1 mg/mL. Administer infusion over 60 minutes; prior to and following administration, the infusion line should be flushed with D",
"     <sub>",
"      5",
"     </sub>",
"     W to minimize venous irritation;",
"     <b>",
"      DO NOT FLUSH",
"     </b>",
"     with saline or heparin solutions due to incompatibility.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F4117676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with saline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin, aztreonam, caspofungin, ciprofloxacin, fenoldopam, fluconazole (used as undiluted solution), haloperidol, metoclopramide (undiluted), or potassium chloride when admixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unopened vials should be stored under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); reconstituted drug is stable for 1 hour at room temperature; infusion bag is stable for 5 hours at room temperature and for 54 hours if refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F);",
"     <b>",
"      incompatible",
"     </b>",
"     with NS and heparin; compatible with aztreonam, ciprofloxacin, fluconazole, haloperidol, metoclopramide, morphine, and potassium chloride during Y-site administration",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of complicated skin and skin structure infections caused by",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     (methicillin-susceptible) or",
"     <i>",
"      Streptococcus pyogenes",
"     </i>",
"     (FDA approved in ages &ge;12 years and adults); has also been used for salvage therapy for invasive MRSA infections in cases of vancomycin treatment failure",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia, increased GGT, increased LDH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Inflammation at infusion site, infusion site reaction, local edema, local pain, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, CPK increased, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, anaphylactoid reaction, angina, apnea, arrhythmia, cardiac arrest, coagulation disorder, dysautonomia, dyspnea, encephalopathy, gout, hematuria, hemolytic anemia, hepatitis, hyperkalemia, hypotension, maculopapular rash, mesenteric artery occlusion, myasthenia, neuropathy, pancreatitis, pancytopenia, paraplegia, paresthesia, pericarditis, pleural effusion, pseudomembranous colitis, respiratory distress, seizure, shock, stomatitis, syncope, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinupristin, dalfopristin, other streptogramins (pristinamycin or virginiamycin), or to any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal dysfunction; dosage reduction may be necessary in patients with hepatic cirrhosis. May cause hyperbilirubinemia (primarily conjugated, up to 5 times ULN) in ~25% of patients. May cause pain and phlebitis when infused through a peripheral line (not relieved with hydrocortisone or diphenhydramine). Episodes of severe arthralgia and myalgia have been reported, reduction in dosage frequency may improve.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quinupristin/dalfopristin inhibit cytochrome P450 3A4 metabolism of cyclosporine, midazolam, nifedipine, and terfenadine. A 77% increase in cyclosporine's half-life with a 63% increase in the AUC has been reported; cyclosporine levels should be closely monitored in patients who are receiving quinupristin/dalfopristin therapy concomitantly. Coadministration of quinupristin/dalfopristin with cytochrome P450 3A4 substrates with narrow therapeutic ranges require serum concentration monitoring of these drugs. Concurrent use with astemizole, terfenadine, and cisapride is not recommended. Drugs metabolized by the cytochrome P450 3A4 system that may prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval should be avoided. Superinfections and",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) have been reported with the use of quinupristin/dalfopristin. Resistance to quinupristin/dalfopristin has been reported in a few cases of",
"     <i>",
"      Enterococcus faecium",
"     </i>",
"     infections.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Quinupristin may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse effects were not observed in animal reproduction studies, quinupristin/dalfopristin is classified pregnancy category B. There are no adequate and well-controlled studies of quinupristin/dalfopristin in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, liver function test; monitor infusion site closely; number and type of stools/day for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial protein synthesis by binding to the 50S bacterial ribosomal subunit resulting in peptide chain elongation inhibition and peptidyl transferase inhibition",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Quinupristin: 0.45 L/kg; Dalfopristin: 0.24 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Quinupristin is conjugated with glutathione and cysteine to active metabolites; dalfopristin is hydrolyzed to an active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quinupristin: 0.85 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dalfopristin: 0.7 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 75% to 77% excreted in the bile and feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by peritoneal dialysis or hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F8017994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/36/16964?source=see_link\">",
"      see \"Quinupristin and dalfopristin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report to physician any venous irritation, arthralgia, myalgia, or the occurrence of persistent watery and bloody stools.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F12924000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Additional dosing information in pediatric patients: Based on the largest reported experience from an Emergency-Use Program [n=127, mean age: 7.3 years (range: 1.2 months-17 years)], quinupristin/dalfopristin was used for the treatment of vancomycin-resistant",
"     <i>",
"      Enterococcus faecium",
"     </i>",
"     infection: 7.5 mg/kg/dose every 8 hours (Loeffler, 2002). For the treatment of vancomycin-resistant",
"     <i>",
"      Enterococcus faecium",
"     </i>",
"     CNS shunt infection: 7.5 mg/kg/dose every 8 hours (plus 1 mg intrathecal dose daily at the time shunt tap was used in an 8-month-old infant for 28 days in one case report; 1 or 2 mg doses every day for 5-33 days have been administered intrathecally in six patients)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Garey KW, Tesoro E, Muggia V, et al, \"Cerebrospinal Fluid Concentrations of Quinupristin-Dalfopristin in a Patient With Vancomycin-Resistant",
"      <i>",
"       Enterococcus faecium",
"      </i>",
"      Ventriculitis,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2001, 21(6):748-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1205/abstract-text/11401187/pubmed\" id=\"11401187\" target=\"_blank\">",
"        11401187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gransden WR, King A, Marossy D, et al, \"Quinupristin/Dalfopristin in Neonatal",
"      <i>",
"       Enterococcus faecium",
"      </i>",
"      Meningitis,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1998, 78(3):F235-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1205/abstract-text/9713046/pubmed\" id=\"9713046\" target=\"_blank\">",
"        9713046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gray JW, Darbyshire PJ, Beath SV, et al, \"Experience With Quinupristin/Dalfopristin in Treating Infections With Vancomycin-Resistant",
"      <i>",
"       Enterococcus faecium",
"      </i>",
"      in Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2000, 19(3):234-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1205/abstract-text/10749466/pubmed\" id=\"10749466\" target=\"_blank\">",
"        10749466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupte G, Jyothi S, Graham S, et al, \"Synercid Use in Children Is Associated With Arthralgia and Myalgia,\"",
"      <i>",
"       Archives of Disease in Childhood",
"      </i>",
"      , 2006, 91(Supp 1):67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1205/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loeffler AM, Drew RH, Perfect JR, et al, \"Safety and Efficacy of Quinupristin/Dalfopristin for Treatment of Invasive Gram-Positive Infections in Pediatric Patients,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2002, 21(10):950-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1205/abstract-text/12394819/pubmed\" id=\"12394819\" target=\"_blank\">",
"        12394819",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nachman SA, Verma R, and Egnor M, \"Vancomycin-Resistant",
"      <i>",
"       Enterococcus faecium",
"      </i>",
"      Shunt Infection in an Infant: An Antibiotic Cure,\"",
"      <i>",
"       Microb Drug Resist",
"      </i>",
"      , 1995, 1(1):95-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1205/abstract-text/9156389/pubmed\" id=\"9156389\" target=\"_blank\">",
"        9156389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12758 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1205=[""].join("\n");
var outline_f1_11_1205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216636\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216637\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049658\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049651\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216618\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216604\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049661\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4117676\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049654\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049660\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216663\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049664\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049650\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049649\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216654\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216613\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216615\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216625\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049657\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049648\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049663\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017994\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12924000\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12758\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12758|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=related_link\">",
"      Quinupristin and dalfopristin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/36/16964?source=related_link\">",
"      Quinupristin and dalfopristin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_11_1206="Pathologic evaluation of regional lymph nodes in melanoma";
var content_f1_11_1206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathologic evaluation of regional lymph nodes in melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1206/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1206/contributors\">",
"     April W Armstrong, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1206/contributors\">",
"     Vincent Liu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1206/contributors\">",
"     Martin C Mihm, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1206/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1206/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1206/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1206/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1206/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/11/1206/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1000624\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous melanoma characteristically spreads via the lymphatic system from its primary site to the locoregional lymph nodes. Knowledge of lymph node status is important for prognosis and to determine the appropriateness of adjuvant systemic therapy.",
"   </p>",
"   <p>",
"    The identification of patients with subclinical nodal metastases has undergone significant evolution over the past two decades. For patients for whom there is a reasonable risk of regional lymph node metastasis (melanomas &gt;1 mm in thickness, ulceration, etc), lymphatic mapping with sentinel lymph node (SLN) biopsy has become the standard staging approach, replacing elective lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/1\">",
"     1",
"    </a>",
"    ]. If melanoma metastasis is present in the SLN, a completion lymphadenectomy is usually recommended and adjuvant therapy considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Sentinel lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of sentinel lymph node biopsy and the management of patients with a positive sentinel lymph node are discussed separately, as is the pathology of the primary lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link\">",
"     \"Pathologic characteristics of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000631\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specimen preparation with hematoxylin and eosin (H&amp;E) staining remains the gold standard for histologic interpretation of nodal material (",
"    <a class=\"graphic graphic_picture graphicRef77565 \" href=\"UTD.htm?41/16/42245\">",
"     picture 1",
"    </a>",
"    ). However, both serial sectioning and immunohistochemical staining for melanoma-associated tumor markers (e.g., the highly sensitive S-100 and the highly specific MART-1) facilitate the detection of metastatic melanoma cells (",
"    <a class=\"graphic graphic_picture graphicRef64086 \" href=\"UTD.htm?20/0/20488\">",
"     picture 2",
"    </a>",
"    ). In one retrospective study of 235 histologically negative SLNs from 94 patients with cutaneous melanoma, deeper serial sections and immunohistochemical stains detected microscopic metastases in approximately 12 percent of cases that would otherwise have been reported as negative for metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protocols for pathologic evaluation of SLNs vary among different hospitals. The practice at the Massachusetts General Hospital for handling formalin-fixed SLNs is to bisect the lymph node through its hilum and section the entire node into slices that are 1 to 2 mm thick (",
"    <a class=\"graphic graphic_figure graphicRef77332 \" href=\"UTD.htm?31/36/32323\">",
"     figure 1",
"    </a>",
"    ). Nine tissue sections are then sampled from each node in groups of three, with each group separated by a distance of 80 microns. The first, fourth, and seventh levels are immunostained for MART-1; the second, fifth, and eighth levels are stained with H&amp;E; the third, sixth, and ninth levels are immunostained for S-100. With the 2009 tumor (T) node (N) metastasis (M) staging system for cutaneous melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/3\">",
"     3",
"    </a>",
"    ], the detection of a single melanoma cell by either H&amp;E or immunohistochemical staining is sufficient to classify the lymph node as positive for metastasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000638\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal lymph node contains innumerable lymphocytes admixed with histiocytes. Although benign nevic cell rests may occasionally be present, the detection of intranodal deposits of melanocytic cells usually indicates metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/4\">",
"     4",
"    </a>",
"    ]. Nevic rests are nests of benign melanocytes that typically reside within the nodal fibrous capsule and nodal trabeculae, but are occasionally found in the subcapsular area of lymph nodes. These nevic rests have no malignant potential but are often mistaken for melanoma cells because they stain similarly to melanoma cells. They are \"nevic\" because they form nests in the lymph nodes and resemble either benign dermal nevus cells, Spitz nevus cells, or blue nevus cells. Benign pigment-laden histiocytes, which are normally scattered throughout the node, can resemble melanoma cells, further adding to the difficulty in identifying a single malignant melanoma cell within a lymph node. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathologic characteristics of melanoma\", section on 'Growth phases of melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subcapsular region is an important area for microscopic examination. Benign nevic cell rests are sometimes located in subcapsular areas and can be difficult to distinguish from metastatic melanoma cells. The lymphatic drainage and therefore metastatic cells enter the node at the level of the subcapsular sinus, and the majority of nodal metastasis involve the subcapsular area. In one study of 281 sentinel lymph node biopsies, 86 percent of nodal metastases involved at least the subcapsular region (32 percent were purely restricted to this region) while 11 percent were purely restricted to the parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic significance of the location of nodal metastases is unclear. However, at least one series suggests that the location of the metastasis within a SLN may predict the likelihood of involvement of other lymph nodes. In a report of 146 patients with melanoma and at least one positive sentinel node, those with isolated subcapsular micrometastases had a significantly lower rate of non-SLN nodal metastases than those with a different microanatomic location pattern (none of 38 [0 percent] compared with 24 of 108 [22 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000645\">",
"    <span class=\"h1\">",
"     IMMUNOHISTOCHEMISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of nodal metastases by H&amp;E alone can lead to either overdiagnosis or underdiagnosis of metastatic disease due to hypercellularity of the lymph node and similar staining of melanoma cells with normal lymph node constituent cells. Utilization of immunohistochemical staining in conjunction with H&amp;E analysis is used to improve sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Several antigens have been identified on melanoma cells that are used for diagnostic immunohistochemistry.",
"   </p>",
"   <p>",
"    These antigens fall into two categories (",
"    <a class=\"graphic graphic_table graphicRef68372 \" href=\"UTD.htm?21/38/22124\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antigens that are highly specific for melanoma include MAGE-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/10\">",
"       10",
"      </a>",
"      ] and MAGE-3 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/11\">",
"       11",
"      </a>",
"      ], which are a part of the family of \"embryonal cancer testis antigens\".",
"     </li>",
"     <li>",
"      Relatively nonspecific immunohistochemical markers are more widely used because of their high sensitivity. The three most widely used markers are S-100, MART-1, and HMB-45.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000652\">",
"    <span class=\"h2\">",
"     S-100",
"    </span>",
"    &nbsp;&mdash;&nbsp;S-100 (100 percent soluble in ammonium sulfate at neutral pH), a calcium- binding protein, is a sensitive marker of melanocyte differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/12\">",
"     12",
"    </a>",
"    ]. The monoclonal antibody directed against S-100 was derived from human melanoma cells, and it targets a 10-kDa cytoplasmic glycoprotein portion of the transmembrane complex [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/13\">",
"     13",
"    </a>",
"    ]. Although highly sensitive, the monoclonal antibody targeting S-100 is not specific for melanoma cells. It stains a variety of other cell types, including benign nevic cells, macrophages, Langerhans cells, adipocytes, chondrocytes, myoepithelial cells, sweat gland cells, and neural crest-derived cells (eg, Schwann cells, glial cells).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000659\">",
"    <span class=\"h2\">",
"     MART-1 and Melan-A",
"    </span>",
"    &nbsp;&mdash;&nbsp;MART-1 (Melanoma Antigen Recognized by T-cells 1) and Melan-A antibodies target the product of the",
"    <span class=\"nowrap\">",
"     MART-1/Melan-A",
"    </span>",
"    complex, which is a small protein that is expressed in melanomas as well as normal adult melanocytes; it was initially identified as the target for cytotoxic T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/14\">",
"     14",
"    </a>",
"    ]. Antibodies against Melan-A are immunoreactive against both benign and malignant melanocytic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/15\">",
"     15",
"    </a>",
"    ]. Anti-Melan-A also reacts with perivascular smooth muscle cells of lymphangiomyomatosis, the so-called clear cell \"sugar\" tumor of the lung (a rare benign perivascular epithelioid cell tumor), renal angiomyolipoma, adrenocortical tumors, as well as sex-cord stromal tumors of the ovary. Because melanomas of spindle-cell morphology do not stain with HMB-45, immunoreactivity with anti-Melan-A is particularly helpful in diagnosing these lesions. Although MART-1 expression is not specific for malignant transformation, its expression by micrometastasis in SLNs has been correlated with poorer survival in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000666\">",
"    <span class=\"h2\">",
"     HMB-45",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antibody HMB-45 (Human Melanoma Black) reacts with a 10-kDa cytoplasmic glycoprotein that is part of the gp100 premelanosome complex. In addition to reacting with most melanomas, it is immunoreactive with fetal and neonatal melanocytes, intraepidermal and superficial dermal components of benign nevi, blue nevi, and deep-penetrating nevi. Although HMB-45 does not differentiate between benign and malignant melanocytic lesions, staining with HMB-45 provides strong evidence of melanocytic histogenesis. In addition, diffuse staining of the deeper dermal components of borderline melanocytic neoplasms is suggestive of melanoma. However, the lack of reactivity with spindle-cell melanomas limits its usefulness as an immunohistochemical marker for melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000673\">",
"    <span class=\"h2\">",
"     Other markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microphthalmia transcription factor (Mitf) and tyrosinase are other melanoma markers to be applied to immunohistochemical analysis. Mitf is a transcription regulator of the tyrosinase gene that exhibits highly sensitive and specific immunoreactivity for melanocytic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/17\">",
"     17",
"    </a>",
"    ], with the exception of desmoplastic melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/18\">",
"     18",
"    </a>",
"    ]. Although Mitf expression is present in both benign and malignant melanocytic lesions, anti-Mitf immunostaining is often positive in melanomas that fail to react with HMB-45 or anti-S100 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/19\">",
"     19",
"    </a>",
"    ]. The expression of Mitf has also been linked to prognosis in melanomas of intermediate thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathologic characteristics of melanoma\", section on 'Desmoplastic melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of Mitf as a component of a panel of immunostains was shown in a study comparing five antibody markers in 40 patients with melanoma and 32 with nonmelanocytic malignant neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/21\">",
"     21",
"    </a>",
"    ]. The sensitivity and specificity of combined testing for Mitf and Melan-A (95 and 100 percent, respectively) was better than that of combined S-100 and HMB-45 (80 and 100 percent, respectively).",
"   </p>",
"   <p>",
"    Tyrosinase is a key enzyme in melanin biosynthesis, catalyzing the conversion of tyrosine to dihydroxyphenylalanine (DOPA), and DOPA to dopaquinone. The monoclonal antibody developed against tyrosinase is immunoreactive against normal melanocytes, nevus cells, and melanoma cells. Tyrosinase expression diminishes in higher stage melanomas, with 100 percent staining in stage I and II lesions, but only 86 percent of stage III and IV tumors (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000680\">",
"    <span class=\"h1\">",
"     RT-PCR POSITIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse transcriptase polymerase chain reaction (RT-PCR) assay for molecular detection of melanoma-specific tumor markers such as tyrosinase messenger RNA in lymph node tissue is more sensitive for the detection of occult metastases than routine histology [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. However, the prognostic significance of a positive RT-PCR remains uncertain. [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1206/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H10#H10\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'RT-PCR analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1000687\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous melanoma characteristically spreads via the lymphatic system from its primary site to the locoregional lymph nodes. Knowledge of lymph node status provides important information about prognosis and for considering the potential role of adjuvant systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Sentinel lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine histology with hematoxylin and eosin (H&amp;E) staining remains the gold standard for lymph node analysis. (See",
"      <a class=\"local\" href=\"#H1000631\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunohistochemistry is an important adjunct to routine histology and can minimize both overdiagnosis and underdiagnosis of metastatic disease in regional lymph nodes. Antibodies directed against S-100,",
"      <span class=\"nowrap\">",
"       MART-1/Melan-A,",
"      </span>",
"      and HMB-45 have proven to be the most useful, although newer candidates are currently being evaluated. (See",
"      <a class=\"local\" href=\"#H1000645\">",
"       'Immunohistochemistry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reverse transcriptase polymerase chain reaction (RT-PCR) for the molecular detection of melanoma-specific tumor markers such as tyrosinase messenger RNA in lymph node tissue is even more sensitive for the detection of occult metastases, although its prognostic significance remains uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H10#H10\">",
"       \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'RT-PCR analysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/1\">",
"      Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update Part I. J Am Acad Dermatol 2010; 62:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/2\">",
"      Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999; 86:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/3\">",
"      Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/4\">",
"      Carson KF, Wen DR, Li PX, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996; 20:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/5\">",
"      Murray CA, Leong WL, McCready DR, Ghazarian DM. Histopathological patterns of melanoma metastases in sentinel lymph nodes. J Clin Pathol 2004; 57:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/6\">",
"      Dewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 2004; 22:3345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/7\">",
"      Gibbs JF, Huang PP, Zhang PJ, et al. Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes. Ann Surg Oncol 1999; 6:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/8\">",
"      Messina JL, Glass LF, Cruse CW, et al. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 1999; 23:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/9\">",
"      Prieto VG. Sentinel lymph nodes in cutaneous melanoma: handling, examination, and clinical repercussion. Arch Pathol Lab Med 2010; 134:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/10\">",
"      Chen YT, Stockert E, Chen Y, et al. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci U S A 1994; 91:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/11\">",
"      Hofbauer GF, Schaefer C, Noppen C, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997; 151:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/12\">",
"      Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 1998; 32:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/13\">",
"      Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999; 1450:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/14\">",
"      Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/15\">",
"      Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 1998; 22:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/16\">",
"      Hochberg M, Lotem M, Gimon Z, et al. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. Br J Dermatol 2002; 146:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/17\">",
"      King R, Googe PB, Weilbaecher KN, et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 2001; 25:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/18\">",
"      Busam KJ, Iversen K, Coplan KC, Jungbluth AA. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/19\">",
"      King R, Weilbaecher KN, McGill G, et al. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis. Am J Pathol 1999; 155:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/20\">",
"      Salti GI, Manougian T, Farolan M, et al. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000; 60:5012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/21\">",
"      Sheffield MV, Yee H, Dorvault CC, et al. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol 2002; 118:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/22\">",
"      Hofbauer GF, Kamarashev J, Geertsen R, et al. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol 1998; 25:204.",
"     </a>",
"    </li>",
"    <li>",
"     Reintgen, DS, Rapaport, et al. Lymphatic mapping and sentinel lymphadenectomy. In: Cutaneous Melanoma, 3rd, Balch, CM, Houghton, AN, Sober, AJ, Soong, SJ (Eds), Quality Medical Publishing, St. Louis 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/24\">",
"      Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17:3238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/25\">",
"      Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 280:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/26\">",
"      Goydos JS, Ravikumar TS, Germino FJ, et al. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 1998; 187:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/27\">",
"      Li W, Stall A, Shivers SC, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000; 231:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/28\">",
"      Blaheta HJ, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000; 114:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1206/abstract/29\">",
"      Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006; 24:2849.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15868 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1206=[""].join("\n");
var outline_f1_11_1206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1000687\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1000624\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1000631\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1000638\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1000645\">",
"      IMMUNOHISTOCHEMISTRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1000652\">",
"      S-100",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1000659\">",
"      MART-1 and Melan-A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1000666\">",
"      HMB-45",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1000673\">",
"      Other markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1000680\">",
"      RT-PCR POSITIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1000687\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15868\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15868|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/36/32323\" title=\"figure 1\">",
"      Sentinel lymph node sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15868|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/16/42245\" title=\"picture 1\">",
"      SLN melanoma metastasis HandE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/0/20488\" title=\"picture 2\">",
"      IHC sentinel lymph node metast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15868|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/38/22124\" title=\"table 1\">",
"      Compare IHC markers melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 2A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 2B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_11_1207="Digoxin immune Fab: Pediatric drug information";
var content_f1_11_1207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Digoxin immune Fab: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/15/27895?source=see_link\">",
"    see \"Digoxin immune Fab: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/56/31619?source=see_link\">",
"    see \"Digoxin immune Fab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DigiFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      DigiFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Digoxin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12669226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acute ingestion of known amount:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Based on amount (in mg) of digoxin ingested:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Step 1: Calculate total body load (mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Total body load (mg) = 0.8 x [amount (mg) digoxin tablets or elixir ingested]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Step 2: Calculate number of vials needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Digoxin Immune Fab Dose (vials) = Total body load (mg) / (0.5)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Based on steady-state serum",
"      <span style=\"text-decoration: underline\">",
"       digoxin",
"      </span>",
"      concentration:",
"     </b>",
"     Consider dilution of the reconstituted vial with NS and administer the dose via a tuberculin syringe.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Digoxin Immune Fab Dose (mg) = [(serum digoxin concentration [ng/mL] x weight [kg]) / 100] x 40 mg/vial",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Dose Estimates of Digoxin Immune Fab (in mg) From Serum Digoxin Concentration",
"     </caption>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Patient Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"7\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Digoxin Concentration (ng/mL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"8\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          A",
"         </sup>",
"         Dilution of reconstituted vial to 1 mg/mL may be desirable.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.4 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.5 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         32 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40 mg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/15/27895?source=see_link\">",
"      see \"Digoxin immune Fab: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Estimation of the dose is based on the body burden of digitalis. This may be calculated if the amount ingested is known or the postdistribution serum drug concentration is known (round the dose up to the nearest whole vial). If the amount ingested is unknown, general dosing guidelines should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute ingestion of unknown amount:",
"     </b>",
"     I.V.: 20 vials is adequate to treat most life-threatening ingestions. In small children, it is important to monitor for fluid overload. May give as a single dose or give 10 vials, observe the response, and give a second dose of 10 vials if indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute ingestion of known amount:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Based on amount of digoxin ingested:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Step 1: Calculate total body load (mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Total body load (mg) = 0.8 x [amount (mg) digoxin tablets or elixir ingested]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Step 2: Calculate number of vials needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Digoxin Immune Fab Dose (vials) = Total body load (mg) / (0.5)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Based on steady-state serum",
"      <span style=\"text-decoration: underline\">",
"       digoxin",
"      </span>",
"      concentration:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Digoxin Immune Fab Dose (mg) = [(serum digoxin concentration [ng/mL] x weight [kg]) / 100] x 40 mg/vial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Digoxin Immune Fab Dose (vials) = (serum digoxin concentration [ng/mL] x weight [kg]) / 100",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Infants and Children &le;20 kg may require smaller doses; calculate the dose in milligrams (mg), consider dilution of the reconstituted vial with NS, and administer the dose via a tuberculin syringe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Alternatively,",
"     </b>",
"     the following table gives an estimation of the amount of Digoxin Immune Fab needed based on the steady-state serum digoxin concentration.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Infants and Children Dose Estimates of Digoxin Immune Fab (in mg) From Serum Digoxin Concentration",
"     </caption>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Patient Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"7\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Digoxin Concentration (ng/mL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"8\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          A",
"         </sup>",
"         Dilution of reconstituted vial to 1 mg/mL may be desirable.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 mg",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         32 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         32 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         32 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         96 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         128 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         160 mg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Adult Dose Estimate of Digoxin Immune Fab (in # of Vials) From Serum Digoxin Concentration",
"     </caption>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"55\">",
"     </col>",
"     <col align=\"center\" width=\"55\">",
"     </col>",
"     <col align=\"center\" width=\"55\">",
"     </col>",
"     <col align=\"center\" width=\"55\">",
"     </col>",
"     <col align=\"center\" width=\"55\">",
"     </col>",
"     <col align=\"center\" width=\"55\">",
"     </col>",
"     <col align=\"center\" width=\"55\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Patient Weight (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"7\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Digoxin Concentration (ng/mL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.5 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         7 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8 vials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.5 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         7 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12 vials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         70",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         6 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         9 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         11 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         14 vials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         7 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         13 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16 vials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20 vials",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic toxicity (serum digoxin concentration unavailable):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &le;20 kg: 1 vial is adequate to reverse most cases of toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;20 kg, Adolescents, and Adults: 6 vials is adequate to reverse most cases of toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment necessary; however, use with caution since digoxin-digoxin immune Fab complex is renally eliminated. Patients should undergo prolonged monitoring for recurrence of toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [ovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DigiFab&reg;: 40 mg [derived from or manufactured using papain]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Reconstitute with 4 mL SWI, resulting in an 10 mg/mL concentration for I.V. infusion. I.V. infusion over at least 30 minutes is preferred. May also be given by bolus injection if cardiac arrest is imminent (infusion-related reaction may occur). Small doses (eg, those required in infants or small children) may be administered using a tuberculin syringe as undiluted digoxin immune Fab or diluted with NS to a concentration of 1 mg/mL digoxin immune Fab. Discontinue the infusion and reinitiate at a slower rate if an infusion-related reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. The following stability information has also been reported: May be stored at room temperature for up to 30 days (Cohen, 2007). Reconstituted solutions are stable for 4 hours when stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of potentially life-threatening digoxin or digitoxin intoxication in carefully selected patients; acute digoxin ingestion (ie, &gt;10 mg in adults; &gt;0.1 mg/kg or &gt;4 mg in children; ingestions resulting in serum concentrations &gt;10 ng/mL), chronic ingestions leading to steady-state digoxin concentrations &gt;6 ng/mL in adults or &gt;4 ng/mL in children; patients experiencing manifestations of digoxin toxicity due to overdose (eg, life-threatening ventricular arrhythmias, progressive bradycardia, second- or third-degree heart block not responsive to atropine, serum potassium &gt;5.5 mEq/L in adults or &gt;6 mEq/L in children) [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F160260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Heart failure exacerbation (due to withdrawal of digoxin), orthostatic hypotension, rapid ventricular response (patients with atrial fibrillation; due to withdrawal of digoxin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to digoxin immune Fab or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in renal or cardiac failure. Digoxin immune Fab is derived from ovine (sheep) Fab immunoglobulin fragments; hypersensitivity reactions (eg, anaphylactic or anaphylactoid reactions, delayed allergic reactions) are possible. Patients with allergies to sheep proteins and patients with prior exposure to ovine antibodies or ovine Fab may be at a higher risk for hypersensitivity reactions. In patients who develop an anaphylactic reaction, discontinue the infusion and administer emergency care. Immediate treatment (eg, epinephrine 1:1000, corticosteroids, diphenhydramine) should be available; the benefit of epinephrine in this situation must be weighed against the potential risk in digoxin toxicity. Digoxin immune Fab is processed with papain and may cause hypersensitivity reactions in patients allergic to papaya, other papaya extracts, papain, chymopapain, or the pineapple-enzyme bromelain. There may also be cross allergenicity with dust mite and latex allergens.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients experiencing acute digitalis toxicity may present with significant hyperkalemia due to shifting of potassium into the extracellular space. Upon treatment with digoxin immune Fab, potassium shifts back into the intracellular space; therefore, hypokalemia may rapidly develop. Monitor potassium closely, especially during the first few hours after administration; treat hypokalemia cautiously when clinically indicated. Total serum digoxin concentrations will rise precipitously following administration of digoxin immune Fab due to the presence of the Fab-digoxin complex; because digoxin bound to Fab fragments is not physiologically active this rise has no clinical meaning. Therefore, avoid monitoring total serum digoxin concentrations until the Fab fragments have been eliminated completely. The Fab-digoxin complex will be eliminated more slowly in patients with renal failure (experience limited). Toxicity may recur due to dissociation of the Fab-digoxin complex; prolonged monitoring for recurrence of symptoms and evaluation of free (unbound) digoxin concentrations (if test available) may be warranted in this patient population. In patients chronically maintained on digoxin for heart failure, administration of digoxin immune Fab may result in exacerbation of heart failure symptoms due to a reduction in digoxin serum concentration. If redigitalization is required, consider postponing until Fab fragments have been eliminated completely; elimination may take several days or longer, especially in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F160227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Safety and efficacy in pregnant women have not been established. Use during pregnancy only if clearly needed. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to the first dose of digoxin immune Fab evaluate serum potassium, serum digoxin concentration, and serum creatinine; closely monitor serum potassium (eg, hourly for 4-6 hours; at least daily thereafter), temperature, blood pressure, and electrocardiogram after administration. Total serum digoxin concentrations will rise precipitously following administration of digoxin immune Fab due to the presence of the Fab-digoxin complex; because digoxin bound to Fab fragments is not physiologically active this rise has no clinical meaning. Therefore, avoid monitoring total serum digoxin concentrations until the Fab fragments have been eliminated completely; this may be several days to weeks in patients with renal impairment (Ujhelyi, 1995).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients with renal failure may experience a recurrence of toxicity; prolonged monitoring for recurrence of symptoms and evaluation of free (unbound) digoxin concentrations (if test available) may be warranted in this patient population.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with molecules of free (unbound) digoxin or digitoxin and then is removed from the body by renal excretion",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Improvement in signs and symptoms occurs within 2-30 minutes following I.V. infusion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 15 hours; renal impairment prolongs half-life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal with concentrations declining to undetectable amounts within 5-7 days",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F14262783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/56/31619?source=see_link\">",
"      see \"Digoxin immune Fab: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact physician immediately if signs or symptoms of delayed allergic reaction or serum sickness (eg rash, pruritus, urticaria) occur after hospital discharge.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1057860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each 40 mg vial (DigiFab&trade;) will bind approximately 0.5 mg digoxin or digitoxin; for individuals at increased risk of sensitivity an intradermal or scratch technique skin test using a 1:100 dilution of reconstituted digoxin immune Fab diluted in NS has been used. Skin test volume is 0.1 mL of 1:100 dilution; evaluate after 20 minutes.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, \"Room-Temperature Storage of Medications Labeled for Refrigeration,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1207/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hickey AR, Wenger TL, Carpenter VP, et al, &ldquo;Digoxin Immune Fab Therapy in the Management of Digitalis Intoxication: Safety and Efficacy Results of an Observational Surveillance Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1991, 17(3):590-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1207/abstract-text/199377/pubmed\" id=\"199377\" target=\"_blank\">",
"        199377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneider PJ, McCollam PL, and Osborn JJ, \"Possible Dissociation of the Digibind-Digoxin Complex in Renal Failure,\"",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(11):1269.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1207/abstract-text/1763546/pubmed\" id=\"1763546\" target=\"_blank\">",
"        1763546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ujhelyi MR and Robert S, \"Pharmacokinetic Aspects of Digoxin-Specific Fab Therapy in the Management of Digitalis Toxicity,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(6):483-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1207/abstract-text/7656506/pubmed\" id=\"7656506\" target=\"_blank\">",
"        7656506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13231 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1207=[""].join("\n");
var outline_f1_11_1207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160237\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160238\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057851\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12669226\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057846\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160219\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160203\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057855\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057848\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057854\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160260\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057859\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057845\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057844\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299196\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219862\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160215\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160227\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057850\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057843\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057857\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057858\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14262783\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057860\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13231|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/15/27895?source=related_link\">",
"      Digoxin immune Fab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/56/31619?source=related_link\">",
"      Digoxin immune Fab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_11_1208="Aortic valve area in aortic stenosis";
var content_f1_11_1208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aortic valve area in aortic stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1208/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1208/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1208/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1208/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1208/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/11/1208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with normal aortic valves, the valve area is 3.0 to 4.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    . As aortic stenosis develops, minimal valve gradient is present until the orifice area becomes less than half of normal. The pressure gradient across a stenotic valve is directly related to the valve orifice area and the transvalvular flow [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, in the presence of a depressed cardiac output, relatively low pressure gradients can be seen in some patients with severe aortic stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    .) On the other hand, during exercise or other high flow states, systolic impulse-gradients can be measured in patients with minimally stenotic or even normal valves [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete assessment of the degree of aortic stenosis requires:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of the transvalvular flow",
"     </li>",
"     <li>",
"      Determination of the transvalvular pressure gradient",
"     </li>",
"     <li>",
"      Calculation of the aortic valve area",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is wide variability in the relationship between the severity of stenosis and symptom onset. In general, symptoms in patients with aortic stenosis occur when the valve area is &lt;1.0 cm2 or the mean transvalvular gradient exceeds 50 mmHg (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link\">",
"     \"Natural history of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the methods of techniques for calculating the aortic valve area and valve resistance in patients with aortic stenosis. A discussion of the use of echocardiography in the evaluation of aortic stenosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of aortic valve disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIAC CATHETERIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simultaneous measurements of cardiac output and the pressure gradient between the left ventricle and the aorta provide the pressure-flow data necessary to calculate the aortic valve area and valve resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Such calculations require painstaking attention to detail in the measurement of pressure and flow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gorlin equation for aortic valve area",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gorlin and Gorlin described the method of evaluating the severity of aortic stenosis by calculating the aortic valve area (AVA) based upon invasive measurement of the transvalvular pressure gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;AVA (in cm2) &nbsp; = &nbsp; (SV &nbsp;&divide; &nbsp;SEP) &nbsp;&divide; &nbsp;(44.3 &nbsp;x &nbsp;[sq rt",
"    <span class=\"nowrap\">",
"     &Delta;P])",
"    </span>",
"   </p>",
"   <p>",
"    where SV = stroke volume (mL per beat), SEP = systolic ejection period (sec per beat), and",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    = mean systolic pressure gradient between the left ventricle and aorta (mmHg) (",
"    <a class=\"graphic graphic_figure graphicRef80837 \" href=\"UTD.htm?8/61/9170\">",
"     figure 1",
"    </a>",
"    ). The area of the normal adult aortic valve is approximately 3.0 cm2. Severe aortic stenosis is said to be present when the calculated effective valve area is less than 1.0 cm2 (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Critical valve area and severity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the historical standard for determining the transvalvular gradient is the simultaneous measurement of pressures obtained from a catheter in the aorta and one in the left ventricle positioned via a transseptal approach, it is more common for the left ventricular catheter to be placed retrograde via the aorta. However, the transvalvular gradient may be increased by the presence of a catheter across the stenotic aortic valve which can reduce the effective antegrade orifice area [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/5\">",
"     5",
"    </a>",
"    ]. This effect is proportional to the severity of the underlying aortic stenosis and is seen only in the most severe aortic stenosis.",
"   </p>",
"   <p>",
"    The SEP is usually measured on the simultaneous aortic and left ventricular pressure tracing from the pressure crossover at the beginning of systole (when left ventricular pressure rises above aortic pressure) to the pressure crossover at the end of systole (when left ventricular pressure drops below aortic pressure) (",
"    <a class=\"graphic graphic_figure graphicRef80837 \" href=\"UTD.htm?8/61/9170\">",
"     figure 1",
"    </a>",
"    ). A careful study of left ventricular ejection using an implantable flowmeter suggested that the end of the SEP actually occurs after the second pressure crossover, and corresponds more closely to the timing of the incisura (the notch in the aortic pressure tracing associated with aortic valve closure) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Aortic valve resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators use pressure and flow data to calculate aortic valve resistance (R, dyne seconds per cm5). Early studies suggested that, compared to valve area calculations, resistance is less sensitive to variations in flow [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;R &nbsp; = &nbsp;",
"    <span class=\"nowrap\">",
"     [(&Delta;P",
"    </span>",
"    &nbsp;x &nbsp;HR &nbsp;x &nbsp;SEP) &nbsp;&divide; &nbsp;CO] &nbsp;x &nbsp;1.33",
"   </p>",
"   <p>",
"    where",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    = mean pressure gradient (mmHg), HR = heart rate (beats per min), SEP = systolic ejection period (sec per beat), and CO = cardiac output",
"    <span class=\"nowrap\">",
"     (L/min).",
"    </span>",
"    Valve resistance exceeds 250 dyne seconds per cm5 in critical aortic stenosis.",
"   </p>",
"   <p>",
"    However, more recent studies suggest that valve resistance does not describe the fluid dynamics of native valve stenosis because the resistance calculation assumes a linear relationship between pressure and flow, whereas the actual relationship is quadratic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Aortic valve resistance calculations are rarely used for clinical decision making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Subvalvular gradients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with aortic stenosis also have resting subvalvular gradients in the absence of an anatomic basis for subvalvular obstruction; the mechanism may be based upon fluid dynamics, with an inertial effect within a rapidly tapering flow field [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/12\">",
"     12",
"    </a>",
"    ]. These subvalvular gradients can constitute as much as 50 percent of the total measured transvalvular pressure gradient and increase further with exercise. The extent of elevation in cardiac output during exercise is inversely related to the subvalvular gradient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transvalvular pressure gradient and valve area may be derived using Doppler echocardiography (",
"    <a class=\"graphic graphic_movie graphicRef79119 \" href=\"UTD.htm?43/22/44398\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef54824 \" href=\"UTD.htm?6/21/6495\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56227 \" href=\"UTD.htm?15/31/15871\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74763 \" href=\"UTD.htm?27/12/27840\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of aortic valve disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transvalvular pressure gradient estimation utilizing the simplified Bernoulli equation demonstrates a high correlation with direct pressure measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    (in mmHg) &nbsp; = &nbsp; 4 &nbsp;x &nbsp;(VAV)2 &nbsp;- &nbsp;4 &nbsp;x &nbsp;(VOT)2",
"   </p>",
"   <p>",
"    where",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    = maximum pressure gradient between the left ventricle and the aorta (mmHg), VAV = maximum stenotic jet velocity",
"    <span class=\"nowrap\">",
"     (m/sec),",
"    </span>",
"    VOT = left ventricular outflow tract (ie, subvalvular) velocity, and 2 refers to the square of the term. In practice, the minimal contribution of left ventricular outflow tract velocity (VOT is usually less than 1",
"    <span class=\"nowrap\">",
"     m/sec)",
"    </span>",
"    is ignored, and the expression simplifies to:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    &nbsp; = &nbsp; 4 &nbsp;x &nbsp;(VAV)2",
"   </p>",
"   <p>",
"    This is the maximum instantaneous pressure gradient (mmHg), and should not to be confused with the so-called peak-to-peak gradient obtained during cardiac catheterization. The mean Doppler gradient correlates highly with the catheter-derived mean value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=see_link\">",
"     \"Principles of Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, eccentric stenotic jets elude accurate recording despite meticulous technique, possibly leading to underestimation of the true gradient. On the other hand, overestimation of the gradient may result from:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mistaken identification of a jet (eg, mitral regurgitation)",
"     </li>",
"     <li>",
"      Failure to consider increased subvalvular velocities (eg, in hypertrophic obstructive cardiomyopathy)",
"     </li>",
"     <li>",
"      Nonrepresentative jet selection (eg, a postextrasystolic beat)",
"     </li>",
"     <li>",
"      Downstream pressure recovery (which is seldom a significant factor with native valves and a normal sized aortic root)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Aortic valve area by continuity principle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler velocities may also be directly applied to an estimation of aortic valve area by the continuity principle. Simply stated, flow volume (Q) measurements at proximate sites in a closed system (such as the heart) should be identical:",
"   </p>",
"   <p>",
"    &nbsp;Q &nbsp; = &nbsp; AOT &nbsp;x &nbsp;VOT &nbsp; = &nbsp; AVA &nbsp;x &nbsp;VAV",
"   </p>",
"   <p>",
"    where AOT = area of the LV outflow tract, VOT = peak velocity in the outflow tract, AVA = area of the stenotic aortic valve, VAV = maximum velocity across the aortic valve. The effective orifice area of the stenotic valve can therefore be calculated after simple equation rearrangement:",
"   </p>",
"   <p>",
"    &nbsp;AVA &nbsp; = &nbsp; (AOT &nbsp;x &nbsp;VOT) &nbsp;&divide; &nbsp;VAV",
"   </p>",
"   <p>",
"    Some experts prefer use of the left ventricular and aortic time-velocity integrals to use of the peak velocities (TVIOT = time velocity integral across the outflow tract and TVIAV = time velocity integral across the aortic valve) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;AVA &nbsp; = &nbsp; (AOT &nbsp;x &nbsp;TVIOT) &nbsp;&divide; &nbsp;TVIAV",
"   </p>",
"   <p>",
"    Doppler-derived effective valve orifice area in aortic stenosis increases during ejection due to the elevation in transvalvular flow, although the valve remains open for a shorter period than in normals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Effective orifice area also changes with physiologic changes in transaortic flow rate, as occurs with exercise. Measurement of this change in valve area may be helpful in the assessment of symptom onset and in the evaluation of low output aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The continuity equation may be expected to be less susceptible to flow variation because the empiric constant of the Gorlin formula is avoided. Similarly, use of Doppler-derived aortic valve resistance should be relatively free of the influence of variations in flow [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/18\">",
"     18",
"    </a>",
"    ]. This hypothesis was confirmed by a study in which Doppler echocardiographic variables were measured at baseline and during an infusion of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/19\">",
"     19",
"    </a>",
"    ]. In another report it was shown that acute changes in transvalvular flow do not alter the planimetered valve area obtained with transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the degree of flow dependence may be related to the structural characteristics of the valve. As an example, one study reported that more flow dependence was associated with tricuspid valves and those with morphologic features of calcific aortic stenosis while less flow dependence was seen with bicuspid valves and those with features of rheumatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, experience with these methods in low-flow states is limited. Overestimation of the severity of stenosis in patients with left ventricular dysfunction and low-output states remains a serious clinical problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Doppler derived velocities have been used to evaluate the function of prosthetic heart valves. One study reported that application of the continuity equation and valve resistance provided a reliable method to distinguish whether a high velocity and gradient across a St. Jude aortic valve was secondary to obstruction or increased flow, such as may be seen with paravalvular aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/22\">",
"     22",
"    </a>",
"    ]. Parameters that differentiated stenotic from regurgitant and normal valves were the effective orifice area, Doppler velocity index, and valve resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=see_link\">",
"     \"Management of patients with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Aortic valve resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve resistance can be calculated noninvasively using Doppler echocardiography based upon the following equation:",
"   </p>",
"   <p>",
"    R &nbsp; = &nbsp; 4 (VAV)2 &nbsp;&divide; &nbsp;AOT &nbsp;x &nbsp;VOT &nbsp;x &nbsp;1.333",
"   </p>",
"   <p>",
"    The value of calculating aortic valve resistance was evaluated in a study of 407 patients with aortic stenosis who underwent Doppler echocardiography prior to valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/23\">",
"     23",
"    </a>",
"    ]. Although aortic valve resistance was strongly related to the severity of aortic stenosis, it did not add any information once the valve area and gradient were determined [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, aortic valve resistance was not related to surgical mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Energy loss index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with aortic stenosis who have similar aortic valve areas (AVAs) may have different clinical outcomes, which suggests that other factors impact upon left ventricular workload. A noninvasive estimation of energy loss might be a useful method for hemodynamic assessment since it more closely reflects the amount of left ventricular energy that is lost during systole due to the valvular obstruction. The energy loss index (ELI) can be calculated noninvasively using Doppler echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;ELI &nbsp;= &nbsp;(AVA &nbsp;x &nbsp;Aa) &nbsp;&divide; &nbsp;(Aa &nbsp;- &nbsp;AVA ) &nbsp;&divide; &nbsp;body surface area",
"   </p>",
"   <p>",
"    where Aa equals the cross-sectional area of the aorta. In a study of 138 patients with moderate to severe AS, the ELI was superior to AVA for predicting the combined end point of death or aortic valve replacement; an ELI &le;0.52",
"    <span class=\"nowrap\">",
"     cm2/m2",
"    </span>",
"    was the best predictor of an adverse outcome (positive predictive value 67 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/24\">",
"     24",
"    </a>",
"    ]. Furthermore, the Doppler calculation of energy loss may correlate better with AVA measured at catheterization than does the Doppler estimate of valve area itself [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Rate of change in aortic valve area",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of change in the aortic valve area (AVA) during the ejection phase of a cardiac cycle, as determined by Doppler echocardiography, is another way to predict hemodynamic progression in patients with asymptomatic aortic stenosis. The rate of change in AVA",
"    <span class=\"nowrap\">",
"     (Md/Ma)",
"    </span>",
"    is established as the ratio of the AVA measured at mid-acceleration and mid-deceleration to the AVA at peak velocity:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     Md/Ma",
"    </span>",
"    &nbsp;= &nbsp;AVA",
"    <span class=\"nowrap\">",
"     t1/2d",
"    </span>",
"    &nbsp;&divide; &nbsp;AVA",
"    <span class=\"nowrap\">",
"     t1/2a",
"    </span>",
"   </p>",
"   <p>",
"    where AVA",
"    <span class=\"nowrap\">",
"     t1/2d",
"    </span>",
"    is the AVA at time to half of the peak velocity during deceleration, and AVA",
"    <span class=\"nowrap\">",
"     t1/2a",
"    </span>",
"    is the AVA at time to half of the peak velocity during acceleration. An individual with a slower rate of change in AVA will have a larger ratio.",
"   </p>",
"   <p>",
"    In one study of 84 patients with asymptomatic aortic stenosis and an AVA &ge;0.9 cm",
"    <sup>",
"     2",
"    </sup>",
"    , rapid progression of aortic stenosis (&ge;0.2",
"    <span class=\"nowrap\">",
"     cm",
"     <sup>",
"      2",
"     </sup>",
"     /year)",
"    </span>",
"    was associated with a",
"    <span class=\"nowrap\">",
"     Md/Ma",
"    </span>",
"    ratio &ge;1.25 (",
"    <a class=\"graphic graphic_figure graphicRef51996 \" href=\"UTD.htm?37/46/38637\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/17\">",
"     17",
"    </a>",
"    ]. The sensitivity, specificity, and positive predictive value was 64, 72, and 80 percent, respectively. The ratio was somewhat more predictive in patients with mild aortic stenosis (initial AVA &ge;1.25 cm",
"    <sup>",
"     2",
"    </sup>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Planimetry of aortic valve area",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planimetry of the aortic valve orifice with transthoracic or transesophageal echocardiography (TEE) produces a valve area determination that has an excellent correlation with the Gorlin equation and the continuity principle described above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/26\">",
"     26",
"    </a>",
"    ]. To visualize the aortic value with TEE, it is necessary to image the aorta in a precise short axis. In one study, the correlation coefficient for this comparison was 0.93, the percent difference between the two methods was small (11 percent), and the TEE method correlated even more closely with the catheterization-determined valve area (using the Gorlin formula) than did the transthoracic echocardiographic value (r = 0.91 versus 0.84) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of multiplane TEE probe technology enables an even more accurate assessment of valve area. In one series of 41 patients with calcific aortic stenosis, the orifice area was successfully measured in 93 percent; in the remaining patients, the stenosis was obviously very severe (\"pinhole stenosis\") [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/28\">",
"     28",
"    </a>",
"    ]. The correlation coefficient with valve area determined by catheterization (Gorlin formula) was 0.95, and the sensitivity was 96 percent for predicting severe stenosis (valve area &lt;0.75 cm2).",
"   </p>",
"   <p>",
"    However, planimetry of valve area has two major limitations: measurement accuracy is limited when valve calcification is present, as occurs in most adults with aortic stenosis, and it corresponds to the anatomic, not physiologic, valve area [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/11,29\">",
"     11,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER IMAGING MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on two other imaging modalities to estimate aortic valve area: cardiovascular magnetic resonance imaging and multislice computed tomography (CT). In addition, both modalities may be used to evaluate accompanying disease of the aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance imaging (CMR) was compared with TEE assessment of aortic valve area in a series of 40 patients with aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/30\">",
"     30",
"    </a>",
"    ]. The mean valve area was 0.91 cm2 by CMR and 0.89 cm2 by TEE; the correlation coefficient between the two methods was 0.96. However, the correlation of CMR with valve area determined by cardiac catheterization was not as good (0.44). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H32#H32\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Valvular heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Multislice CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multislice CT using a 16-slice scanner was compared to transthoracic echocardiography in 30 patients with aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/31\">",
"     31",
"    </a>",
"    ]. The mean aortic valve area was 0.94 cm2 by multislice CT and there was a high rate of correlation with echocardiography (0.89) with which the mean aortic valve area was 0.90 cm2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CRITICAL VALVE AREA AND SEVERITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Valve area and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculated valve area depicts an effective area that does not always represent the actual anatomic area or functional impairment. As a result, some patients with severe aortic stenosis are asymptomatic, while some symptomatic patients have only moderate stenosis. Nevertheless, valve area data are an essential part of the assessment of patients with aortic stenosis even though there are limitations inherent in the clinical application of such information.",
"   </p>",
"   <p>",
"    The term &ldquo;critical&rdquo; stenosis was defined based upon theoretical considerations showing that the aortic valve area must be reduced to one-fourth of its natural size before significant changes in circulation occur. As a result, since the triangular orifice area of the normal (adult) aortic valve is approximately 3.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    , an area exceeding 0.75 cm",
"    <sup>",
"     2",
"    </sup>",
"    would not be defined as critical [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these theoretical considerations, symptoms can occur at aortic valve areas that are not \"critical.\" Many of these symptomatic patients have valve areas that are severely stenosed (&lt;1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    but &gt;0.75 cm",
"    <sup>",
"     2",
"    </sup>",
"    ). However, the possibility that valve stenosis is responsible must be considered in symptomatic patients with borderline severe stenosis (eg, valve area of 1.1 cm",
"    <sup>",
"     2",
"    </sup>",
"    ) if a thorough evaluation reveals no other cause for symptoms.",
"   </p>",
"   <p>",
"    In some cases, it may be helpful to index valve area for body size to avoid overestimation of stenosis severity in small adults and underestimation of severity in larger adults. Guidelines suggest that an indexed valve area &lt;0.6",
"    <span class=\"nowrap\">",
"     cm",
"     <sup>",
"      2",
"     </sup>",
"     /m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    represents severe stenosis.",
"   </p>",
"   <p>",
"    Of note, most prospective studies indicate that aortic velocity or mean gradient is a stronger predictor of clinical outcome than valve area. With very severe aortic stenosis (velocity over 5",
"    <span class=\"nowrap\">",
"     m/s),",
"    </span>",
"    valve area does not provide additional prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon a variety of hemodynamic and natural history data, clinicians generally grade the severity of stenosis as mild, moderate, severe, or critical (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/15,35\">",
"     15,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild &mdash; valve area exceeds 1.5 cm",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Moderate &mdash; valve area of 1.0 to 1.5 cm",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Severe &mdash; valve area is less than 1.0 cm",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although such an assessment may be useful in clinical discussions, the absolute valve area is",
"    <strong>",
"     not",
"    </strong>",
"    the primary determinant that defines the optimum timing of valve replacement surgery. As long as there are truly no symptoms, patients with severe aortic stenosis (those with a critical or near-critical valve area) should be evaluated and followed with special care. Prompt valve replacement is indicated when symptoms develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One reason for dissociation between aortic valve area and symptoms is concurrent disease. For example, some patients may have symptomatic aortic valve disease with concurrent moderate stenosis and moderate regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Indexing for body size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe aortic stenosis has also been defined as an aortic valve area indexed by body surface area &lt;0.6",
"    <span class=\"nowrap\">",
"     cm2/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/15,35\">",
"     15,35",
"    </a>",
"    ]. Indexing valve area for body surface area is important in children, adolescents, and small adults in whom the valve area may be small but not severely stenotic when adjusted for body size. However, use of body surface area to index aortic valve area in obese individuals may produce misleading results because valve area does not scale with increases in body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach to adjust for body size differences is to calculate the velocity ratio, which is the peak left ventricular outflow tract velocity (VOT) divided by the maximum aortic jet velocity (VAV). This ratio does not require a consideration of body size because it is dimensionless.",
"   </p>",
"   <p>",
"    Velocity ratio = VOT &divide; VAV",
"   </p>",
"   <p>",
"    Alternatively, the ratio of the time velocity-integrals for the left ventricular outflow tract and aortic valve can be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LOW GRADIENT AORTIC STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe aortic stenosis, left ventricular systolic dysfunction, and a low cardiac output often present with only modest transvalvular pressure gradients (less than 30 mmHg). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such patients can be difficult to distinguish from those with a low cardiac output and only mild to moderate aortic stenosis. In both settings, the low-flow state contributes to a calculated valve area consistent with severe aortic stenosis. As an example, a cardiac output of 3",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    and a transvalvular pressure gradient of 16 to 25 mmHg yield a valve area of 0.6 to 0.7 cm2 if the standard hemodynamic formula is used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/1\">",
"     1",
"    </a>",
"    ]. However, this formula is known to underestimate the valve area and should not be used alone in low flow states. In theory, Doppler derived valve areas should be less susceptible to low flow states, but this has not been borne out in clinical practice.",
"   </p>",
"   <p>",
"    It has been suggested that aortic valve resistance might provide a better separation between critical and noncritical aortic stenosis, particularly in patients with low transvalvular pressure gradients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Although valve resistance is less sensitive to flow than valve area, the resistance calculations have not proven to be substantially better than valve area calculations alone.",
"   </p>",
"   <p>",
"    In patients with low gradient aortic stenosis (thought to be related to low flow), it can be useful to determine the transvalvular pressure gradient and calculate the valve area and resistance during a baseline state and again during exercise or other hemodynamic stress, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    infusion. This concept is based upon the observation that the valve area may increase during an increase in the cardiac output in some patients with low gradient aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1208/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. If dobutamine produces an increment in cardiac output, an increase in valve area, and a decrease in resistance, it is likely that the baseline calculations produced an overestimation of the stenosis severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cardiac output is normal or near normal, the severity of aortic stenosis can be accurately assessed with echocardiography. Catheterization is reserved for patients in whom echocardiography is nondiagnostic or when clinical and echocardiographic data are discrepant. More detailed evaluation is needed in patients with low output aortic stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13954259\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Edgar C. Schick for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/1\">",
"      GORLIN R, GORLIN SG. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. I. Am Heart J 1951; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/2\">",
"      Murgo, JP, Altobelli, SA, Dorethy, JF, et al. Normal ventricular ejection dynamics in man during rest and exercise. Am Heart Assoc Monogr 1975; 46:92.",
"     </a>",
"    </li>",
"    <li>",
"     Hirshfeld JW, Kolansky DM. Valve function: Stenosis and regurgitation. In: Diagnostic and Therapeutic Cardiac Catheterization, 2nd ed, Pepine CJ, Hill JA, Lambert CR (Eds), Williams &amp; Wilkins, Baltimore 1994. p.443.",
"    </li>",
"    <li>",
"     Carabello BA, Grossman W. Calculation of stenotic valve orifice area. In: Cardiac Catheterization and Angiography, 3rd ed, Grossman W (Ed), Lea and Febiger, Philadelphia 1986. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/5\">",
"      Adele C, Vaitkus PT, Tischler MD. Evaluation of the significance of a transvalvular catheter on aortic valve gradient in aortic stenosis: a direct hemodynamic and Doppler echocardiographic study. Am J Cardiol 1997; 79:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/6\">",
"      Bermejo J, Rojo-Alvarez JL, Antoranz JC, et al. Estimation of the end of ejection in aortic stenosis: an unreported source of error in the invasive assessment of severity. Circulation 2004; 110:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/7\">",
"      Badano L, Cassottano P, Bertoli D, et al. Changes in effective aortic valve area during ejection in adults with aortic stenosis. Am J Cardiol 1996; 78:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/8\">",
"      Ford LE, Feldman T, Chiu YC, Carroll JD. Hemodynamic resistance as a measure of functional impairment in aortic valvular stenosis. Circ Res 1990; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/9\">",
"      Bermejo J, Antoranz JC, Burwash IG, et al. In-vivo analysis of the instantaneous transvalvular pressure difference-flow relationship in aortic valve stenosis: implications of unsteady fluid-dynamics for the clinical assessment of disease severity. J Heart Valve Dis 2002; 11:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/10\">",
"      Kadem L, Rieu R, Dumesnil JG, et al. Flow-dependent changes in Doppler-derived aortic valve effective orifice area are real and not due to artifact. J Am Coll Cardiol 2006; 47:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/11\">",
"      Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006; 47:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/12\">",
"      Laskey WK, Kussmaul WG. Subvalvular gradients in patients with valvular aortic stenosis: prevalence, magnitude, and physiological importance. Circulation 2001; 104:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/13\">",
"      Cannon JD Jr, Zile MR, Crawford FA Jr, Carabello BA. Aortic valve resistance as an adjunct to the Gorlin formula in assessing the severity of aortic stenosis in symptomatic patients. J Am Coll Cardiol 1992; 20:1517.",
"     </a>",
"    </li>",
"    <li>",
"     Feigenbaum H. Echocardiography, 5th ed, Feigenbaum H (Ed), Lea and Febiger, Philadelphia 1994. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/15\">",
"      Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/16\">",
"      Arsenault M, Masani N, Magni G, et al. Variation of anatomic valve area during ejection in patients with valvular aortic stenosis evaluated by two-dimensional echocardiographic planimetry: comparison with traditional Doppler data. J Am Coll Cardiol 1998; 32:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/17\">",
"      Lester SJ, McElhinney DB, Miller JP, et al. Rate of change in aortic valve area during a cardiac cycle can predict the rate of hemodynamic progression of aortic stenosis. Circulation 2000; 101:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/18\">",
"      Ho PP, Pauls GL, Lamberton DF, et al. Doppler derived aortic valve resistance in aortic stenosis: its hemodynamic validation. J Heart Valve Dis 1994; 3:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/19\">",
"      Bermejo J, Garc&iacute;a-Fern&aacute;ndez MA, Torrecilla EG, et al. Effects of dobutamine on Doppler echocardiographic indexes of aortic stenosis. J Am Coll Cardiol 1996; 28:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/20\">",
"      Tardif JC, Rodrigues AG, Hardy JF, et al. Simultaneous determination of aortic valve area by the Gorlin formula and by transesophageal echocardiography under different transvalvular flow conditions. Evidence that anatomic aortic valve area does not change with variations in flow in aortic stenosis. J Am Coll Cardiol 1997; 29:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/21\">",
"      Shively BK, Charlton GA, Crawford MH, Chaney RK. Flow dependence of valve area in aortic stenosis: relation to valve morphology. J Am Coll Cardiol 1998; 31:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/22\">",
"      Saad RM, Barbetseas J, Olmos L, et al. Application of the continuity equation and valve resistance to the evaluation of St. Jude Medical prosthetic aortic valve dysfunction. Am J Cardiol 1997; 80:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/23\">",
"      Roger VL, Seward JB, Bailey KR, et al. Aortic valve resistance in aortic stenosis: Doppler echocardiographic study and surgical correlation. Am Heart J 1997; 134:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/24\">",
"      Garcia D, Pibarot P, Dumesnil JG, et al. Assessment of aortic valve stenosis severity: A new index based on the energy loss concept. Circulation 2000; 101:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/25\">",
"      Garcia D, Dumesnil JG, Durand LG, et al. Discrepancies between catheter and Doppler estimates of valve effective orifice area can be predicted from the pressure recovery phenomenon: practical implications with regard to quantification of aortic stenosis severity. J Am Coll Cardiol 2003; 41:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/26\">",
"      Kim CJ, Berglund H, Nishioka T, et al. Correspondence of aortic valve area determination from transesophageal echocardiography, transthoracic echocardiography, and cardiac catheterization. Am Heart J 1996; 132:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/27\">",
"      Stoddard MF, Arce J, Liddell NE, et al. Two-dimensional transesophageal echocardiographic determination of aortic valve area in adults with aortic stenosis. Am Heart J 1991; 122:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/28\">",
"      Hoffmann R, Flachskampf FA, Hanrath P. Planimetry of orifice area in aortic stenosis using multiplane transesophageal echocardiography. J Am Coll Cardiol 1993; 22:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/29\">",
"      Baumgartner H. Hemodynamic assessment of aortic stenosis: are there still lessons to learn? J Am Coll Cardiol 2006; 47:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/30\">",
"      John AS, Dill T, Brandt RR, et al. Magnetic resonance to assess the aortic valve area in aortic stenosis: how does it compare to current diagnostic standards? J Am Coll Cardiol 2003; 42:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/31\">",
"      Feuchtner GM, Dichtl W, Friedrich GJ, et al. Multislice computed tomography for detection of patients with aortic valve stenosis and quantification of severity. J Am Coll Cardiol 2006; 47:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/32\">",
"      McMILLAN IK. Aortic stenosis; a post-mortem cinephotographic study of valve action. Br Heart J 1955; 17:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/33\">",
"      WOOD P. Aortic stenosis. Am J Cardiol 1958; 1:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/34\">",
"      Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis. Circulation 2010; 121:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/35\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/36\">",
"      Bache RJ, Wang Y, Jorgensen CR. Hemodynamic effects of exercise in isolated valvular aortic stenosis. Circulation 1971; 44:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1208/abstract/37\">",
"      deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. Am J Cardiol 1995; 75:191.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8115 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-5CD169F5DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1208=[""].join("\n");
var outline_f1_11_1208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIAC CATHETERIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gorlin equation for aortic valve area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Aortic valve resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Subvalvular gradients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Aortic valve area by continuity principle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Aortic valve resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Energy loss index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Rate of change in aortic valve area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Planimetry of aortic valve area",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER IMAGING MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Multislice CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CRITICAL VALVE AREA AND SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Valve area and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Indexing for body size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LOW GRADIENT AORTIC STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13954259\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8115|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/31/15871\" title=\"diagnostic image 1\">",
"      Aortic stenosis CW Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/12/27840\" title=\"diagnostic image 2\">",
"      AS AR continuous wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8115|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/61/9170\" title=\"figure 1\">",
"      Pressures aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/46/38637\" title=\"figure 2\">",
"      Rate change AV area progress AS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8115|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/22/44398\" title=\"movie 1\">",
"      Aortic stenosis continuous wave doppler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/33/17948\" title=\"table 1\">",
"      Severity of AS in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8115|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/21/6495\" title=\"waveform 1\">",
"      AS continuous wave Doppler",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=related_link\">",
"      Low gradient aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=related_link\">",
"      Management of patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=related_link\">",
"      Natural history of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=related_link\">",
"      Principles of Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of aortic valve disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_11_1209="Testosterone: Drug information";
var content_f1_11_1209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Testosterone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/27/22966?source=see_link\">",
"    see \"Testosterone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/35/29240?source=see_link\">",
"    see \"Testosterone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9632723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Androderm&reg;;",
"     </li>",
"     <li>",
"      AndroGel&reg;;",
"     </li>",
"     <li>",
"      Axiron&reg;;",
"     </li>",
"     <li>",
"      Delatestryl&reg;;",
"     </li>",
"     <li>",
"      Depo&reg;-Testosterone;",
"     </li>",
"     <li>",
"      First&reg;-Testosterone;",
"     </li>",
"     <li>",
"      First&reg;-Testosterone MC;",
"     </li>",
"     <li>",
"      Fortesta&trade;;",
"     </li>",
"     <li>",
"      Striant&reg;;",
"     </li>",
"     <li>",
"      Testim&reg;;",
"     </li>",
"     <li>",
"      Testopel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Andriol&reg;;",
"     </li>",
"     <li>",
"      Androderm&reg;;",
"     </li>",
"     <li>",
"      AndroGel&reg;;",
"     </li>",
"     <li>",
"      Andropository;",
"     </li>",
"     <li>",
"      Delatestryl&reg;;",
"     </li>",
"     <li>",
"      Depotest&reg; 100;",
"     </li>",
"     <li>",
"      Everone&reg; 200;",
"     </li>",
"     <li>",
"      PMS-Testosterone;",
"     </li>",
"     <li>",
"      Testim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F226028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Androgen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F226000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conditions associated with a deficiency or absence of endogenous testosterone:",
"     </b>",
"     <i>",
"      Oral capsule (Andriol&reg;; not available in U.S.):",
"     </i>",
"     Initial: 120-160 mg/day in 2 divided doses for 2-3 weeks; adjust according to individual response; usual maintenance dose: 40-120 mg/day (in divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Inoperable metastatic breast cancer (females):",
"     </b>",
"     <i>",
"      I.M. (testosterone enanthate):",
"     </i>",
"     200-400 mg every 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypogonadism or hypogonadotropic hypogonadism (males):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (testosterone enanthate or testosterone cypionate):",
"     </i>",
"     50-400 mg every 2-4 weeks (FDA-approved dosing range); 75-100 mg/week or 150-200 mg every 2 weeks (Bhasin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pellet (for subcutaneous implantation):",
"     </i>",
"     150-450 mg every 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Topical:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Buccal: 30 mg twice daily (every 12 hours) applied to the gum region above the incisor tooth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gel: Apply to clean, dry, intact skin.",
"     <b>",
"      Do not apply testosterone gel to the genitals.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AndroGel&reg; 1%: 50 mg applied once daily in the morning to the shoulder and upper arms, or abdomen. Dosage may be increased to a maximum of 100 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Dose adjustment based on testosterone levels:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Less than normal range: Increase dose from 50 mg to 75 mg or from 75 mg to 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Greater than normal range: Decrease dose. Discontinue if consistently above normal at 50 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AndroGel&reg; 1.62%: 40.5 mg applied once daily in the morning to the shoulder and upper arms. Dosage may be increased to a maximum of 81 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Dose adjustment based on testosterone levels:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &gt;750 ng/dL: Decrease dose by 20.25 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &ge;350 ng/dL to &le;750 ng/dL: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &lt;350 ng/dL: Increase dose by 20.25 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Fortesta&trade;: 40 mg once daily in the morning. Apply to the thighs. Dosing range: 10-70 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Dose adjustment based on serum testosterone levels:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &ge;2500 ng/dL: Decrease dose by 20 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &ge;1250 to &lt;2500 ng/dL: Decrease dose by 10 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &ge;500 and &lt;1250 ng/dL: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &lt;500 ng/dL: Increase dose by 10 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Testim&reg;: 5 g (containing 50 mg of testosterone) applied once daily (preferably in the morning) to the shoulder and upper arms. Dosage may be increased to a maximum of 10 g (containing 100 mg of testosterone) daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Dose adjustment based on testosterone levels:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Less than normal range: Increase dose from 5 g (50 mg testosterone) to 10 g (100 mg testosterone) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Greater than normal range: Decrease dose. Discontinue if consistently above normal at 5 g (50 mg testosterone) daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Solution (Axiron&reg;): 60 mg once daily (dosage range: 30-120 mg daily). Apply to the axilla at the same time each morning; do not apply to other parts of the body. Apply to clean, dry, intact skin.",
"     <b>",
"      Do not apply testosterone solution to the genitals.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Dose adjustment based on serum testosterone levels:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;1050 ng/dL: Decrease 60 mg daily dose to 30 mg daily; if levels &gt;1050 ng/dL persist after dose reduction, discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &lt;300 ng/dL: Increase 60 mg daily dose to 90 mg daily, or increase 90 mg daily dose to 120 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Transdermal system (Androderm&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose is either 4 mg daily or 5 mg and dose adjustment varies as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 4 mg daily (as one 4 mg/day patch; do",
"     <b>",
"      not",
"     </b>",
"     use two 2 mg/day patches)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Dose adjustment based on testosterone levels:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &gt;930 ng/dL:  Decrease dose to 2 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     400-930 ng/dL: Continue 4 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &lt;400 ng/dL: Increase dose to 6 mg daily(as one 4 mg/day and one 2 mg/day patch)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 5 mg daily (as one 5 mg/day or two 2.5 mg/day patches)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Dose adjustment based on testosterone levels:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &gt;1030 ng/dL: Decrease dose to 2.5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     300-1030 ng/dL: Continue 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &lt;300 ng/dL: Increase dose to 7.5 mg daily (as one 5 mg/day and one 2.5 mg/day patch)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Dosing conversion:",
"     </b>",
"     The 2.5 mg/day and the 5 mg/day patches have been discontinued in the U.S.; patients may be switched from the 2.5 mg/day patch, 5 mg/day patch, or the combination (ie, 7.5 mg/day) as follows.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     From 2.5 mg/day patch to 2 mg/day patch",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     From 5 mg/day patch to 4 mg/day patch",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     From 7.5 mg daily (one 2.5 mg/day and one 5 mg/day patch) to 6 mg daily (one 2 mg/day and one 4 mg/day patch)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patch change should occur at the next scheduled dosing. Measure early morning testosterone concentrations ~2 weeks after switching therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Delayed puberty (males):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      I.M. (testosterone enanthate):",
"     </i>",
"     50-200 mg every 2-4 weeks for a limited duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pellet (for subcutaneous implantation):",
"     </i>",
"     150-450 mg every 3-6 months",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F226019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/35/29240?source=see_link\">",
"      see \"Testosterone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Delayed puberty (adolescent males):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      I.M. (testosterone enanthate):",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pellet (for subcutaneous implantation):",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypogonadism or hypogonadotropic hypogonadism (adolescent males):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (testosterone enanthate or testosterone cypionate):",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pellet (for subcutaneous implantation):",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F226001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11386628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution; may enhance edema formation.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F226002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution; may enhance edema formation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [compounding kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&reg;-Testosterone MC: 2% (60 g) [contains benzyl alcohol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AndroGel&reg;: 1% [25 mg/packet] (30s); 1% [50 mg/packet] (30s); 1% [12.5 mg/actuation] (75 g); 1.62% [40.5 mg/packet] (30s); 1.62% [20.25 mg/actuation] (75 g); 1.62% [20.25 mg/packet] (30s) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortesta&trade;: 10 mg/actuation (60 g) [contains ethanol; 0.5 g gel/actuation; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Testim&reg;: 1% [50 mg/tube] (30s) [contains ethanol 74%; may be chemically synthesized from soy]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, subcutaneous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Testopel&reg;: 75 mg (10s, 24s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as cypionate: 100 mg/mL (10 mL [DSC]); 200 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo&reg;-Testosterone: 100 mg/mL (10 mL); 200 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, benzyl benzoate, cottonseed oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as enanthate: 200 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delatestryl&reg;: 200 mg/mL (5 mL) [contains chlorobutanol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mucoadhesive, for buccal application [buccal system]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Striant&reg;: 30 mg (60s) [may be chemically synthesized from soy]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical [compounding kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&reg;-Testosterone: 2% (60 g) [contains benzyl alcohol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Androderm&reg;: 2 mg/24 hours (60s); 4 mg/24 hours (30s) [contains ethanol, metal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as propionate: USP: 100% (25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Axiron&reg;: 30 mg/actuation (110 mL) [contains ethanol, isopropyl alcohol; 60 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, gelatin, as undecanoate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Andriol&trade;: 40 mg (10s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection, powder",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F226030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9632804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AndroGel&reg; 1%:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188474.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188474.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AndroGel&reg; 1.62%:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM255313.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM255313.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Axiron&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249396.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249396.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fortesta&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM239932.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM239932.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Testim&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188475.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188475.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Testosterone Gel:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM294248.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM294248.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F225974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Warm to room temperature; shaking vial will help redissolve crystals that have formed after storage. Administer by deep I.M. injection into the upper outer quadrant of the gluteus maximus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral, buccal application (Striant&reg;): One mucoadhesive for buccal application (buccal system) should be applied to a comfortable area above the incisor tooth. Place the flat side of the system on your fingertip. Gently push the curved side against your upper gum. Rotate to alternate sides of mouth with each application. Hold buccal system firmly in place for 30 seconds to ensure adhesion. The buccal system should adhere to gum for 12 hours. If the buccal system falls out, replace with a new system. If the system falls out within 4 hours of next dose, the new buccal system should remain in place until the time of the following scheduled dose. System will soften and mold to shape of gum as it absorbs moisture from mouth. Do not chew or swallow the buccal system. The buccal system will not dissolve; gently remove by sliding downwards from gum; avoid scratching gum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral, capsule (Andriol&reg;; not available in the U.S.): Should be administered with meals. Should be swallowed whole; do not crush or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Subcutaneous implant (Testopel&reg;): Using strict sterile technique, must be surgically implanted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal patch (Androderm&reg;): Apply patch to clean, dry area of skin on the back, abdomen, upper arms, or thigh. Do not apply to bony areas or parts of the body that are subject to prolonged pressure while sleeping or sitting.",
"     <b>",
"      Do not apply to the scrotum.",
"     </b>",
"     Avoid showering, washing the site, or swimming for 3 hours after application. Following patch removal, mild skin irritation may be treated with OTC hydrocortisone cream. A small amount of triamcinolone acetonide 0.1% cream may be applied under the system to decrease irritation; do not use ointment. Patch should be applied nightly. Rotate administration sites, allowing 7 days between applying to the same site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical gel and solution: Apply to clean, dry, intact skin. Application sites should be allowed to dry for a few minutes prior to dressing. Hands should be washed with soap and water after application.",
"     <b>",
"      Do not apply testosterone gel or solution to the genitals.",
"     </b>",
"     Alcohol-based gels and solutions are flammable; avoid fire or smoking until dry. Testosterone may be transferred to another person following skin-to-skin contact with the application site. Strict adherence to application instructions is needed in order to decrease secondary exposure. Thoroughly wash hands after application and cover application site with clothing (ie, shirt) once gel or solution has dried, or clean application site thoroughly with soap and water prior to contact in order to minimize transfer. In addition to skin-to-skin contact, secondary exposure has also been reported following exposure to secondary items (eg, towel, shirt, sheets). If secondary exposure occurs, the other person should thoroughly wash the skin with soap and water as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AndroGel&reg; 1%, AndroGel&reg; 1.62%, Testim&reg;: Apply (preferably in the morning) to the shoulder and upper arms. AndroGel&reg; 1% may also be applied to the abdomen; do not apply AndroGel&reg; 1.62% or Testim&reg; to the abdomen. Area of application should be limited to what will be covered by a short sleeve t-shirt. Apply at the same time each day. Upon opening the packet(s), the entire contents should be squeezed into the palm of the hand and immediately applied to the application site(s). Alternatively, a portion may be squeezed onto palm of hand and applied, repeating the process at the same or other site until entire packet has been applied. Application site(s) should not be washed for &ge;2 hours following application of AndroGel&reg; 1.62% or Testim&reg;, or &gt;5 hours for AndroGel&reg; 1%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     AndroGel&reg; 1% multidose pump: Prime pump 3 times (and discard this portion of product) prior to initial use. Each actuation delivers 12.5 mg of testosterone (4 actuations = 50 mg; 6 actuations = 75 mg; 8 actuations = 100 mg); each actuation may be applied individually or all at the same time. Application site should not be washed for &gt;5 hours following application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     AndroGel&reg; 1.62% multidose pump: Prime pump 3 times (and discard this portion of product) prior to initial use. Each actuation delivers 20.25 mg of testosterone (2 actuations = 40.5 mg; 3 actuations = 60.75 mg; 4 actuations = 81 mg); each actuation may be applied individually or all at the same time. Avoid washing the site or swimming for &ge;2 hours following application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Axiron&reg;: Apply using the applicator to the axilla at the same time each morning. Do not apply to other parts of the body (eg, abdomen, genitals, shoulders, upper arms). Avoid washing the site or swimming for 2 hours after application. Prior to first use, prime the applicator pump by depressing it 3 times (discard this portion of the product). After priming, position the nozzle over the applicator cup and depress pump fully one time; ensure liquid enters cup. Each pump actuation delivers testosterone 30 mg. No more than 30 mg (one pump) should be added to the cup at one time. The total dose should be divided between axilla (example, 30 mg/day: apply to one axilla only; 60 mg/day: apply 30 mg to each axilla; 90 mg/day: apply 30 mg to each axilla, allow to dry, then apply an additional 30 mg to one axilla; etc). To apply dose, keep applicator upright and wipe into the axilla; if solution runs or drips, use cup to wipe. Do not rub into skin with fingers or hand. If more than one 30 mg dose is needed, repeat process. Apply roll-on or stick antiperspirants or deodorants prior to testosterone. Once application site is dry, cover with clothing. After use, rinse applicator under running water and pat dry with a tissue. The application site and dose of this product are not interchangeable with other topical testosterone products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Fortesta&trade;: Apply to skin of front and inner thighs. Do not apply to other parts of the body. Use one finger to rub gel evenly onto skin of each thigh. Avoid showering, washing the site, or swimming for 2 hours after application. Prior to first dose, prime the pump by holding canister upright and fully depressing the pump 8 times (discard this portion of the product). Each pump actuation delivers testosterone 10 mg. The total dose should be divided between thighs (example, 10 mg/day: apply 10 mg to one thigh only; 20 mg/day: apply 10 mg to each thigh; 30 mg/day: apply 20 mg to one thigh and 10 mg to the other thigh; etc). Once application site is dry, cover with clothing. The application site and dose of this product are not interchangeable with other topical testosterone products.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F225973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Androgen replacement therapy in the treatment of delayed male puberty; male hypogonadism (primary or hypogonadotropic); inoperable metastatic female breast cancer (enanthate only)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pellet: Androgen replacement therapy in the treatment of delayed male puberty; male hypogonadism (primary or hypogonadotropic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Buccal system, topical gel, topical solution, transdermal system: Male hypogonadism (primary or hypogonadotropic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule (not available in U.S.): Conditions associated with a deficiency or absence of endogenous testosterone",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F226035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Testosterone may be confused with testolactone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Testoderm may be confused with Estraderm&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AndroGel&reg; 1% may be confused with AndroGel&reg; 1.62%",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bio-T-Gel may be confused with T-Gel",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - weak).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F226026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Deep venous thrombosis, edema, hypertension, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, aggressive behavior, anger, amnesia, anxiety, blood pressure increased/decreased, chills, depression, dizziness, emotional lability, excitation, fatigue, headache, hostility, insomnia, malaise, memory loss, mood swings, nervousness, seizure, sleep apnea, sleeplessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, contact dermatitis, dry skin, erythema, folliculitis, hair discoloration, hirsutism (increase in pubic hair growth), pruritus, rash, seborrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain/soreness, gonadotropin secretion decreased, growth acceleration, gynecomastia, hot flashes, hypercalcemia, hyperchloremia, hypercholesterolemia, hyper-/hypoglycemia, hyper-/hypokalemia, hyperlipidemia, hypernatremia, inorganic phosphate retention, libido changes, menstrual problems (including amenorrhea), virilism, water retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased, diarrhea, gastroesophageal reflux, GI bleeding, GI irritation, nausea, taste disorder, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Following buccal administration (most common): Bitter taste, gum edema, gum or mouth irritation, gum pain, gum tenderness, taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder irritability, impotence, oligospermia, penile erections (spontaneous), priapism, prostatic carcinoma, prostatic hyperplasia, prostatitis, PSA increased, testicular atrophy, urination impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, cholestatic hepatitis, cholestatic jaundice, hepatic dysfunction, hepatic necrosis, hepatocellular neoplasms, liver function test changes, peliosis hepatis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding, hematocrit/hemoglobin increased, leukopenia, polycythemia, suppression of clotting factors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reaction (gel, solution), injection site inflammation/pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal system: Pruritus at application site (17% to 37%), burn-like blisters under system (12%), erythema at application site (&le;7%), vesicles at application site (6%), allergic contact dermatitis to system (4%), burning at application site (3%), induration at application site (3%), exfoliation at application site (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, hemarthrosis, hyperkinesias, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Creatinine increased, hematuria, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasopharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, diaphoresis, hypersensitivity reactions, smell disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Injection: Cough, coughing fits, respiratory distress; migraine; virilization of children following secondary exposure to topical gel (advanced bone age, aggressive behavior, enlargement of clitoris requiring surgery, enlargement of penis, erections increased, libido increased, pubic hair development); vitreous detachment",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F225977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to testosterone or any component of the formulation; males with known or suspected carcinoma of the breast or prostate; women who are breast-feeding, pregnant, or who may become pregnant (",
"     <b>",
"      Note:",
"     </b>",
"     Striant&reg; and Testim&reg; are contraindicated in all women.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depo&reg;-Testosterone: Also contraindicated in serious hepatic, renal, or cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F225958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyslipidemia: May alter serum lipid profile; use caution with history of MI or coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gynecomastia: May cause gynecomastia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Prolonged use of high doses of oral androgens has been associated with serious hepatic effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, jaundice). Prolonged use of intramuscular testosterone enanthate has been associated with multiple hepatic adenomas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: May cause hypercalcemia in patients with prolonged immobilization or cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: Has both androgenic and anabolic activity, the anabolic action may enhance hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polycythemia: May increase hematocrit requiring dose adjustment or discontinuation. Discontinue therapy if  hematocrit exceeds 54%; may reinitiate at lower dose (Bhasin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate cancer: May increase the risk of prostate cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Spermatogenesis: Large doses may suppress spermatogenesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benign prostatic hyperplasia (BPH): Discontinue therapy if urethral obstruction develops in patients with BPH (use lower dose if restarted). Withhold therapy pending urological evaluation in patients with palpable prostate nodule or induration, PSA &gt;4 ng/mL, or PSA &gt;3 ng/mL in men at high risk of prostate cancer (Bhasin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal or hepatic impairment) or medications that enhance edema formation (eg, corticosteroids); testosterone may cause fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep apnea: May potentiate sleep apnea in some male patients (obesity or chronic lung disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be inappropriate in this age group due to potential risk of cardiac problems and contraindication for use in men with prostate cancer; in general, avoid use in older adults except in the setting of moderate-to-severe hypogonadism (Beers Criteria). In addition, elderly patients may be at greater risk for prostatic hyperplasia, prostate cancer, fluid retention, and transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May accelerate bone maturation without producing compensatory gain in linear growth in children; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers. Gels, solution,  transdermal, and buccal system have not been evaluated in males &lt;18 years of age; safety and efficacy of injection have not been established in males &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women: During treatment for metastatic breast cancer, women should be monitored for signs of virilization; discontinue if mild virilization is present to prevent irreversible symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gel: Fortesta&trade; is not interchangeable with other topical testosterone products.  AndroGel&reg; 1% and AndroGel&reg; 1.62% are not interchangeable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Solution: Axiron&reg; is not interchangeable with other topical testosterone products. Use in males with BMI &gt;35 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Soy: Some testosterone products may be chemically synthesized from soy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary exposure: Testosterone may be transferred to another person following skin-to-skin contact with the application site.",
"     <b>",
"      [U.S. Boxed Warning]: Virilization in children has been reported following contact with unwashed or unclothed application sites of men using topical testosterone. Patients should strictly adhere to instructions for use in order to prevent secondary exposure.",
"     </b>",
"     Virilization of female sexual partners has also been reported with male use of topical testosterone. Symptoms of virilization generally regress following removal of exposure; however, in some children, enlarged genitalia and bone age did not fully return to age appropriate normal. Signs of inappropriate virilization in women or children following secondary exposure to topical testosterone should be brought to the attention of a healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F226024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F225991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease testosterone levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Testosterone may cause adverse effects, including masculinization of the female fetus, if used during pregnancy. Females who are or may become pregnant should also avoid skin-to-skin contact to areas where testosterone has been applied topically on another person.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F226006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4472757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High levels of endogenous maternal testosterone, such as those caused by certain ovarian cysts, suppress milk production. Maternal serum testosterone levels generally fall following pregnancy and return to normal once breast-feeding is stopped. The amount of testosterone present in breast milk or the effect to the nursing infant following maternal supplementation is not known. Some products are contraindicated while breast-feeding. Females who are nursing should avoid skin-to-skin contact to areas where testosterone has been applied topically on another person.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F225981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Testosterone USP may be synthesized from soy. Food and beverages have not been found to interfere with buccal system; ensure system is in place following eating, drinking, or brushing teeth.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F225979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (First-Testosterone MC Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60 g): $74.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (AndroGel Pump Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 GM/ACT (1%) (75 g): $212.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20.25 MG/ACT (1.62%) (75 g): $412.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (AndroGel Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20.25 MG/1.25GM (1.62%) (1.25 g): $13.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/2.5 g (2.5 g): $13.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40.5 MG/2.5GM (1.62%) (2.5 g): $14.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 g (5 g): $14.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Fortesta Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 MG/ACT (2%) (60 g): $394.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Testim Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 g (5 g): $13.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Misc",
"     </b>",
"     (Striant Buccal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (60): $450.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Delatestryl Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/mL (5 mL): $99.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Depo-Testosterone Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (10 mL): $76.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/mL (1 mL): $28.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Testosterone Cypionate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (10 mL): $59.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/mL (10 mL): $101.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Testosterone Enanthate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/mL (5 mL): $84.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (First-Testosterone Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60 g): $71.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Androderm Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/24 hrs (1): $6.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/24 hrs (1): $13.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pellet",
"     </b>",
"     (Testopel Implant)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (10): $962.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Axiron Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/ACT (90 mL): $396.96",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F225967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, lipid panel, hemoglobin and hematocrit (prior to therapy, at 3-6 months, then annually); radiologic examination of wrist and hand every 6 months (when using in prepubertal children). Withhold initial treatment with hematocrit &gt;50% (discontinue therapy if hematocrit exceeds 54% [Bhasin, 2010]), hyperviscosity, untreated obstructive sleep apnea, or uncontrolled severe heart failure. Monitor urine and serum calcium and signs of virilization in women treated for breast cancer. Serum glucose (may be decreased by testosterone, monitor patients with diabetes). Evaluate males for response to treatment and adverse events 3-6 months after initiation and then annually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bone mineral density: Monitor after 1-2 years of therapy in hypogonadal men with osteoporosis or low trauma fracture (Bhasin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PSA: In men &gt;40 years of age with baseline PSA &gt;0.6 ng/mL, PSA and prostate exam (prior to therapy, at 3-6 months, then as based on current guidelines). Withhold treatment pending urological evaluation in patients with palpable prostate nodule or induration or PSA &gt;4 ng/mL or if PSA &gt;3 ng/mL in men at high risk of prostate cancer (Bhasin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Do not treat with severe untreated BPH with IPSS symptom score &gt;19.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum testosterone: After initial dose titration (if applicable), monitor 3-6 months after initiating treatment, then annually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection: Measure midway between injections. Adjust dose or frequency if testosterone concentration is &lt;400 ng/dL or &gt;700 ng/dL (Bhasin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AndroGel&reg; 1%, Testim&reg;: Morning serum testosterone levels ~14 days after start of therapy or dose adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AndroGel&reg; 1.62%: Morning serum testosterone levels after 14 and 28 days of starting therapy or dose adjustments and periodically thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Androderm&reg;: Morning serum testosterone levels (following application the previous evening) ~14 days after start of therapy or dose adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Axiron&reg;: Serum testosterone levels can be measured 2-8 hours after application and after 14 days of starting therapy or dose adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortesta&trade;: Serum testosterone levels can be measured 2 hours after application and after 14 and 35 days of starting therapy or dose adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Striant&reg;: Application area of gums; total serum testosterone 4-12 weeks after initiating treatment, prior to morning dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Testopel&reg;: Measure at the end of the dosing interval (Bhasin, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F225971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Total testosterone, males:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     12-13 years: &lt;800 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     14 years: &lt;1200 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     15-16 years: 100-1200ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     17-18 years: 300-1200 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     19-40 years: 300-950 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;40 years: 240-950 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Free testosterone, males: 9-30 ng/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F225982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Androderm (AU);",
"     </li>",
"     <li>",
"      Androgel (BE, CZ, EC, EE, FR, HK, HN, IE, IL, IT, NL, PT, RU, SG);",
"     </li>",
"     <li>",
"      Andropatch (GR);",
"     </li>",
"     <li>",
"      Aquaviron (IN);",
"     </li>",
"     <li>",
"      Depo-TCP (KP);",
"     </li>",
"     <li>",
"      Depo-Test (TH);",
"     </li>",
"     <li>",
"      Depo-Testosterone (MY, NZ, ZA);",
"     </li>",
"     <li>",
"      Depot Hormon-M (TW);",
"     </li>",
"     <li>",
"      Intrinsa Patch (FR, GB, IE);",
"     </li>",
"     <li>",
"      Lowtiyel (MX);",
"     </li>",
"     <li>",
"      Omnadren (PL);",
"     </li>",
"     <li>",
"      Primoniat Depot (CN);",
"     </li>",
"     <li>",
"      Primoteston Depot (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Proviron Depot (VE);",
"     </li>",
"     <li>",
"      Striant SR Buccal (GB);",
"     </li>",
"     <li>",
"      Testex (ES);",
"     </li>",
"     <li>",
"      Testim (BE, GB, IE, NO, PT);",
"     </li>",
"     <li>",
"      Testo Gel (IE);",
"     </li>",
"     <li>",
"      Testoderm (AT);",
"     </li>",
"     <li>",
"      Testogel (AU, BG);",
"     </li>",
"     <li>",
"      Testomax (IL);",
"     </li>",
"     <li>",
"      Testopatch (FR);",
"     </li>",
"     <li>",
"      Testosteron Ferring (AT);",
"     </li>",
"     <li>",
"      Testosteronum propionicum (PL);",
"     </li>",
"     <li>",
"      Testotop (LU);",
"     </li>",
"     <li>",
"      Testoviron (PK);",
"     </li>",
"     <li>",
"      Testoviron-Depot (AR, CH, CO, DE, DK, PE, PY, SE, UY);",
"     </li>",
"     <li>",
"      Tostran (GB);",
"     </li>",
"     <li>",
"      Tostrex (ID);",
"     </li>",
"     <li>",
"      Virormone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F225957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Principal endogenous androgen responsible for promoting the growth and development of the male sex organs and maintaining secondary sex characteristics in androgen-deficient males",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F225976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (route and ester dependent): I.M.: Cypionate and enanthate esters have longest duration, &le;2-4 weeks; gel: 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Transdermal gel: ~10% of applied dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%; bound to sex hormone-binding globulin (40%) and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms metabolites, including dihydrotestosterone (DHT) and estradiol (both active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Variable: 10-100 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90%); feces (6%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1209/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhasin S, Cunningham GR, Hayes FJ, et al, &ldquo;Testosterone Therapy In Men With Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(6):2536-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1209/abstract-text/20525905/pubmed\" id=\"20525905\" target=\"_blank\">",
"        20525905",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petak SM, Nankin HR, Spark RF, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients &minus; 2002 Update,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2002, 8(6):440-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1209/abstract-text/15260010/pubmed\" id=\"15260010\" target=\"_blank\">",
"        15260010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wierman ME, Basson R, Davis SR, et al, &ldquo;Androgen therapy in Women: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2006, 91(10):3697-710.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/11/1209/abstract-text/17018650/pubmed\" id=\"17018650\" target=\"_blank\">",
"        17018650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9981 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1209=[""].join("\n");
var outline_f1_11_1209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9632723\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225996\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225997\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226028\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226000\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226019\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226001\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11386628\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226002\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950983\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225954\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226030\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9632804\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225974\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225973\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226035\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226026\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225977\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225958\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226024\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225962\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225991\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225965\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225980\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226006\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4472757\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225981\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225979\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225967\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225971\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225982\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225957\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225976\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9981\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9981|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/27/22966?source=related_link\">",
"      Testosterone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/35/29240?source=related_link\">",
"      Testosterone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_11_1210="Drug allergy: Classification and clinical features";
var content_f1_11_1210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug allergy: Classification and clinical features",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1210/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1210/contributors\">",
"     Werner J Pichler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1210/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/11/1210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/11/1210/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/11/1210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DEFINITION OF DRUG ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A drug allergy, or an allergic drug reaction, is an adverse drug reaction that results from a specific immunologic response to a medication. The term immunologic drug reaction is also used to describe these reactions.",
"   </p>",
"   <p>",
"    The classification and clinical features of drug allergy will be reviewed here, beginning with a categorization of the different types of adverse drug reactions. The pathogenesis of drug allergy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link\">",
"     \"Drug allergy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADVERSE DRUG REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adverse drug reaction is a general term referring to any untoward reaction to a medication. Adverse drug reactions may be broadly divided into two types (",
"    <a class=\"graphic graphic_table graphicRef51797 \" href=\"UTD.htm?6/32/6668\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type A reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type A reactions can affect any individual, given sufficient dose and exposure, and are predictable from the known pharmacologic properties of a drug. These make up 85 to 90 percent of all adverse drug reactions. Examples of type A reactions include diarrhea in response to antibiotics, gastritis in association with nonsteroidal antiinflammatory drugs, or aminoglycoside nephrotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type B reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type B reactions make up 10 to 15 percent of adverse drug reactions. These are hypersensitivity reactions that occur in a susceptible subgroup of patients, have signs and symptoms that are different from the pharmacologic actions of the drug, and usually cannot be predicted.",
"   </p>",
"   <p>",
"    Notable exceptions are the",
"    <strong>",
"     predictable",
"    </strong>",
"    hypersensitivity reactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , and flucloxacillin in patients with certain HLA types. HLA testing of patients is recommended before administering abacavir and carbamazepine in populations in which there is appreciable prevalence of the genotype. Specific screening recommendations are discussed in more detail separately. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Drug-induced hypersensitivity syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link&amp;anchor=H6#H6\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\", section on 'Abacavir'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type B reactions may be further subdivided as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Exaggerated sensitivity to known drug toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients experience the pharmacologically predictable toxicity of a drug (or several drugs) at low and sometimes subtherapeutic doses. An example would be the individual who develops tinnitus in response to a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . This putatively reflects altered drug metabolism or increased end-organ sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with this type of drug intolerance are usually identifiable by a careful review of past adverse drug reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Idiosyncratic drug reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiosyncratic drug reactions are qualitatively distinct from the known pharmacologic toxicities of the drug. These reactions can arise from genetic differences in the patient, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    causing nonimmune hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aside from a few well-described examples, the mechanisms of most idiosyncratic drug reactions remain obscure and probably reflect complex interactions of metabolic and constitutional factors. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Pseudoallergic reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Immunologic drug reactions (drug allergy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug allergies result from specific immunologic responses to medications. Allergic drug reactions account for about 6 to 10 percent of all adverse drug reactions, but up to 10 percent of fatal reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF DRUG ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are different systems of classifying immunologic drug reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Classification based upon timing of symptom onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Allergy Organization (WAO) has recommended dividing immunologic drug reactions into immediate reactions (ie, onset within one hour of exposure) and delayed reactions (onset after one hour), based upon the timing of the appearance of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Immediate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WAO distinction between immediate and delayed drug reactions is intended to distinguish IgE-mediated, type I reactions from other types. Type I reactions classically begin within one hour of the first administered dose. However, some IgE-mediated reactions appear after one hour, particularly after oral administration of a drug. In addition, taking the medication with food further slows absorption. Nevertheless, this period of one hour identifies the majority of IgE-mediated reactions, which carry the risk of anaphylaxis if the patient is re-exposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Delayed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions appearing after one hour are classified as delayed, although most delayed reactions begin after six hours and typically after days of treatment. As an example, delayed reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    classically start on day 7 to 10 of treatment, and may even begin 1 to 3 days after cessation of treatment. These reactions may be caused by several different mechanisms, but are not IgE-mediated.",
"   </p>",
"   <p>",
"    Some delayed reactions begin after weeks of continuous treatment. One such disorder is \"drug rash with eosinophilia and systemic symptoms\" (DRESS), which is a systemic drug reaction that begins 1 to 12 weeks into continuous treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/5\">",
"     5",
"    </a>",
"    ]. This reaction, which is also called \"drug-induced hypersensitivity syndrome\" (DiHS), is characterized by fever, rash, and multiorgan involvement. The liver (hepatitis) and heart (hypersensitivity myocarditis) may be affected. These reactions can persist for weeks to months, even after the medication is stopped. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Type IV Reactions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Hypersensitivity myocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Classification by reaction types",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, immunologic reactions, whether caused by drugs, infections, or autoimmune processes, have been divided into four categories (I to IV) according to the Gell and Coombs system (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I: Immediate in onset and mediated by IgE and mast cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      basophils",
"     </li>",
"     <li>",
"      Type II: Delayed in onset and caused by antibody (usually IgG) mediated cell destruction",
"     </li>",
"     <li>",
"      Type III: Delayed in onset and caused by IgG:drug immune complex deposition and complement activation",
"     </li>",
"     <li>",
"      Type IV: Delayed in onset and T cell-mediated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, this classification was established before a detailed analysis of T cell subsets and functions was technically possible. As new immunologic tools were developed, type IV reactions were further subdivided into types IVa, IVb, IVc, and IVd (",
"    <a class=\"graphic graphic_figure graphicRef75626 \" href=\"UTD.htm?8/5/8280\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Subcategories of type IV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Medications cause types I and IV reactions far more commonly than types II and III. Most medications cause just one type, although certain drugs, such as penicillin, can induce all four types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TYPE I REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I reactions require the presence of drug-specific immunoglobulin E (IgE). Some patients form drug-specific IgE upon exposure to a medication, although most do not.",
"   </p>",
"   <p>",
"    Once formed, drug-specific IgE occupies surface receptors on mast cells and basophils throughout the body. If the drug is encountered again, it may bind to these IgE molecules, causing crosslinking of the receptors and activation of the cells, resulting in symptoms. IgE-mediated reactions are dose-dependent, although this may not be clinically apparent because even very low doses can cause severe systemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of type I reactions are directly attributable to the vasoactive mediators released by mast cells and basophils. The most common signs and symptoms are urticarial rash (",
"    <a class=\"graphic graphic_picture graphicRef75230 \" href=\"UTD.htm?27/16/27905\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72519 \" href=\"UTD.htm?29/2/29728\">",
"     picture 2",
"    </a>",
"    ); pruritus; flushing; angioedema of the face, extremities, or laryngeal tissues (leading to throat tightness with stridor, or rarely asphyxiation); wheezing; gastrointestinal symptoms;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension.",
"   </p>",
"   <p>",
"    Anaphylaxis is the most severe presentation of an IgE-mediated drug reaction. Mast cell tryptase and histamine can be elevated in the circulation just after anaphylaxis, and the detection of these mediators implicates mast cells and basophils in the reaction, supporting the diagnosis of anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither fever nor elevations in serum C-reactive protein are seen with IgE-mediated reactions. The absence of these features can help distinguish IgE-mediated reactions from some other adverse drug reactions.",
"   </p>",
"   <p>",
"    The presence of urticaria is useful in identifying IgE-mediated reactions, because the classical wheal and flare are hallmark signs of mast cell degranulation. However, other skin findings in drug reactions can mimic urticaria and it can be difficult to discern if a rash was truly urticarial based upon history alone. Many delayed reactions involve a pruritic exanthem or rash that causes diffuse swelling of the skin, and affected patients will report raised, itchy areas of skin. However, these delayed-onset edematous exanthems are NOT urticarial rashes. In addition, they are generally not dangerous, provided the skin does not blister or slough and there are no signs of organ inflammation. Reactions involving rash and organ inflammation are discussed below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Type IV Reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of onset of type I reactions is rapid but varies with the clinical setting and presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgE-mediated reactions occur rapidly after the last administered dose, which underlies the designation of immediate by the World Allergy Organization. The time to onset is influenced by the route of administration: intravenously administered medications may cause symptoms in seconds to minutes, while the same drug administered orally may cause symptoms in 3 to 30 minutes if taken on an empty stomach, and in 10 to 60 minutes if taken with food.",
"     </li>",
"     <li>",
"      IgE-mediated anaphylactic reactions should NOT begin several days into a course of therapy, if the patient's exposure to the drug has been continuous. However, if several doses are skipped, symptoms can appear when the drug is resumed.",
"     </li>",
"     <li>",
"      Isolated urticarial rashes can occur late during continuous therapy. These rashes are relatively common and sometimes look like an intermediate between an urticarial and maculopapular eruption. The delayed appearance of urticarial rashes with known allergenic drugs like beta lactam antibiotics may reflect time required for significant IgE responses, just as for late-occurring serum sickness reactions. However, late urticarial rashes with drugs that rarely cause acute allergy (eg, macrolide antibiotics) makes it unlikely that many of these reactions are IgE-mediated and T cells may also be involved, although the pathogenesis is not known. Tests for immediate-type allergy are usually negative.",
"     </li>",
"     <li>",
"      Rash and urticaria appearing within minutes to hours after drug intake can also be seen in \"pseudoallergic\" reactions. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Pseudoallergic reactions'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Commonly-implicated drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drugs most commonly implicated in type I reactions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta lactam drugs (penicillins and cephalosporins). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuromuscular blocking agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link\">",
"       \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Quinolones: Quinolone antibiotics have been implicated as a common cause of hypersensitivity reactions in Europe but less commonly in the United States, so there may be important geographical variations that will become more apparent over time [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/7\">",
"       7",
"      </a>",
"      ]. Only a subset of these reactions is IgE-mediated [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Platinum containing chemotherapeutic agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link\">",
"       \"Infusion reactions to systemic chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Foreign proteins, including chimeric antibodies such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      : The frequency with which these agents cause anaphylaxis can also vary by geographical location (eg, cetuximab-induced anaphylaxis has been reported mostly in the Southern United States). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link\">",
"       \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Previous exposure to the suspect drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated reactions generally require previous exposure to the drug in question. However, the absence of a known prior exposure does not exclude an IgE-mediated reaction, because sensitization may have occurred from exposure to a cross-reactive compound, even though the patient showed no signs of allergy to the sensitizing product.",
"   </p>",
"   <p>",
"    The following examples illustrate this phenomenon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant percentage of patients experiencing anaphylaxis upon first exposure to neuromuscular blocking agents are believed to have been previously sensitized through the use of various cosmetics, personal products, and nonprescription cough remedies (eg, pholcodine in Norway) that contain tertiary and quaternary ammonium groups [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. The ammonium groups shared by all of these agents are highly immunoreactive and can induce cross-reactive IgE antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link\">",
"       \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients develop anaphylaxis to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      and appear to have been previously sensitized to oligosaccharides present on the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/13\">",
"       13",
"      </a>",
"      ]. The same oligosaccharides are found on several nonprimate mammalian proteins, such as beef, pork, and lamb, although the source of the original sensitization is still uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"       \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TYPE II REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II reactions are uncommon and involve antibody-mediated cell destruction. Type II reactions may arise when drugs bind to surfaces of certain cell types and act as antigens. Subsequent binding of antibodies to the cell surface results in the cells being targeted for clearance by macrophages. Type II reactions may involve complement activation, but this is variable.",
"   </p>",
"   <p>",
"    Clinical manifestations require the presence of high titers of preformed drug-specific IgG (or rarely IgM) antibodies, which are only made by a small percentage of individuals and usually in the setting of high-dose, long-term, or recurrent drug exposure. The factors predisposing individuals to form these antibodies are not fully understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical features and timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II drug reactions usually present as hemolytic anemia, thrombocytopenia, or neutropenia, since these are the cell types that are most often affected.",
"   </p>",
"   <p>",
"    The clinical presentation can vary widely in severity; patients may be asymptomatic or present with fulminant illness. Symptoms usually appear at least five to eight days after exposure, but may begin after much longer periods of treatment. Symptoms can start within hours if the causative drug is stopped and then restarted.",
"   </p>",
"   <p>",
"    Specific manifestations depend upon the cell type involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemolytic anemia may present with dyspnea, varying degrees of fatigue, pallor, jaundice, dark urine, or signs and symptoms of the hyperdynamic state, such as bounding pulses, palpitations, and \"roaring in the ears.\"",
"      <br/>",
"      <br/>",
"      The drugs most commonly implicated in hemolytic anemia are cephalosporins, penicillins, nonsteroidal antiinflammatory drugs (NSAIDs), and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"        quinine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"        quinidine",
"       </a>",
"       .",
"      </span>",
"      The evaluation and diagnosis of drug-induced hemolytic anemia are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Drug-related immune hemolysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced thrombocytopenia typically presents with petechial bleeding in the skin and buccal mucosa and isolated thrombocytopenia, often severe (ie,",
"      <span class=\"nowrap\">",
"       &lt;20,000/microL)",
"      </span>",
"      in a patient taking one or several medications. There may be splenomegaly and hepatomegaly due to platelet sequestration in these organs.",
"      <br/>",
"      <br/>",
"      Drugs implicated in thrombocytopenia include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , sulfonamides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , gold compounds, beta-lactam antibiotics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , nonsteroidal antiinflammatory drugs, and others. This evaluation and diagnosis of this disorder are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"       \"Drug-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe neutropenia or agranulocytosis due to type II drug reactions presents days to weeks after beginning the medication, often with acute and clinically apparent symptoms of infection, such as fever, stomatitis, pharyngitis, pneumonia, or sepsis. Rechallenge or inadvertent subsequent administration is associated with a prompt recurrence, even with low doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Culprit drugs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU), the antimalarial drug amodiaquine and one of its major metabolites, mono-desethyl amodiaquine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    . The evaluation and diagnosis of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TYPE III REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type III reactions are mediated by antigen-antibody complexes. These reactions are uncommon and usually seen in the context of high-dose, prolonged drug administration, similar to type II reactions.",
"   </p>",
"   <p>",
"    In a type III reaction, the drug acts as a soluble antigen and binds drug-specific IgG, forming small immune complexes that precipitate in various tissues, including blood vessels, joints, and renal glomeruli. These immune complexes bind to Fc-IgG receptors of inflammatory cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activate complement, and an inflammatory response ensues. Reexposure to similar or higher doses of the same drug can cause a more rapid and severe recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms take one or more weeks to develop after drug exposure, since significant quantities of antibody are needed to generate symptoms related to antigen-antibody complexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type III reactions can take several forms:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic serum sickness involves fever, urticarial or purpuric rash, arthralgias,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute glomerulonephritis. Alternatively, just one or two of these features may be apparent. Other findings include lymphadenopathy, low serum complement levels, and an elevated erythrocyte sedimentation rate. The most common culprits are penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced hypersensitivity vasculitis typically presents as palpable purpura",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    petechiae, fever, urticaria, arthralgias, lymphadenopathy, elevated erythrocyte sedimentation rate, and low complement levels. Purpuric lesions often affect the lower extremities. Uncommonly, other organs, such as the gastrointestinal tract or kidneys, are involved. The most common culprits are penicillins, cephalosporins, sulfonamides (including most loop and thiazide-type diuretics),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Drug fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever can be the sole symptom or the most prominent symptom of drug hypersensitivity, accompanied in a minority of cases by nonurticarial rash or other organ involvement. Medications implicated in causing drug fever include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Drug fever can arise from type IV immunologic reactions as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=see_link&amp;anchor=H4#H4\">",
"     \"Drug fever\", section on 'Fever associated with hypersensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TYPE IV REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type IV reactions are not mediated by antibodies, in contrast to the other three types above. Type IV drug reactions involve the activation and expansion of T cells, which requires time (normally many hours or days after antigen exposure), hence the name delayed type hypersensitivity (DTH). In some cases, other cell types (eg, macrophages, eosinophils, or neutrophils) are also involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions involving T cells have prominent skin findings, because the skin is a repository for an enormous number of T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/14\">",
"     14",
"    </a>",
"    ]. Many cutaneous T cells are primed memory-effector cells, which react rapidly if immunogenic agents penetrate the skin barrier or diffuse into the skin from the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recognized patterns of cutaneous involvement include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Contact dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact dermatitis is a reaction to topically applied drugs, which is characterized by erythema and edema with vesicles or bullae that often rupture, leaving a crust [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/16\">",
"     16",
"    </a>",
"    ]. Subacute and chronic contact dermatitis are characterized by lichenification, erythema, and scaling (",
"    <a class=\"graphic graphic_picture graphicRef71913 \" href=\"UTD.htm?33/61/34782\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=see_link\">",
"     \"Contact dermatitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Morbilliform eruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbilliform or maculopapular eruptions are common and may arise from type IV immunologic reactions, as well as from other mechanisms. (",
"    <a class=\"graphic graphic_picture graphicRef70062 \" href=\"UTD.htm?31/30/32239\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H3#H3\">",
"     \"Drug eruptions\", section on 'Drug-induced exanthems'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Stevens-Johnson syndrome and toxic epidermal necrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe exfoliative dermatitides, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, are potentially life-threatening reactions characterized by fever and mucocutaneous lesions leading to necrosis and sloughing of the epidermis. (",
"    <a class=\"graphic graphic_picture graphicRef66134 \" href=\"UTD.htm?17/63/18419\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67632 \" href=\"UTD.htm?24/48/25345\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68682 \" href=\"UTD.htm?41/55/42866\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Drug-induced hypersensitivity syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced hypersensitivity syndrome (DiHS), also called drug rash with eosinophilia and systemic symptoms (DRESS), is a severe drug hypersensitivity reaction involving rash, fever (38 to 40&deg;C) and multi organ failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/5,22,23\">",
"     5,22,23",
"    </a>",
"    ]. The liver, kidneys, heart,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lungs are most often affected. Drugs that have been implicated in causing",
"    <span class=\"nowrap\">",
"     DRESS/DiHS",
"    </span>",
"    include several antiepileptics (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Debate is ongoing about the most accurate name for this syndrome, as fewer than one-half of cases show peripheral eosinophilia (eg, those caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    typically do not). The presence of atypical lymphocytes (CD8+) is a more consistent finding, which may persist for months after drug withdrawal.",
"   </p>",
"   <p>",
"    Certain medications tend to cause inflammation predominantly affecting a specific organ. For example, anticonvulsant-induced DiHS frequently involves hepatitis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    can cause nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/24\">",
"     24",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    can cause pneumonitis.",
"   </p>",
"   <p>",
"    Occasionally with T cell-mediated hypersensitivity, organ involvement occurs in the absence of skin findings. Presentations include isolated, drug-induced hepatitis, isolated interstitial nephritis, and isolated pneumonitis. Identification of this presentation as drug allergy can be challenging.",
"   </p>",
"   <p>",
"    Some",
"    <span class=\"nowrap\">",
"     DiHS/DRESS",
"    </span>",
"    reactions occur more frequently in patients with certain HLA types, a phenomenon that is also seen in Stevens-Johnson syndrome and toxic epidermal necrolysis. Specific examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       DiHS/DRESS",
"      </span>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      is associated with HLA-B*5801 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       DiHS/DRESS,",
"      </span>",
"      and in some cases",
"      <span class=\"nowrap\">",
"       SJS/TEN,",
"      </span>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      disproportionately affects several groups",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Han Chinese patients with HLA-B1502 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/26\">",
"       26",
"      </a>",
"      ], as well as Thai, Malaysian, and Indian patients with this same allele [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Japanese and European patients with HLA-A*3101 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       DiHS/DRESS",
"      </span>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      occur predominantly in patients with HLA-B*5701",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a patient has been identified as having a high risk HLA profile, family members of that patient should also be advised to avoid the relevant drug, as familial occurrence of such hypersensitivity reactions has been noted. Recommendations have been made for screening patients for specific alleles prior to administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link&amp;anchor=H21#H21\">",
"     \"Abacavir hypersensitivity reaction\", section on 'Screening prior to abacavir exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Acute generalized exanthematous pustulosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute generalized exanthematous pustulosis (AGEP) is a rare type of reaction characterized by superficial pustules, usually appearing within 24 hours after the administration of the culprit drug (",
"    <a class=\"graphic graphic_picture graphicRef56807 \" href=\"UTD.htm?39/59/40883\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68610 \" href=\"UTD.htm?30/29/31189\">",
"     picture 9",
"    </a>",
"    ). This disorder is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H19#H19\">",
"     \"Drug eruptions\", section on 'Acute generalized exanthematous pustulosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Timing of type IV reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type IV reactions are typically delayed in onset by at least 48 to 72 hours and sometimes by days to weeks following exposure to the culprit drug. Upon rechallenge, symptoms may appear within 24 hours. The time to symptom onset for reactions depends in part upon the number of T cells activated by the drug. These responses are polyclonal, and symptoms appear rapidly if the drug stimulates a large number of different T cell clones. In contrast, a drug that activates just a few clones may not cause clinical symptoms until these T cells have proliferated for several weeks.",
"   </p>",
"   <p>",
"    Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    epidermal necrolysis",
"    <span class=\"nowrap\">",
"     (SJS/TEN)",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     DRESS/DiHS,",
"    </span>",
"    the most dangerous of the delayed drug hypersensitivity reactions, often appear after weeks of uncomplicated treatment. Patients suddenly develop signs and symptoms of a fulminant immune reaction. This presentation results from uncontrolled expansion of oligoclonal T cells that have been massively stimulated by the drug, reminiscent of superantigen-like stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Association with viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a higher risk of some type IV drug allergic reactions during generalized viral infections and exacerbations of autoimmune diseases, disorders in which T cell reactivity is enhanced by widespread immune activation of T cells, high cytokine levels, and an increased expression of MHC- and costimulatory molecules.",
"   </p>",
"   <p>",
"    Viral infections that predispose patients to reactions to certain drugs include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epstein Barr virus (with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cytomegalovirus (with antibiotics).",
"     </li>",
"     <li>",
"      Human herpes virus 6 (with anticonvulsants and other agents) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link&amp;anchor=H8#H8\">",
"       \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\", section on 'Medication hypersensitivity syndromes'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Human immunodeficiency virus (HIV) infection (with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      sulfamethoxazole and other agents).",
"     </li>",
"     <li>",
"      In young children, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (and to a lesser extent with other antibiotics) often elicits exanthematous reactions. Most of these children tolerate the same drug if given again later on [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/34\">",
"       34",
"      </a>",
"      ]. It is likely that systemic viral infections are facilitating these reactions as well, although this has not been conclusively demonstrated. Rhinoviruses, which cause only local infections of the nasopharynx and respiratory tract, should not have this effect because they do not stimulate the immune system to the same degree.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12276329\">",
"    <span class=\"h2\">",
"     Association with dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain the extent to which drug dose (daily dose or duration of treatment) contribute to the development of delayed, T cell mediated drug allergies. Certain examples suggest that dose is important; more than 10 days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    caused maculopapular exanthema in nearly one-third of females, while this was rare with three days of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8553?source=see_link&amp;anchor=H365986#H365986\">",
"     \"Hypersensitivity reactions to fluoroquinolones antimicrobials\", section on 'Delayed maculopapular exanthema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    hypersensitivity, there are data to suggest that starting dose may be relevant for developing hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Subcategories of type IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells can orchestrate different forms of inflammation depending upon the cytokines produced and the other types of cells that become involved, leading to the subcategories of types IVa to IVd (",
"    <a class=\"graphic graphic_figure graphicRef75626 \" href=\"UTD.htm?8/5/8280\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/6\">",
"     6",
"    </a>",
"    ]. These subcategories are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link\">",
"     \"Drug allergy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     OTHER TYPES OF REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Drug-induced autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs can induce autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/36\">",
"     36",
"    </a>",
"    ]. Despite intensive scrutiny, the pathogenesis of these reactions has not been elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The best known example is a lupus-like disease, which can develop after exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/36,38-40\">",
"       36,38-40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"       \"Drug-induced lupus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       Penicillamine",
"      </a>",
"      can also cause a pemphigus-like disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link&amp;anchor=H118261971#H118261971\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\", section on 'Drug exposure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IgA bullous dermatosis has been associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef77601 \" href=\"UTD.htm?8/59/9136\">",
"       picture 10",
"      </a>",
"      ) and various other drugs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link&amp;anchor=H20#H20\">",
"       \"Vancomycin hypersensitivity\", section on 'Other forms of hypersensitivity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Fixed drug eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are other drug-induced disorders that cannot be readily classified. As an example, fixed drug eruption is a relative common reaction, which is characterized by erythematous and edematous plaques with a grayish center or frank bullae. Lesions recur at exactly the same sites (typically lips and tongue, genitalia, face, and acral areas) with drug reexposure (",
"    <a class=\"graphic graphic_picture graphicRef52192 \" href=\"UTD.htm?16/19/16691\">",
"     picture 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65991 \" href=\"UTD.htm?10/16/10499\">",
"     picture 12",
"    </a>",
"    ). These site(s) develop postinflammatory pigmentation. Fixed drug eruption can occur in response to sulfonamides, anticoagulants, and many other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/42\">",
"     42",
"    </a>",
"    ]. The mechanism is unknown, although T cells residing in the skin produce interferon gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     PSEUDOALLERGIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoallergic drug reactions are adverse drug reactions with signs and symptoms that mimic immunologic drug allergies, but in which immunologic mechanisms have not been demonstrated. They are a subset of idiosyncratic reactions and are also called \"non-immune hypersensitivity reactions\" [",
"    <a class=\"abstract\" href=\"UTD.htm?1/11/1210/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Type B reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pseudoallergic reactions are difficult to distinguish clinically because they are similar or identical in presentation to true allergic reactions. The complete mechanisms underlying most of them are not known and may be different (",
"    <a class=\"graphic graphic_table graphicRef79967 \" href=\"UTD.htm?12/42/12972\">",
"     table 3",
"    </a>",
"    ). Some pseudoallergic reactions arise from direct (rather than immunologic) activation of immune and inflammatory cells, so the final steps in pathogenesis and the resultant clinical features are indistinguishable from those of allergic reactions. However, the diagnosis, prognosis, and prevention are different. In particular, pseudoallergic reactions are not diagnosed with skin or in vitro allergy testing and do not worsen with repeated exposure. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Common culprit drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Reactions that resemble anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiosyncratic reactions that mimic IgE-mediated, type I allergic reactions are among the most important for clinicians to understand. Like IgE-mediated reactions, nonimmunologic activation of mast cells and basophils results in the release of vasoactive mediators. These pseudoallergic reactions range in severity from mild to fatal. Accordingly, acute nonimmunologic anaphylaxis should be treated in the same manner as immunologic anaphylaxis.",
"   </p>",
"   <p>",
"    Nonimmunologic reactions resembling anaphylaxis are often referred to as \"anaphylactoid.\" Unfortunately, the term anaphylactoid has been widely misinterpreted to mean a reaction that was similar to anaphylaxis but less severe, and has led to the undertreatment of patients with nonimmunologic anaphylaxis. Therefore, the term anaphylactoid is now discouraged, and the concept of nonimmunologic anaphylaxis is preferred. Clinicians should understand that all forms of anaphylaxis are potentially life-threatening and should treat affected patients appropriately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear how certain drugs elicit these reactions. Some affected patients have underlying dermographism and seem to have an \"instability\" of their mast cells, which degranulate already upon pressure or by exposure to various small molecules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Common culprit drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that can cause nonimmunologic anaphylaxis are listed below, and the clinical syndromes associated with each are reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiocontrast agents (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link\">",
"       \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Opiates",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"       \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link\">",
"       \"Vancomycin hypersensitivity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Local anesthetic agents (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=see_link\">",
"       \"Allergic reactions to local anesthetics\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chemotherapeutic agents (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link\">",
"       \"Infusion reactions to systemic chemotherapy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Monoclonal antibodies and other biologic therapies used in cancer therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link\">",
"       \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/3/23603?source=see_link\">",
"       \"Patient information: Drug allergy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse drug reactions may be broadly divided into types A and B (",
"      <a class=\"graphic graphic_table graphicRef51797 \" href=\"UTD.htm?6/32/6668\">",
"       table 1",
"      </a>",
"      ). Type A represent the majority of reactions, can affect any individual, and are predictable from the known pharmacologic properties of a drug. Type B reactions are less common, occur in susceptible patients, and usually cannot be predicted from the known pharmacologic properties of a drug. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adverse drug reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunologic drug reactions, or allergic drug reactions, are a subset of type B reactions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Definition of drug allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunologic drug reactions may be divided into four categories according to the Gell and Coombs system (",
"      <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"       table 2",
"      </a>",
"      ). Types I and IV are far more common in clinical practice than types II and III. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Classification of drug allergy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type I: Immediate in onset and mediated by IgE and mast",
"      <span class=\"nowrap\">",
"       cells/basophils",
"      </span>",
"     </li>",
"     <li>",
"      Type II: Delayed in onset and caused by antibody (usually IgG) mediated cell destruction",
"     </li>",
"     <li>",
"      Type III: Delayed in onset and caused by IgG:drug immune complex deposition and complement activation",
"     </li>",
"     <li>",
"      Type IV: Delayed in onset and T cell-mediated. Type IV reactions are further subdivided into types IVa, IVb, IVc, and IVd, depending upon the other cell types involved (",
"      <a class=\"graphic graphic_figure graphicRef75626 \" href=\"UTD.htm?8/5/8280\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically, the different types of reactions have characteristic signs and symptoms, and the timing of onset of symptoms may also be helpful in distinguishing one type from another. However, there is significant clinical overlap among them. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Type I reactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Type II reactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Type III reactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Type IV Reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudoallergic drug reactions are a subset of type B (hypersensitivity) drug reactions with signs and symptoms that mimic immunologic drug allergies but are not immunologic. Pseudoallergic reactions are especially difficult to distinguish clinically because they can be similar or identical in presentation to true allergic reactions. However, the diagnosis, prognosis, and prevention of pseudoallergic reactions are different. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Pseudoallergic reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/1\">",
"      Muszkat M. Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. Clin Pharmacol Ther 2007; 82:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/2\">",
"      Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. J Lab Clin Med 1981; 97:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/3\">",
"      Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/4\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/5\">",
"      Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/6\">",
"      Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/7\">",
"      Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf 2006; 29:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/8\">",
"      Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004; 113:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/9\">",
"      Schmid DA, Campi P, Pichler WJ. Hypersensitivity reactions to quinolones. Curr Pharm Des 2006; 12:3313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/10\">",
"      Johansson SG, Florvaag E, Oman H, et al. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy 2010; 65:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/11\">",
"      Birnbaum J, Vervloet D. Allergy to muscle relaxants. Clin Rev Allergy 1991; 9:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/12\">",
"      Florvaag E, Johansson SG. The pholcodine story. Immunol Allergy Clin North Am 2009; 29:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/13\">",
"      Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/14\">",
"      Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176:4431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/15\">",
"      Schaerli P, Ebert L, Willimann K, et al. A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med 2004; 199:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/16\">",
"      Storrs FJ. Contact dermatitis caused by drugs. Immunol Allergy Clin North Am 1991; 11:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/17\">",
"      Hertl M, Geisel J, Boecker C, Merk HF. Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993; 128:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/18\">",
"      Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/19\">",
"      Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/20\">",
"      Strom BL, Carson JL, Halpern AC, et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 1991; 127:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/21\">",
"      Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/22\">",
"      Peyri&egrave;re H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/23\">",
"      Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/24\">",
"      Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 2006; 17:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/25\">",
"      Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/26\">",
"      Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/27\">",
"      Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010; 49:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/28\">",
"      Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/29\">",
"      Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/30\">",
"      Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/31\">",
"      McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/32\">",
"      Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/33\">",
"      Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/34\">",
"      Caubet JC, Kaiser L, Lema&icirc;tre B, et al. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011; 127:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/35\">",
"      Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/36\">",
"      Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev 2005; 4:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/37\">",
"      Vergne P, Bertin P, Bonnet C, et al. Drug-induced rheumatic disorders: incidence, prevention and management. Drug Saf 2000; 23:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/38\">",
"      Gait RC, Affleck AG, Leach IH, Varma S. Perinuclear antineutrophilic cytoplasmic antibody-positive polyarteritis nodosa secondary to minocycline treatment for acne vulgaris. J Am Acad Dermatol 2008; 58:S123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/39\">",
"      Li GC, Greenberg CS, Currie MS. Procainamide-induced lupus anticoagulants and thrombosis. South Med J 1988; 81:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/40\">",
"      Sheikhzadeh A, Sch&auml;fer U, Schnabel A. Drug-induced lupus erythematosus by amiodarone. Arch Intern Med 2002; 162:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/41\">",
"      Onodera H, Mihm MC Jr, Yoshida A, Akasaka T. Drug-induced linear IgA bullous dermatosis. J Dermatol 2005; 32:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/42\">",
"      Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges 2008; 6:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/43\">",
"      Mizukawa Y, Shiohara T. Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep 2009; 9:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/11/1210/abstract/44\">",
"      Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2086 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-9B173040F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1210=[""].join("\n");
var outline_f1_11_1210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DEFINITION OF DRUG ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADVERSE DRUG REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type A reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type B reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Exaggerated sensitivity to known drug toxicities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Idiosyncratic drug reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Immunologic drug reactions (drug allergy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLASSIFICATION OF DRUG ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Classification based upon timing of symptom onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Immediate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Delayed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Classification by reaction types",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TYPE I REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Commonly-implicated drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Previous exposure to the suspect drug",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TYPE II REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical features and timing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TYPE III REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Serum sickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TYPE IV REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical presentations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Morbilliform eruptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Stevens-Johnson syndrome and toxic epidermal necrolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Drug-induced hypersensitivity syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Acute generalized exanthematous pustulosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Timing of type IV reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Association with viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12276329\">",
"      Association with dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Subcategories of type IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      OTHER TYPES OF REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Drug-induced autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Fixed drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      PSEUDOALLERGIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Reactions that resemble anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Common culprit drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2086\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2086|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/5/8280\" title=\"figure 1\">",
"      Gell Coombs IVa-d",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2086|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/16/27905\" title=\"picture 1\">",
"      Urticarial drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/2/29728\" title=\"picture 2\">",
"      Urticaria 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/61/34782\" title=\"picture 3\">",
"      Allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32239\" title=\"picture 4\">",
"      Morbilliform eruption 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/63/18419\" title=\"picture 5\">",
"      Toxic epidermal necrolysis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/48/25345\" title=\"picture 6\">",
"      Cutaneous changes of Stevens Johnson Syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/55/42866\" title=\"picture 7\">",
"      Stevens-Johnson syndrome - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/59/40883\" title=\"picture 8\">",
"      AGEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/29/31189\" title=\"picture 9\">",
"      AGEP detail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/59/9136\" title=\"picture 10\">",
"      Vancomycin allergy skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/19/16691\" title=\"picture 11\">",
"      Fixed drug eruption arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/16/10499\" title=\"picture 12\">",
"      Fixed drug eruption penis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2086|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/32/6668\" title=\"table 1\">",
"      ADR types AB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 2\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/42/12972\" title=\"table 3\">",
"      Pseudoall drug rxn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=related_link\">",
"      Allergic reactions to local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=related_link\">",
"      Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8553?source=related_link\">",
"      Hypersensitivity reactions to fluoroquinolones antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/3/23603?source=related_link\">",
"      Patient information: Drug allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_11_1211="Six item screen for confusion in adults";
var content_f1_11_1211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Six item screen for confusion in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Give the patient three items to remember (eg, apple, table, and penny), and ask the patient to repeat them aloud.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Ask the patient to state the current year, month, and day of week.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Ask the patient to repeat the original three items.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         One point is given for each correct answer; a score below five connotes cognitive impairment.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1211=[""].join("\n");
var outline_f1_11_1211=null;
var title_f1_11_1212="Developmental screening medical evaluation";
var content_f1_11_1212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the medical evaluation when assessing development",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical examination",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Looking for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head circumference",
"       </td>",
"       <td>",
"        Microcephaly, macrocephaly, altered growth velocity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight and height",
"       </td>",
"       <td>",
"        <p>",
"         Growth deficiency (failure to thrive, short stature)",
"        </p>",
"        <p>",
"         Overgrowth",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General appearance",
"       </td>",
"       <td>",
"        Dysmorphic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyes",
"       </td>",
"       <td>",
"        Visual acuity, tracking, strabismus, cataracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ears",
"       </td>",
"       <td>",
"        Unusual shape or placement, signs of recurrent otitis media or chronic otitis media with effusion, hearing acuity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdomen",
"       </td>",
"       <td>",
"        Hepatosplenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        Neurocutaneous lesions and vascular markings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic examination",
"       </td>",
"       <td>",
"        Persistent primitive reflexes; abnormalities of symmetry, tone, strength, deep tendon reflexes, protective reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory evaluation*",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Looking for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin/hematocrit",
"       </td>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood lead level",
"       </td>",
"       <td>",
"        Lead poisoning",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Additional evaluation may be warranted for some children with historical or examination findings suggestive of a medical etiology. The evaluation should be tailored to the clinical findings and may include thyroid function testing, genetic testing, metabolic screening, and/or neuroimaging or encephalography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1212=[""].join("\n");
var outline_f1_11_1212=null;
var title_f1_11_1213="Fetal kidney length";
var content_f1_11_1213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal fetal renal lengths",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gestational age, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean kidney length, cm",
"       </td>",
"       <td class=\"subtitle1\">",
"        95% CI, cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        1.6 - 2.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"       <td>",
"        1.5 - 3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        1.8 - 3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"       <td>",
"        2.1 - 3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"       <td>",
"        2.0 - 3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        2.2 - 3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"       <td>",
"        1.9 - 4.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"       <td>",
"        2.5 - 4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        2.4 - 4.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        2.7 - 4.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        2.6 - 4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"       <td>",
"        2.3 - 4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"       <td>",
"        2.9 - 4.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        2.8 - 4.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        3.1 - 5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        3.3 - 4.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        3.3 - 5.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        3.2 - 5.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        3.3 - 5.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        3.3 - 5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        3.2 - 5.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        3.5 - 4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        3.2 - 5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        3.9 - 5.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Cohen HL, Cooper J, Eisenberg P, et al. Normal length of fetal kidneys: sonographic study in 397 obstetric patients. AJR Am J Roentgenol 1991; 157:545. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1213=[""].join("\n");
var outline_f1_11_1213=null;
var title_f1_11_1214="Drugs that cause or prolong delirium";
var content_f1_11_1214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs believed to cause or prolong delirium or confusional states*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Analgesics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonsteroidal anti-inflammatory agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opioids (especially meperidine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antibiotics and antivirals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acyclovir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aminoglycosides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amphotericin B",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antimalarials",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cephalosporins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cycloserine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoroquinolones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interferon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Linezolid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Macrolides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metronidazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nalidixic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rifampin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfonamides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atropine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benztropine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diphenhydramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scopolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trihexyphenidyl",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anticonvulsants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Levetiracetam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Valproate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vigabatrin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mirtazapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Selective serotonin reuptake inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiovascular and hypertension drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antiarrhythmics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clonidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Digoxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diuretics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methyldopa",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Corticosteroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dopamine agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amantadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bromocriptine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Levodopa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pergolide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pramipexole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ropinirole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antiemetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antispasmodics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histamine-2 receptor blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Loperamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Herbal preparations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atropa belladonna extract",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Henbane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mandrake",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Jimson weed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            St. John's Wort",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Valerian",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypoglycemics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypnotics and sedatives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzodiazepines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Muscle relaxants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Baclofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclobenzaprine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other CNS-active agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disulfiram",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholinesterase inhibitors (eg, donepezil)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interleukin-2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenothiazines",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Not exhaustive, all medications should be considered.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1214=[""].join("\n");
var outline_f1_11_1214=null;
var title_f1_11_1215="The effect of cadmium on renal stone risk";
var content_f1_11_1215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    The effect of cadmium exposure on renal stone risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative incidence of renal stones in relation to the estimated cumulative inhaled exposure to cadmium among cadmium battery workers in Sweden. The risk for experiencing renal stones increased with the cumulative inhaled dose of cadmium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Jarup L, Elinder, CG, Br J Ind Med 1993; 50:598.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_11_1215=[""].join("\n");
var outline_f1_11_1215=null;
